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Abstract 
Dengue is a vector-borne disease found across much of the world, with an increasing number 
of cases annually. This thesis explores the dynamics of dengue infection within an individual, 
and the possible impact of this at a population level.  
I use mathematical modelling and statistical analysis, tightly coupled with data, as a way of 
tying together the important components and processes during infection. I model the virus 
and immune dynamics, capturing the differences between individuals, disease severity and 
primary/secondary disease (with a focus on hypothesised secondary mechanisms). Within the 
immune dynamics I concentrate on antibody, looking at the role of antibody in limiting 
infection. Within this framework I also consider the impact on these dynamics of an antiviral. 
The final section of this thesis brings together this closer consideration of virus dynamics and 
considers their impact at a population level. Using data from biting experiments I am able to 
characterise the “infectivity” of an individual over time, how this varies between individuals 
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and groups (as above), and how this compares to previous transmission modelling 
assumptions. In terms of control I look at how this “infectivity” is altered by antivirals and by 
wolbachia infected mosquitoes. 
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Chapter 1 : Introduction 
Dengue is a mosquito borne flavivirus found across much of South East Asia, parts of Central 
and South America, Africa and Australia. There are four distinct serotypes (DENV1-4) and 
within these serotypes, different genotypes. Dengue virus is transmitted by the aedes aegypti 
and aedes albopictus mosquitoes (Lambrechts et al., 2011). WHO estimates there to be 
around 50 million cases of dengue a year with two fifths of the world’s population now at 
risk from dengue, and reported incidence increasing 30-fold in the last decade (WHO, 2010). 
There is a spectrum of disease from asymptomatic, to dengue fever (DF), through to severe 
disease. It is thought that infection with one serotype leads to lifelong immunity to that 
serotype, and that subsequent infection with a heterologous serotype (secondary infection) are 
more likely to result in severe disease than primary infection. 
The preceding section is the standard introduction to a dengue paper and these things are 
generally taken as given. Many of the specifics however, still elude full understanding. I will 
provide in the next sections, as a background to the PhD research that follows, an overview of 
research to date on these and other areas of importance to dengue research and control. To 
provide a setting to this work I discuss the distribution of infection and disease across the 
world, and particularly in Vietnam, from where the data used in this PhD comes. Other 
17 
 
particular areas of interest for the research that follows are the nature and length of immunity, 
mechanisms of primary/secondary disease, the spectrum of disease from asymptomatic to 
severe, serotype differences and the infectious relationship between the human and mosquito.  
1.1. Burden of disease and transmission around the 
world 
Dengue is a major problem across much of the world, causing morbidity and mortality. The 
burden of disease varies greatly across the world due to varying forces of infection with 
varying infections and cases across age groups and across time (within and between years).. . 
In some places such as Thailand or Vietnam, all four serotypes circulate though with often 
one serotype more dominant at a time (Cummings et al., 2004, Thai et al., 2005, Cummings 
et al., 2009), In other places however, Cuba for example, serotypes are generally seen one at 
a time (Alvarez et al., 2006). At any time the population’s previous exposure to dengue will 
be very important in shaping the current dynamics and cases observed.     
The 50 million cases of dengue a year, estimated by WHO (WHO, 2010) is subject to great 
uncertainty. The spectrum of disease makes it difficult to estimate the number of cases, as 
many may be too mild to attend a health care facility, possibly termed sub-clinical cases. 
Further along this spectrum there are a largely unknown number of infections that are not 
cases at all, and would be classed as asymptomatic.. The possibility of new control measures 
has led to a need for a greater understanding of the underlying epidemiology of dengue 
disease distribution and transmission, to understand how to best use interventions. To this 
end, recent papers have estimated the burden of disease and the economic impact of dengue 
in various countries(Halstead et al., 2007, Beaute and Vong, 2010, Carrasco et al., 2011, 
Wichmann et al., 2011, Vong et al., 2012)., much work has been undertaken in Cambodia. In 
2012 using capture-recapture methods, Vong, estimated substantial underreporting in the 
Cambodian healthcare system, with the 3.9-22 fold lower number of cases reported in the 
healthcare system. Wichmann et al estimated 9 fold differences between actual cases and 
those seen in the healthcare system in another study in Cambodia. Beaute and Vong 
estimated DALYs of 24-100 per 100, 000 individuals in Cambodia, with variation between 
years (Halstead et al., 2007, Beaute and Vong, 2010, Carrasco et al., 2011, Wichmann et al., 
2011, Vong et al., 2012). The mapping of dengue incidence or suitability has recently been 
taken on by the Malaria Atlas Project team (Hay, 2012). An draft map appears in the review 
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by Simmons and colleagues (Simmons et al., 2012a) and is reproduced here (Error! 
Reference source not found.). More detail on the methods and the consensus of evidence is 
presented in work by Brady and colleagues (Brady et al., 2012) and a discussion of the 
similarities and differences between mapping malaria and dengue (Anders and Hay, 2012). 
Brady and colleagues find 128 countries of the world where there is good evidence for 
dengue transmission.  
 
Figure 1-1: Map highlights areas of high to low suitability for dengue transmission 
(Simmons et al., 2012a).  
Figure from Simmons et al. NEJM paper (Simmons et al., 2012a) from personal 
communication by S Bhatt, PW Gething, O Brady and S Hay. Reproduced with 
permission from NEJM. Copyright Massachusetts Medical Society. 
 
It was traditionally thought dengue was found in mainly urban and semi-urban areas (WHO, 
2009, WHO, 2010) though rural transmission is now thought to be relatively common, for 
example in studies in the Kamphaeng Phet region of Thailand (Mammen et al., 2008) and in 
rural Cambodia (Vong et al., 2012) .   
Dengue is an important cause of mortality is Singapore (Wilder-Smith et al., 2004, Ooi et al., 
2006) where transmission has increased in recent years following 15 years of low incidence.  
Carrasco et al (Carrasco et al., 2011) found the burden of dengue In Singapore to be 
comparable to that of hepatitis B or syphilis, with  9–14 DALYs per 100 000 individuals. In 
South America, dengue is found endemically in Brazil (Honorio et al., 2009, Cavalcanti et al., 
2011, Cordeiro et al., 2011, Allicock et al., 2012), where it has been fairly extensively 
studied, and there are outbreaks in Northern Argentina (Berberian et al., 2011). Dengue is 
common in Puerto Rico and has been well studied due to the US Centre for Disease Control 
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(CDC) presence there (Allicock et al., 2012). There have been recent outbreaks also in 
mainland US states (DOH Florida, 2010). Dengue is found in Peru (Chowell et al., 2008, 
Morrison et al., 2010a, Liebman et al., 2012) and in Nicaragua (Balmaseda et al., 2010, 
Reyes et al., 2010, OhAinle et al., 2011).  
Little is known about dengue in Africa. Recent studies have indeed found evidence of a large 
amount of dengue infections there, e.g. (Phoutrides et al., 2011), with dengue thought to be 
endemic in 34 African countries (Were, 2012) ,. Recent large outbreaks in India, in the news 
in 2012 (The New York Times, 2012), and in Pakistan, in the news in 2011 and 2012 
(Pakistan Today, 2012) have highlighted other regions where little is known about dengue, 
but where it is increasingly a problem. Transmission on Madeira, Portugal has brought the 
disease closer to home in Europe (ECDC, 2012). 
 
1.1.1. Heterogeneity 
As well as great heterogeneity across the world, the local transmission dynamics of dengue 
are highly heterogeneous. Early studies concentrated on the clustering of cases (Beckett et al., 
2005, Mammen et al., 2008, Reyes et al., 2010, Thai et al., 2010).  
There are two main ways that heterogeneity could be important in modelling dengue 
transmission. The first is heterogeneity in behaviours of both mosquitoes and humans, 
ultimately resulting in differential contacts between humans and mosquitoes. Research in 
Peru has shown that movement and mosquito habitats are clustered and lead to differential 
exposure to mosquitoes between patients (Chowell et al., 2008, Stoddard et al., 2009, Xu et 
al., 2010). The second type of heterogeneity is biological. As discussed in earlier chapters of 
this thesis (Chapter 3 mainly), there is heterogeneity between patients in virus dynamics. I 
will discuss how this translates to heterogeneity in human infectivity below. Heterogeneity in 
mosquito infectivity will also be important but is not discussed in this thesis.  
1.2. Serotypes and genotypes 
The four dengue serotypes are labelled DENV1, DENV2, DENV3 and DENV4. Within each 
serotypes there is considerable genetic diversity (different genotypes). Genotypes may differ 
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in their ability to transmit or cause severe disease (Rico-Hesse, 2007, Fried et al., 2010). 
Genotypes are thought to vary in their ability to replicate in cells (Cologna et al., 2005), 
which could lead to differential infectivity, or in their ability to cause disease (Halsey et al., 
2012). Differences between serotypes in the within-host virus dynamics have been observed 
in two studies in Vietnam the data from which is used later in this thesis (Duyen et al., 2011, 
Tricou et al., 2011).  
1.3. TRANSMISSION CYCLE 
 
Figure 1-2: Dengue transmission cycle, adapted from: (Whitehead et al., 2007) 
Reprinted by permission from Macmillan Publishers Ltd: Nature Reviews 
Microbiology, copyright 2007. 
1.3.1. The Vector 
The relevant mosquitoes for dengue transmission are aedes aegypti and aedes albopictus. 
Aedes aegypti generally breed in standing water such as containers that are found in urban 
areas (though also possibly in trees in rural areas). Albopictus can survive in more rural areas 
– dwelling mainly in trees – and are thought to have a lower vector competence for dengue 
(Lambrechts et al., 2010), with only one feed per gonotrophic cycle and a propensity to feed 
Mosquito 
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on other vertebrates. In one observed outbreak in Hawaii, aedes albopictus would appear to 
have led to different dynamics than aedes aegypti with sustained low-level transmission seen 
(Effler et al., 2005). Though there are many other possibilities that could explain the 
differences seen in dynamics, the possible differences between the two vectors should be 
remembered when considering transmission in different settings and possible control 
strategies. The main vector in Vietnam is the aedes aegypti. 
The intrinsic incubation period in mosquitoes is thought to be around 10-14 days (Sabin, 
1952). It is thought to depend on the mean temperature (Watts et al., 1987), though this was 
not seen in other studies (Lambrechts et al., 2011) where they see a relationship with the 
diurnal temperature variation, viraemia levels in the host, and virus genotype (Lambrechts et 
al., 2012). However there is still much to understand about viral pathogenesis in the vector. 
 
1.3.2. Dengue in Vietnam 
The data used in this thesis is from Southern Vietnam, so it is useful to review this particular 
transmission setting. From the beginning of 2012 up until end of August 2012 there were 47, 
927 cases reported in Vietnam (with 41 deaths), with 39,471 (39 deaths) in the same period in 
the previous year (WHO, 2012). Using data from the Vietnam Ministry of Health 
Surveillance Data and Institute Pasteur, Figure 1-3 shows the dynamics and serotype isolation 
of dengue in Southern Vietnam from 1996-2007 (Recker et al., 2009, Wikramaratna et al., 
2010). We see  possible cycling of serotypes (though it is not clear if this behaviour is 
periodic), with DENV3 responsible for the highest proportion of cases around 1998 when 
there were many cases, followed by a trough in case numbers. During this trough, DENV2 
and DENV4 had the highest percentage of cases. There has been an increase in the number of 
cases in recent years, with DENV2 and then DENV1 the most prevalent serotype. In this 
work, I mainly use data collected from cases from 2008 onwards, but Figure 1-3 data can 
inform us about the serotype a past primary infection could have been for the secondary 
infections we see in the data. In these data virus is only isolated from clinical cases, with the 
virological confirmed case incidence data shown, reflecting both underlying serotype 
infection incidence and the relative severity of disease for infections with each serotype. In 
particular, such data will tend to reflect secondary infection severity (as more secondary cases 
will be seen in a hospital setting), which is also a function of the previous infecting serotype. 
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It will also depend upon the immunity in a population, how this changes with age, and how 
disease severity relates to age. Disentangling this relationship is complex and will require 
serosurveys and a greater understanding of the relationship between serotypes (and 
genotypes) in terms of transmissibility and disease severity.  
Other studies have described the epidemiological picture of dengue in Southern Vietnam. 
Two studies used phylogenetic data: one describing transmission from Ho Chi Minh City 
(HCMC) outwards (Raghwani et al., 2011), and the other viral exchange between HCMC and 
other areas (using a gravity model of transmission within HCMC) (Rabaa et al., 2010). Other 
modelling studies used data from Vietnam to consider the possibility of tertiary and 
quaternary infections (Wikramaratna et al., 2010) and serotype oscillations over time (Recker 
et al., 2009). Thai and colleagues describe the situation in more rural Southern Vietnam, 
looking particularly at two villages (Thai et al., 2010, Thai et al., 2011), where strong case 
clustering and transmission “hotspots” were observed.  
 
Figure 1-3: Annual cases per 100000 people in Southern Vietnam and the proportion of 
each serotype isolated at Hospital of Tropical Diseases. Figure © 2010 Wikramaratna et 
al. (Wikramaratna et al., 2010), a similar figure also appears in (Recker et al., 2009).  
Data from 1996-2008. Data is passive surveillance data from the Ministry of Health 
Vietnam and Institute Pasteur.  
1.4. Dengue virus 
Dengue is a single-strand positive sense RNA flavivirus. Other flavivirus include yellow 
fever, West Nile, Japanese Encephalitis and tick-borne encephalitis,,arboviruses, transmitted 
by mosquitoes or ticks. DENV genome is made up of 10,600 nucleotides. Translation of viral 
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RNA yields a single polypeptide , which results in 3 structural proteins and at least 7 non-
structural proteins. DENV virion is spherical. The three structural proteins are the capsid (C) 
protein and also the envelope protein, made up on envelope (E) and membrane (M) proteins. 
There is in addition a pre-membrane state (prM), immature virus, the virus state within the 
cell. This prM is cleaved upon release from the cell to form M protein, the mature virus form. 
There are also virus non-structural proteins, the main one of which is NS1, as well as NS4 
and NS5 (Whitehead et al., 2007) The four dengue serotypes are in fact four antigenically and 
genetically distinct viruses which cause similar disease in humans. 
 
Figure 1-4: Dengue virus structure, adapted from (Kuhn et al., 2002), with permission, 
copyright Cell, Elsevier Domains I, II, and III in red, yellow, and blue, respectively, the 
fusion peptide is in green.  
 
Replication of dengue virus involves entry to the cell by attachment to the plasma membrane 
and then uptake via receptor mediated endocytosis and pH dependent fusion with the 
endocytic vesicle membrane (Rodenhuis-Zybert et al., 2010b). Once inside the cell, as with 
all positive sense-RNA viruses, the virus uncoats and uses the cell machinery to replicate. It 
is also thought that virus can enter the cell (possibly while in complexes with antibody in a 
secondary infection) via Fc receptor cells. Recent studies have used live imaging techniques 
to observe these infection events, observing the virion enter the target cells in vitro (van der 
Schaar et al., 2007, van der Schaar et al., 2008, Rodenhuis-Zybert et al., 2010b).After fusion 
the RNA genome dissociates from the viral nucleocapsid and then functions as mRNA in the 
cytoplasm where it is translated, The virion is assembled in the endoplasmic reticulum and 
via the Golgi network the virus exits the cell (Whitehead et al., 2007). 
24 
 
1.5. Natural history of disease 
Severity of disease varies greatly from subclinical, classical dengue fever (DF), to more 
severe forms, previously called dengue haemorrhagic fever (DHF) and dengue shock 
syndrome (DSS), now collectively named severe dengue (Deen et al., 2006). The introduction 
of the new classifications has been due to the previous fairly strict definitions of DHF not 
incorporating some cases that were in fact very severe, and some cases classified as DHF not 
being very severe. The new classifications have been taken up in many countries, and reports 
on the ease of use are available (Barniol et al., 2011). It is unclear what impact the change in 
severe dengue case classification will have on time series of reported cases and interpreting 
long term trends.  
Dengue infection in humans occurs after a bite from an infected mosquito, aedes aegypti or 
aedes albopictus (though there also reported cases of transmission via blood transfusion 
(Linnen et al., 2008, Mohammed et al., 2008, Tambyah et al., 2008, Seed et al., 2009, Wilder-
Smith et al., 2009)). 
Mild disease may be mistaken for a flu-like illness, with at least subclinical, if not totally 
asymptomatic, disease occurring. In those we see symptoms, following the bite there is an 
incubation period of around 3-7 days (Nishiura and Halstead, 2007) Symptoms include rash, 
muscle and joint pain, headache, fever and vomiting. An interesting facet of dengue infection 
is that at the early stage of infection, the very severe cases have not shown themselves, and 
the more severe symptoms develop around the time of defervescence (when fever subsides). 
It is at this time that haemorrhaging can occur (with bleeding under the skin, from gums and 
nose) or at which plasma leakage leading to shock can occur.  
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Figure 1-5: Natural history of infection. Reprinted from The Lancet, Volume 370, Issue 
9599, Pages 1644 - 1652, Halstead, Dengue, Copyright (2007), with permission from 
Elsevier.” (Halstead, 2007),  
1.6. Diagnosis 
Dengue is usually diagnosed using virological or serological methods, with the sensitivity of 
each varying throughout infection. RT-PCR can be used early in infection to detect virus, and 
later (from 4 days after fever- though also see Chapter 4) IgM assays can be used to detect 
seroconversion. NS-1 (non-structural protein 1) can be used in the absence of PCR 
technology, though is possibly less sensitive (Vu Ty et al., 2009). Combinations of these 
measures have been shown to also be of use for diagnosis (Guzman et al., 1984, Sadon et al., 
2008, Vu Ty et al., 2009, Kassim et al., 2011, Fry et al., 2011, Simmons et al., 2012a). There 
have been recent developments in the use of dried blood spot or oral swabs for detection of 
infection (Anders et al., 2012) without the need for drawing large amounts of blood. 
Secondary infection is generally diagnosed using antibody titres, with antibody titres early in 
infection compared to titres from later in infection, and the change determining a primary or 
secondary infection (Innis et al., 1989).  
During infection the infecting serotype is determined by PCR-based virus detection. After an 
infection, the antibody response is not clear-cut and it is difficult to determine the infecting 
serotype. Though it is generally thought the primary serotype is easy to identify after 
infection, and the secondary not recent studies have shown this is not necessarily the case. 
Recent studies have attempted to determine the serotype using pre- and post- illness titres, 
with a success rate of correctly identifying the infecting serotype (assessed by PCR during 
infection) of around 77% in primary and 67% in secondary infections (and 60% using only 
post-illness samples) (van Panhuis et al., 2010). Though this success rate is higher in primary, 
there is still difficulty in assessing the correct infecting serotype.  
1.7. Target cells 
In early experiments in vitro, monocytes (Halstead and Orourke, 1977, Libraty et al., 2001, 
Kou et al., 2008) found in blood, dendritic cells found in tissues (Libraty et al., 2001) and 
endothelial cells, those lining the blood vessels (Liu et al., 2007), were all found to support 
dengue virus replication. However it is not clear how these findings relate to in vivo 
26 
 
infection. In vivo, Langerhans cells (Wu et al., 2000) and macrophages in skin 
(Boonpucknavig et al., 1979) have been shown to be infected. Infection in the liver and 
lymphoid organs has been seen in autopsies, (Rosen et al., 1999) though as these were fatal 
cases they may not be representative of all infections. Capillary endothelial cells were 
thought to be infected and have a role in plasma leakage, but autopsy studies appear to show 
no viral replication in these cells, so it is thought that somehow infection alters their function 
(Jessie et al., 2004). Virus enters cells through the endocytic pathway (Acosta et al., 2008, 
van der Schaar et al., 2008, Ayala-Nuñez et al., 2011). Once virus has replicated within the 
cell, the virus is thought to be released from the cells via the endoplasmic reticulum (ER) and 
Golgi- apparatus (Halstead, 2008).  
1.8. Virus and immune response during infection 
 There is evidence for multiple facets of the immune system playing a role in controlling 
infection (Halstead, 2008, Martina et al., 2009). An increasing body of evidence, from both 
human and mouse studies, shows that interferon α and β and γ (IFN-α, IFN-β, IFN-γ) of the 
innate immune response have an impact on the acute phase of illness (Kurane et al., 1989, 
Kurane et al., 1993, Diamond et al., 2000, Gunther et al., 2011, Tolfvenstam et al., 2011). 
Tumor necrosis factor, complement activation and NK cell activation (Hober et al., 1993, 
Hober et al., 1998, Liu et al., 2007, St John et al., 2011, Wati et al., 2011) have all been noted 
in acute infection, but the link between these and the control of infection or disease is still not 
fully clear. 
Macrophages and dendritic cells have been shown to be possible target cells for dengue 
infection, but with also a possible role in activating the immune response (Avirutnan et al., 
2008, Boonnak et al., 2008). T-cells play a role during infection through the secretion of 
cytokines. Both cross-reactive (heterologous) and specific (homologous) CD4 and CD8 T- 
cells have been implicated in the control of infection (Green et al., 1999, Bashyam et al., 
2006, Mathew and Rothman, 2008, Rothman, 2009, Beaumier et al., 2010, Hatch et al., 
2011). T-cells are also much studied in relation to the phenomenon of antigenic sin 
(Dejnirattisai et al., 2008, Midgley et al., 2011). 
In early work by Innis and others, the authors hypothesis a role for antibody in controlling 
infection (Innis et al., 1989). They infer, from an increase in antibody as the virus becomes 
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undetectable, that antibody is controlling the infection, though this was not the focus of the 
paper. Antibody has also been shown to neutralise virus in vitro (Kochel et al., 2002) or to be 
able to destroy infected cells by antibody dependent cell cytotoxicity (ADCC) (Garcia et al., 
2006). Antibody is discussed in greater depth at the start of Chapter 4. In relation to possible 
enhancement activity during infection, antibody has been studied in depth both ex-vivo, in-
vitro and in mouse models (Chen et al., 2001, Dejnirattisai et al., 2010, Ubol et al., 2010, Moi 
et al., 2011b, Moi et al., 2012). 
1.9. Dengue Antibody 
Antibody is hypothesised to be important in providing protection against dengue infection. In 
an infection that establishes itself, antibody is hypothesised to have dual (conflicting) roles: in 
enhancing (Beltramello et al., 2010) and controlling (van der Schaar et al., 2009) the 
infection. In this chapter I explore the role of antibody throughout acute infection.  
The main antibodies of relevance to dengue are IgG and IgM. IgG and IgM are different 
classes of antibody, distinguished by differences is the constant (Fc) region (Sompayrac, 
2003). Both IgM and IgG are good opsonisers. IgM is the first antibody to develop and is a 
good complement fixer. IgG is fairly good at complement fixing, and also helps NK cells kill 
(ADCC). Only IgG passes across the placenta.  
1.9.1. Measurement of Antibody 
There are multiple ways of measuring antibody. It is possible to measure the overall capacity 
of sera to neutralise (or indeed enhance) virus, the concentration of a certain type of antibody 
(IgG or IgM), or of an antibody towards a specific part of the virion. The method for the data 
presented in this chapter is indirect ELISA. In this process the serum to be tested is added to a 
well of the antigen. A secondary binding agent is then added which binds to the antigen-
antibody complexes. This reaction gives a colour change, depending on how much antigen-
antibody complex is present. The colour change is evaluated to give a quantitative value to 
the amount of antibody (optical density) as described in (Cardosa et al., 2002). Alternatively, 
serial dilutions of sera can be tested and the reciprocal of the dilution that produces a specific 
optical density used as the outcome titre e.g. anti-E IgG in (Chau et al., 2009). Overall titres 
of IgG and IgM can be measured, as well as subsets of antibodies directed towards specific 
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parts of the virus protein, for example E (envelope), prM (pre Membrane) or NS-1 (non-
structural protein 1).   
Plaque reduction neutralisation test (PRNT), another commonly used measure to quantify 
antibody titre and/or effectiveness, is a test of neutralisation. In this test different dilutions of 
sera are incubated with virus. The incubated virus and antibody mix is then added to host 
cells, incubated and the number of infected host cells (plaques) counted after a certain time. 
PRNT-50 is often the summary measure output, defined as the dilution needed to stop 50% of 
plaques that would occur without the antibody, as in (Roehrig et al., 2008, Thomas et al., 
2009, Rainwater Lovett et al., 2012). PRNT-50 however, does not indicate whether the 
antibody level is enough to control an infection in vivo, as this will depend on other 
parameters. Hemagglutination inhibition (whereby a titre of antibody is determined 
depending on concentrations of serum and how effectively this stops virus and cells binding) 
has also been used historically, but is less commonly adopted today.  
1.9.2. Role of Antibody  
Antibodies can work by opsonising (tagging virus ready for uptake by a phagocyte or 
complement) or neutralising virus (van der Schaar et al., 2009) and eliminating infected cells 
(by antibody dependent cell cytotoxicity (ADCC) (Garcia et al., 2006)). The main target of 
neutralising antibodies is thought to be the E protein (Wahala and de Silva, 2011). Mouse 
model work stimulated much interest in domain 3 of E protein during the infection period 
(Bernard et al., 2008, Rajamanonmani et al., 2009, Shrestha et al., 2010). However work has 
also shown that if these antibodies are removed from sera there is no difference in the 
neutralising ability of human sera (Wahala et al., 2009, Williams et al., 2012), suggesting 
other antibodies are predominant in human infection. Differences have been shown to exist 
between different genotypes of DENV2 in the neutralising properties of monoclonal 
antibodies against various viral antigens, including domain 1 of the E protein (Sukupolvi-
Petty et al., 2010). An overview of the antibody neutralisation process is given in the review 
by Dowd and Pierson, where they consider antibody function, antibody interactions and the 
role of occupancy throughout infection (Dowd and Pierson, 2011). Whether antibodies are 
cross-reactive or serotype specific is also important and discussed in greater detail in the next 
section.  
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Antibodies against NS1 are thought to promote the infected cell lysis, as NS1 is expressed on 
the cell surface. However as NS1 antibodies can also induce complement, so may not directly 
eliminate the cell (Rothman, 2004). Overall, there is limited data on the role of antibody in 
cell cytotoxicity. ADCC activity (measured by antibody incubated with infected and non-
infected cells and the change in cell numbers assessed) was shown during acute infection in 
DHF/DSS cases but not DF cases (Garcia et al., 2006). In this study one year after infection, 
all sera showed ADCC activity.  
  
1.9.3. Antibody dynamics  
Recent studies have considered the dynamics of antibody and B cell populations over time 
after infection, or considered the dynamics of maternally derived antibodies in infants. In a 
few of these studies, the antibody levels were related to subsequent disease outcomes.  
1.9.3.1. Decay kinetics of antibodies 
Mathew and colleagues consider the dynamics of B cells over time by sampling patients 
immediately post-illness, and then approximately 6 months later (Mathew et al., 2011). The 
sampling was conducted for a variety of serotypes and for primary and secondary disease. 
For DENV1, they observed a high proportion of DENV1-E serotype specific B cells, with 
higher levels reached in primary compared with secondary infections. B cells waned to 
undetectable levels in the majority of (but not all) DENV1 primary cases, though in a few 
patients the number of B cells detected increased between samples. They observed cross-
reactive B cells to E protein after secondary infection (as expected). There were also 
detectable NS1 antibodies- particularly to DENV2, despite no DENV2 infections being seen 
in the cohort. Anti- prM B cells were also observed, the authors think for the first time.  
Two studies by Prince and colleagues describe antibody dynamics over time (Prince and 
Matud, 2011, Prince et al., 2011). Similarly to the Mathew et al. (2011) study, these studies 
noted higher levels of IgM after primary than secondary infections, but did not observe any 
difference in the rate of decay of IgM between primary and secondary infection. They 
examined the dynamics of IgG and IgM over time as a potential means for differentiating 
primary and secondary infection. Of the different measurements of antibody considered in 
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these studies, the avidity of IgG was determined to be the best measure for distinguishing 
primary from secondary infection (avidity was higher after secondary infection compared to 
primary). 
A recent review of antibody responses to dengue (Halstead, 2008) concluded that following 
primary infection, prM (pre Membrane) and E (envelope), IgG antibodies dominate, with C 
(capsid) and NS-1, -3, -5 IgG antibodies developing post-secondary infection.  
A recent study dissected the antibody response post primary infection in more detail than 
previous work (de Alwis et al., 2011). It studied two travellers who contracted primary 
dengue, with samples taken 1 year after infection with DENV3 from one individual, and 8 
years after DENV2 infection of another individual. Initially the binding properties of the 
serum and polyclonal antibodies were assessed to the E protein of all 4 serotypes using 
ELISA (as for the antibody data I analyse below). They found a greater proportion of 
antibody not binding to the envelope protein than to it, and the majority of antibodies were 
found to be broadly cross reactive and weakly neutralising. Only a small proportion of 
antibody clones were responsible for the strong neutralisation of the homologous virus.  
In another similar study Beltramello and colleagues analysed the monoclonal antibody 
response in 5 individuals after primary and secondary infection with differing serotypes (all 
1-4 covered) (Beltramello et al., 2010). Both serotype and cross-reactive antibodies against 
domain III of the E protein were found and shown to “potently” neutralise the virus. Other 
antibodies were found to be less neutralising and were broadly cross- reactive. 
During and lasting after infection a wide variety of antibodies to multiple different epitopes 
appear to be produced, both those specific to the infecting serotype and cross reactive. It 
would appear that only a small proportion of these antibodies are effective at neutralising. 
Antibodies for dengue have the capacity to enhance and neutralise or bring about cell 
cytotoxicity, and it is probably not the same types of antibodies that are capable of both. 
1.9.3.2. Antibody titre and subsequent infection 
There is still much uncertainty how antibody affects subsequent infection. Substantial 
attention has been given to antibody-dependent enhancement and finding a marker in sera 
which is predictive of whether enhancement will occur and lead to a severe infection. In a 
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series of studies in Thailand with a cohort of school children, Endy (Endy et al., 2004), 
Laoprasopwattana and colleagues (Laoprasopwattana et al., 2004), assessed the in vitro 
neutralising and enhancing activity of antibodies sampled before secondary infection in the 
study participants and the subsequent infection observed in these individuals. Higher levels of 
neutralising antibodies (measured by PRNT) to DENV3 post primary infection were 
associated with subsequent lower viraemia levels and less severe disease, but this effect was 
not seen for DENV1 or DENV2 primary infections. Enhancement activity (EA) was 
measured in the Thai studies by the adding antibody-virus complexes to cells in vitro. The 
subsequent infection of these cells was then measured using flow-cytometry. No correlation 
was observed between enhancing activity as measured by this method, and subsequent 
plasma virus titre measurements in DENV2 secondary infections, and a significant negative 
correlation only when plasma was diluted (Endy et al., 2004). This finding was at odds with 
an earlier study (Kliks et al., 1989) which observed that enhanced infection of monocytes in 
DENV2 infection was associated with severe disease. The discrepancies in results provoked 
lively debate in the pages of Journal of Infectious Disease where the study by 
Laoprasopwattana and colleagues was published (Halstead, 2006, Burke and Kliks, 2006). 
One point made by Halstead adds to one of the central arguments of my PhD: that the 
consideration of many measurements over time and their relationship is the best way to 
understand infection. The point made (though refuted by the study authors as they had 
considered serial measurements in previous studies) was that as only one virus sample was 
taken what is being measured is almost certianly not the “peak” virus. Another problem with 
such cohort studies is that the measurements of pre-illness sera can be taken 6-9 months 
before infection and antibody titres can change substantially in that intervening period 
(another infection or decay of antibody at a rate that can differ markedly between people). 
The differences between serotypes are mentioned, and accepted by the original authors as a 
possible reason for the discrepancies between the two studies, but without a great amount of 
evidence behind it at the time. Such differences between serotypes are also highlighted by my 
in Chapter 3 in relation to the dynamics of infection.  
Current work with cohorts is looking at the pre infection sera and differences between these 
for sub-clinical and clinical disease. 
32 
 
1.9.3.3. Antibody titres and recent vaccine studies  
The recently published phase IIb trial of the Sanofi-Pasteur tetravalent vaccine presented 
some interesting findings with regard to dengue antibody (Sabchareon et al., 2012). Firstly, 
antibody titres (measured via PRNT) that would previously have been thought to render an 
individual “immune” did not protect against disease for DENV2. There are two possible 
reasons for this. There was heterogeneity in the immune response and the PRNT titres in 
individuals who became infected were lower than those who did not (the analysis of these 
titres on an individual level has not yet been published and was only undertaken for a 
subsection of the study group). Alternatively, this level of titre of the vaccine-induced 
antibody as quantified by PRNT does not in fact endow protection (in which case, do they 
pose a risk of enhancement?). For the other serotypes the measured antibody titres did seem 
to be protective, though due to the small samples size there are large confidence intervals on 
the efficacy estimates, and such stratification also suffers from the problem of being post-hoc 
(i.e. not included in the randomisation). Overall, the Sanofi trial raises question about 
whether all the relevant immunological correlates of protection were being measured.   
1.9.3.4. Maternal Antibodies 
One of the main arguments for antibodies causing secondary disease to be more severe is the 
observation of apparently increased severity of disease in infants, where the only “exposure” 
to dengue is through maternally derived antibodies.  
The observation of severe disease in infants has motivated the study of newborns and the 
dynamics of antibody titres (and other immune responses) in early life (Chau et al., 2009, 
Libraty et al., 2009, van Panhuis et al., 2011). In initial studies some authors used maternal 
antibody titres at birth as a proxy for infant titres (assuming a certain rate of decay over time 
of maternally-derived titres) (Libraty et al., 2009), though other studies have since shown 
such a measure is not a good proxy, as there is great variation in the rate of decay (van 
Panhuis et al., 2011). Libraty and colleagues found no relationship between the inferred titres 
at the time of infection and DHF (Libraty et al., 2009), though this result may be due to the 
way titres at the time of infection were inferred. Chau and colleagues (Chau et al., 2009) 
collected measurements from infants at 3-month intervals in the first year of life, and so were 
able (like van Panhuis and colleagues later) to characterise the decline in individual titres 
over time. In their cohort, by 6 months almost all infants have no antibody to DENV1-4 E 
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protein, with no antibody reactive with the whole DENV1 virion and only 10% antibody 
reactive with DENV2-4 virion. There were no confirmed cases of clinical dengue in the Chau 
et al. cohort so it was not possible to examine the relationship of antibody titres with disease, 
though observed increases in antibody titres over the study period suggested 10 sub-clinical 
infections had occured. 
1.9.3.5. Antibody dynamics during infection pathogenesis  
The main focus of this chapter is an aspect of antibody function less studied experimentally: 
the role of antibody during infection pathogenesis. Other immune responses during infection 
are discussed in Chapter 3. I will focus on exploring the extent to which the measured 
kinetics of antibody concentrations over time can explain viral dynamics in dengue patients.  
Recently, a small serial antibody measurements from primary dengue infections was analysed 
(Hu et al., 2011) with the aim of including antibody, with NS1 measurements, as an 
alternative way of diagnosing dengue disease. The study showed that IgM antibodies were 
detectable in 43% of cases on day 3 of symptoms, though in some it was detectable from day 
1 and by day 8 it was detectable in 100%. Some individuals also had detectable IgG 
antibodies by day 8. Though generally only two measurements were available per patient, 
this study highlights the heterogeneity between people- and is a restart of considering 
antibody dynamics during the acute phase of infection.  
These results echo what was seen in primary infection in studies by Innis and colleagues, 
with IgM developing more quickly and to higher levels, and IgG increasing more slowly 
(Innis et al., 1989). This latter study also showed that, in secondary infection, IgG developed 
more quickly and to higher levels, with IgM following more slowly behind (Innis et al., 
1989). This work led to the use of the ratio of IgG vs. IgM titres to classify primary and 
secondary infection, and was the first study of antibodies over time for dengue during 
infection. IgM was also noted to become detectable at around the same time point as virus 
became undetectable, but the main focus of the Innis paper was the use of antibody titre 
measurements as a diagnostic tool, and mechanistic explanations of antibody and virus 
dynamics were not considered.  
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1.10.Immunity outcome at a population level 
It is thought that after infection with one serotype, long-lived neutralising homologous 
immunity is generated. After primary infection, a strong neutralising response to the infecting 
serotype is generated. Any subsequent infection with the same serotype is believed to be 
controlled. There is also thought to be a short period of cross-protective immunity to all 
serotypes after primary infection. The original evidence for this came from a study in the U.S. 
army (Siler et al., 1926b, Siler et al., 1926a) This study was reanalysed by Nishiura who 
estimated this protective period as 1-2 weeks (Nishiura, 2008). Whether infection in this 
cross-protective time leads to the development of antibodies or indeed some viraemia is not 
clear. More recent modelling work presented at ASTMH conference last year, has looked at 
this period using population level data and estimated it to be on the order of months or years 
rather than weeks (Cummings et al., 2011). Modelling work has considered the differences 
between immunity to infection or disease in the cross-protective period, with or without the 
development of an immune response (Nagao and Koelle, 2008). In this paper it was shown, 
counter-intuitively, that under the assumption that those infected in the cross-immune period 
did not develop disease, but did develop a protective antibody response against further 
infection, a decrease in transmission could lead to an increase in cases. Continued exploration 
of what happens when an “immune” individual is challenged and how this interacts with the 
case numbers seen is important, and will become more important after the introduction of a 
vaccine.  
After this period of cross-protection, a subsequent infection with a different serotype is 
thought to have a greater possibility of resulting in severe disease. Whether tertiary and 
quaternary infections of dengue occur is a matter of debate. Antibody tests would not be able 
to distinguish a secondary from a later infection (van Panhuis et al., 2010), and third 
infections have been seen in cohorts (Kosasih et al., 2006). However, much of the thinking is 
that after a second infection, a person is assumed to be immune to all serotypes (Fischer and 
Halstead, 1970) , the usual assumption in modelling studies e.g. (Ferguson et al., 1999a). 
However a recent modelling paper concluded that tertiary and quaternary infections must 
occur (and be infectious) in order for the force of infection to be as observed in Vietnam 
(Wikramaratna et al., 2010).  
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1.11.Secondary infection and severe disease 
How severe disease is caused in a secondary (or primary) infection is thought to be a complex 
combination of many factors. The prevailing hypothesis for the mechanism behind severe 
disease in secondary infection is antibody dependant enhancement (ADE), whereby 
antibodies from the previous infection are not sufficient to neutralise the virus, but instead 
attach to the virus particles and aid entry into Fc receptor-bearing cells, such as macrophages 
(Dejnirattisai et al., 2010).  
It is also thought ADE could work by antibody binding with immature “non-infectious” virus, 
i.e. not fully cleaved virus that still contains prM, and enabling it to become “infectious” 
(Rodenhuis-Zybert et al., 2010a, Rodenhuis-Zybert et al., 2011, Voorham et al., 2012).  
There are other theories such as T cell based ‘original antigenic sin’, in which there is 
preferential activation of memory T cells with lower avidity for the infecting virus 
(Mongkolsapaya et al., 2003, Mongkolsapaya et al., 2006). The same could be true for B cells 
and antibody (Halstead et al., 1983), though this has not received much attention. Original 
antigenic sin implies that the first infection is the important one, where as it could be possible 
for multiple previous infections to impact infection, which would more accurately be termed 
antigenic sin. 
The exact mechanism by which either of these may cause severe disease is not clear, but 
higher peak viraemia has been shown to correlate with severe disease in some studies 
(Vaughn et al., 2000), though not in others (Murgue et al., 2000, Yeh et al., 2006). Higher 
rate of virus clearance has also been shown in DHF (Vaughn et al., 2000). It is hypothesised 
this greater peak viral load, due to increased infection through ADE, or antigenic sin allowing 
the virus to reach higher levels before it is controlled, leads to an increase in immune 
response intensity which can cause severe disease (Kurane et al., 1994, Chaturvedi et al., 
2000, Halstead, 2008), though how exactly this works is not clear. There is also some 
evidence for immunity against NS1 being implicated in disease severity (Avirutnan et al., 
2011, Falconar and Martinez, 2011, Lima et al., 2011). There is evidence that several aspects 
of the immune response being involved in severe disease, including cytokines (termed 
“cytokine storm”) (Nguyen et al., 2004, Pacsa et al., 2000, Dewi et al., 2007), complement 
(Avirutnan et al., 2006, Nascimento et al., 2009), multiple parts of the innate immune 
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response (Ubol and Halstead, 2010) and cellular immunity (Mathew and Rothman, 2008, 
Duangchinda et al., 2010, Nguyen et al., 2010). This “cytokine storm” could be via virus 
differences or alone the difference in a sensitized secondary infection, or over activation of 
the immune response in individual sin which severe disease results.  
Whether there are signs early in infection that might predict whether a person will develop 
severe disease is an area of much clinical research (Kalayanarooj et al., 1995, Green et al., 
1999, Libraty et al., 2002, Simmons et al., 2005). Work by the Screaton lab has shown links 
with T cell activation and subsequent disease (Mongkolsapaya et al., 2003, Mongkolsapaya et 
al., 2006, Dejnirattisai et al., 2008). In addition, the work on peak viraemia outlined above is 
relevant to this research goal. Recent work linked multiple clinical features over time, leading 
to a fuller picture of possible predictors, and the outcome of infection (Biswas et al., 2012). 
Other work in Singapore has highlighted the importance of considering serial measurements, 
along with possible predictors of severe disease identified (Low et al., 2011, Tolfvenstam et 
al., 2011). Although secondary disease is more likely to be severe there are also subclinical 
secondary infections and primary infections can be severe. 
Evidence for secondary infections being more severe was firstly epidemiological (Fischer and 
Halstead, 1970, Valdes et al., 1999) with severe disease having two peaks in age, the first in 
very young children (under one year old) and another later, as secondary infections occur, 
and this piece of information is a major piece of evidence for the ADE hypothesis.  The first 
peak in severe disease with age occurs in young children and is hypothesised to be due to 
primary infection that can be enhanced following the decline of maternal antibodies to sub-
neutralising levels (Chau et al., 2008). This is an argument for antibodies having some role in 
severe outcomes, as only antibody will pass from mother to child. 
Once again the differences between serotypes and genotypes are thought to be a factor in 
severe disease. There may be serotype combinations (or serotypes alone) that for primary-
secondary infection (or for any infection) are more likely to result in severe disease. For 
example, in a Thai cohort study only secondary DENV2 infections resulted in DSS, even 
though secondary DENV1 infection was more common (Sangkawibha et al., 1984). However 
in Indonesia, severe disease was associated with secondary DENV1, 3 and 4 but not 2 
(Graham et al., 1999). As well as the trouble in determining infecting serotype from 
secondary serology, this study is hampered by the wide variation in severity and differences 
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in what will be reported. Within serotypes, there are also differences between genotypes, the 
most often cited example is the “American” and “Asian” DENV2 genotypes, with evidence 
of severe disease only from “Asian”, not “American” (Watts et al., 1999). 
This aetiology of disease is further complicated by the fact that an outcome of a dengue 
infection may differ with age (Egger and Coleman, 2007). As mentioned previously there is 
thought to be a peak in severe disease in infants under one, but there may be other differences 
in disease outcome with age. It is thought that infection in adults is more likely to result in 
apparent disease (Egger and Coleman, 2007). In DENV2 infections death rates from severe 
disease were higher in children than adults with secondary infections (Guzman et al., 2002). 
Recent work has shown differences in the pathogenesis between adults and children in 
Vietnam with regard to platelets and bleeding risk (Dinh The et al., 2012). There is still work 
to be done to elucidate what the relationship is on an individual and a population level.  
Last, there may be host genetic differences that lead to differences in immune expression, for 
example, differences in human leukocyte antigen (HLA) – A and B have been implicated in 
differential disease outcomes (Stephens et al., 2002, Coffey et al., 2009, Appanna et al., 
2010). There is also evidence for a role of MHC class I polypeptide-related sequence B 
(MIC- B ) (Khor et al., 2011).  
1.12.Animal models  
There are few animal models of dengue. Rhesus monkeys are used, but they do not display 
clinical signs of disease (Halstead et al., 1973). More recently immune depleted mouse 
models and humanised mouse models (Mota and Rico-Hesse, 2009, Williams et al., 2009) 
have shown some of the characteristics of disease seen in humans (Zompi and Harris, 2012). 
Much antibody work has occurred in mouse models (Wahala and de Silva, 2011), and some 
new therapeutic compounds are first tested in mouse models e.g. work by Stein and 
colleagues on interfering particles (Stein et al., 2011). There is a lack of conclusive evidence, 
and even some evidence to the contrary (Wahala et al., 2009), concerning whether mouse 
results are extendable to humans. More recently monkeys have been the renewed focus of 
research due to their possible role for testing vaccines (Barban et al., 2012) and as a reservoir 
for disease in the possible post-vaccination era (Althouse et al., 2012). 
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1.13. Dengue transmission models overview 
The many published mathematical modelling studies of dengue transmission can crudely be 
partitioned into two groups: those considering serotype interactions, and those focussed on 
interventions. The former group has largely been motivated by understanding the temporal 
dynamics of dengue epidemics, looking at the effect of one or more of the following factors: 
(a) seasonality (Bartley et al., 2002); (b) antibody dependent enhancement (ADE) (Fischer 
and Halstead, 1970, Ferguson et al., 1999a, Adams et al., 2006, Recker et al., 2009); (c) cross 
protective immunity (Nagao and Koelle, 2008, Chikaki and Ishikawa, 2009); (d) genotype 
competition (Lourenco and Recker, 2010); (e) population structure (Cummings et al., 2009); 
and (f) human movement (Adams and Kapan, 2009). Most of these studies used differential 
equation models of transmission in attempts to understand what is necessary to recreate the 
observed temporal dynamics of dengue incidence and where able to create the possible 
cycling of dynamics with all of the above processes. Notably, a majority of the models used 
did not explicitly model mosquito dynamics, though that trend is changing; e.g. (Lourenco 
and Recker, 2010).  
Antibody dependent enhancement has been included in two ways in these models: (a) by 
increasing the susceptibility of an individual to a secondary infection with a heterologous 
serotype e.g. (Ferguson et al., 1999a); (b), by assuming secondary infections are more 
infectious e.g. (Bartley et al., 2002, Cummings et al., 2005). The latter assumption is 
motivated by the higher peak of virus seen in DHF patients in a study in Thailand (Vaughn et 
al., 2000), to which we will return later. 
The impact of (possible asymptomatic) third and fourth infections was modelled by 
Wikramaratna and was shown to recreate dynamics seen in Vietnam without an 
unrealistically high basic reproduction number, R0 (Wikramaratna et al., 2010). Thailand. 
(Cummings et al., 2009) and Vietnam (Recker et al., 2009, Wikramaratna et al., 2010) have 
been popular contexts of transmission for dengue modelling, but it is unclear how applicable 
this work is for other regions with differing transmission patterns. There are papers 
considering the outbreak dynamics in other areas, for example Brazil (Pinho et al., 2010), 
though it is difficult to compare these, with varying levels of data on cases and population 
level data (serological or cases over time). 
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There has been recent progress on formalising the fitting of multistrain dengue transmission 
models to data (Shrestha et al., 2011), an approach which will also be of use when combining 
datasets containing different information and data from different regions.  
Model-based evaluation of the impact of interventions on dengue is a rather less developed 
area. Some studies have considered the impact of vector control (Focks et al., 1995, Focks et 
al., 2000, Magori et al., 2009, Luz et al., 2011), and more recently the impact of GM and 
wolbachia infected mosquitoes (Medlock et al., 2009, Thome et al., 2010, Xu et al., 2010, 
Alphey et al., 2011, Walker et al., 2011, Schraiber et al., 2012). This work has included work 
on the ability of wolbachia infected mosquitoes to spread in a population (Barton and Turelli, 
2011), and on the best way to monitor release of genetically modified mosquitoes (Alphey et 
al., 2011). Dengue vaccine has been included theoretically in few published models to date 
(Billings et al., 2008), though as vaccine development programs progress (Sabchareon et al., 
2012), more work in this area is likely. The first publication of more research was recently 
published by Chao and colleagues (Chao et al., 2012), considering the best dengue use of 
vaccine in a small area of Thailand, concluding that children should be the priority to receive 
the vaccine. A position paper has been published on how the vaccine should be considered 
within a modelling framework (Beatty et al., 2012), and a review of dengue transmission 
modelling and its role in evaluating vaccination programme options (Johansson et al., 2011). 
Modelling is also an important component of the work being undertaken by the Dengue 
Vaccine Initiative (DVI) (Dengue Vaccine Initiative, 2012).  
1.13.1. Infectivity assumptions 
As dengue is a vector-borne disease, its transmission dynamics are more complex than those 
of directly transmitted pathogens. The models that include mosquitoes have begun to take this 
biological reality into account but the assumptions about infectivity are still fairly 
rudimentary.  
Generally models considering serotype cycling have assumed humans have constant 
infectivity for a defined infectious period. Assumptions about the length of this period vary, 
examples are 3.65 days (without a latent period) (Recker et al., 2009), 5 days (without a latent 
period) (Wikramaratna et al., 2010) ,  6 days (with a 5 days latent period) (Wearing and 
Rohani, 2006) to 2 weeks (Shrestha et al., 2011).  Of course, what difference this makes 
depends on the other parameters of the model and the questions the model is answering. 
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However, references for this length of infectiousness come from a few papers (Gubler et al., 
1981, Vaughn et al., 2000), or are chosen for computational ease. The explicit within-host 
dynamics have not been considered within models of dengue transmission. Two papers have 
a more realistic description of infective period (Otero et al., 2011, Focks et al., 1995). Error! 
Reference source not found. shows the infectivity assumptions of the Otero et al. 2011 
paper, which were in turn taken from (Nishiura and Halstead, 2007).  
 
Day of infectivity 1 2 3 4 5 
probability of 
infecting mosquito 
0.25 0.8 1 0.95 0.5 
Table 1-1: Infectivity of human to mosquito assumption throughout infection (after 
latent period) for transmission model in (Otero et al., 2011) from (Nishiura and 
Halstead, 2007).   
The Focks et al. model (Focks et al., 1995) explicitly models virus titres. Though the titre 
values are not directly comparable to those measured by PCR, it is of interest to observe the 
shape of the titre: infectivity relationship (see Error! Reference source not found.). 
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Figure 1-6: Infectivity of human to mosquito as in (Focks et al., 1995). 
The assumption that secondary infections are more infectious than primary infections has 
been propagated in the modelling literature from a few studies looking at the clinical 
predictors of severe infection (Vaughn et al., 1997, Vaughn et al., 2000). The argument has 
gone along the lines of: secondary infections are more likely to be severe, severe infections 
have been shown to have a higher viral load peak, so therefore secondary infections are more 
infectious. An overview of the assumptions of transmission models with regard to primary 
and secondary infection is given in (Johansson et al., 2011), but broadly they can be grouped 
as increased infectiousness in a secondary infection, or increased susceptibility to a secondary 
infection. 
A few papers have also considered the effect of secondary infections having shorter 
infectious periods than primary infections (Adams and Boots, 2006, Lourenco and Recker, 
2010, Stollenwerk et al., 2012, Chao et al., 2012). This assumption has been motivated by the 
idea that secondary infections are more severe and that hospitalisation or death will truncate 
the infectious period. While this justification is biologically dubious (severe dengue is rare 
and when it does occur, severe symptoms post-date fever and therefore most of the infectious 
period), we do see slight faster declines in viral load in secondary infections in the dataset 
analysed in Chapter 3 (and this is also seen to some extent in Vaughn et al. (Vaughn et al., 
2000) , which is the motivation for the Chao et al. assumption).  
Differences between serotypes have been rarely included in dengue transmission models 
Adams and Boots considered differing infectivity between serotypes (Adams and Boots, 
2006), with this leading to different parameter regions in which two strains can coexist. 
Lourenco and Recker (Lourenco and Recker, 2010) have also considered infectivity 
differences between strains within the same serotype.  
The role of asymptomatic or inapparent infections in dengue transmission is an important but 
little explored topic. In his book, “Dengue”, Halstead asks if there is any doubt that primary 
asymptomatic peak viraemias will be lower than peak viraemias in secondary asymptomatic 
(Halstead, 2008). I will start to consider this issue in Chapter 5.  
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1.14.Control methods 
Due to the current lack of vaccine or treatment to limit infection or prevent disease, current 
dengue interventions focus on vector control. This has taken the form of insecticide spraying 
and encouraging individuals to remove all possible breeding containers around their homes 
and workplaces. The historical success of vector control is mixed, with some reported 
successes in Vietnam involving spraying and community engagement (Kay and Nam, 2005) 
and early successes in Singapore (Ooi et al., 2006). In Vietnam infection is still widespread, 
and after 15 years of low incidence, Singapore is now seeing higher numbers of cases, despite 
huge intervention efforts: local case reports are now available to view online (NEA, 2012b), 
and penalties are imposed on those found having mosquitoes in their homes/workplaces 
(NEA, 2012a). Whether control in Singapore is viewed as a success or a failure is a matter of 
debate. Low incidence for 15 years is certainly an achievement, and the numbers of cases 
now is lover than pre control level. However, it is now once again a major public health 
problem and elimination was not achieved.  
Two recent important efforts in vector-based control research have been in developing 
genetically modified (GM) mosquitoes and Wolbachia-infected mosquitoes. The goal is to 
limit the mosquito’s lifespan, capacity to reproduce (thereby indirectly reducing their ability 
to transmit dengue), or to reduce vector competence. Wolbachia is a bacteria widely 
occurring in nature, and in many insect species, but not naturally in aedes aegypti 
mosquitoes. Wolbachia strains were originally developed to limit mosquito lifespan 
(McMeniman et al., 2009).  
Wolbachia is maintained in the mosquito population by cytoplasmic incompatibility, whereby 
male infected mosquitoes will only produce viable offspring when mating with a wolbachia 
infected female, and the offspring will be infected with wolbachia. An infected female will 
also produce wolbachia infected offspring when mating with a non-wolbachia infected male. 
This means  wolbachia is maintained in the mosquito population (McMeniman et al., 2009). 
This trait would be of use as it would limit the number of mosquitoes that survive past the 
extrinsic incubation period and are therefore able to infect humans. This trait however is also 
difficult to maintain in the population as there are fitness costs to having a shorter lifespan 
(Schraiber et al., 2012). More recent work has shown wolbachia to be refractory to dengue 
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infection in aedes aegypti (Hoffmann et al., 2011). It is not entirely clear how this works, but 
either by competing directly for resources in an infected mosquito or by up-regulating the 
immune system (Rances et al., 2012).  Different strains of wolbachia are thought to have 
different profiles with varying levels of life shortening or dengue blocking. These different 
profiles will probably lead to different success at being maintained in the population and in 
reducing transmission of dengue. 
 
There are also multiple approaches to developing genetically modified mosquitoes. Perhaps 
the furthest developed are the sterile male constructs developed by Oxitec Ltd. In this system, 
GM sterile males are released, which mate with wild females and produce no viable offspring 
(de Valdez et al., 2011). The disadvantage of this approach for sustained population 
suppression is the need for on-going repeated releases. Other genetic modifications to 
lifespan and fecundity are being developed, including gene-drive as a way of maintaining this 
trait in the population (Sinkins and Gould, 2006).  
However, the greatest hope in dengue control is that an effective vaccine is developed. There 
have been much recent activity in this area, with both live attenuated and recombinant 
vaccines being developed (Guy et al., 2011). Though early work considered monovalent 
vaccines, all current vaccine candidates are tetravalent, intended to induce a broadly 
neutralising response against all 4 serotypes (Kanesa-Thasan et al., 2003, Durbin et al., 
2011a, Durbin et al., 2011b), due to the concern about enhancement being possibly caused by 
monovalent vaccines. There is still some worry with tetravalent vaccines that antibody levels 
to some serotypes could reduce over years to sub neutralising and enhancing levels 
(Anderson et al., 2011). Long-term follow-up will be needed to determine whether this is risk 
is real. 
There are multiple candidate vaccines at various stages of development. Walter Reed Army 
Institute of Research/GSK (Guy et al., 2011), Inviragen, Merck and joint US NIH and 
Instituto Butantan have vaccines in Phase I- Phase II trials (Dengue Vaccine Initiative, 2012). 
The vaccine currently furthest in development is the Sanofi Pasteur vaccine. Phase I trials 
were conducted in the Philippines (Morrison et al., 2010b, Capeding et al., 2011), and results 
from the latest trial for efficacy (Phase IIb) have just been published. In this trial the vaccine 
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showing some efficacy (with large confidence intervals) for DENV1, 3 and 4, but no efficacy 
against DENV2 (Sabchareon et al., 2012).  
Dengue treatment is currently supportive and aims to limit symptoms. Dengue antivirals 
would ultimately hope to limit infection and therefore symptoms, but are not yet available. 
Two approaches to antiviral drug discovery are being pursued: screening drugs that are 
already available for treating other infections for anti-dengue activity, and de novo 
development of dengue-specific drugs. The trials of chloroquine (Tricou et al., 2010) and 
balapavir (Nguyen et al., 2012) undertaken in Vietnam pursued the first of these avenues. It 
was hoped chloroquine, a treatment for malaria, might inhibit dengue replication by altering 
the pH. Originally developed to treat Hepatitis C, it was hoped Balapavir would interrupt 
virus replication in the cell. Unfortunately, neither drug appeared to have any impact.  
De novo antiviral discovery is underway at the Novartis Institute for Tropical Diseases in 
Singapore and other labs, targeting various stages in the virus replication cycle (Bollati et al., 
2010, Anwar et al., 2011, Chen et al., 2011, Fagundes et al., 2011, Wang et al., 2011, Xie et 
al., 2011). These are being developed and tested in vitro and in mouse models. Guidelines for 
the testing of dengue therapeutics in humans have recently been published (Simmons et al., 
2012b). 
1.15.Thesis structure and aims 
Following this introduction, this thesis has four further chapters. Since the models developed, 
their dynamics, and model fitting methods used, are applicable to multiple chapters, I 
describe these together in Chapter 2, along with a brief review of previous within-host 
modelling of viral infections. This chapter also describes the virus and immune response 
datasets used, highlighting the important characteristics of each. 
In Chapter 3, I show results from fitting the basic model of dengue infection to virus titre data 
from multiple primary and secondary individuals, and present resulting model parameter 
estimates. I use a second dataset to validate these, and consider serotype differences. I also 
consider the impact of hypothetical antivirals within this model.  
In Chapter 4, I extend the previously used model to incorporate antibody data, along with 
additional statistical analysis, to consider the role of antibody during infection.  
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Chapter 5 then discusses the relevance of my work on within-host dynamics, for our 
understanding of the epidemiology and transmission of dengue. I describe experimental 
mosquito feeding study data collected by our collaborators in Vietnam, which, combined with 
my within-host model, I use to provide estimates of the infectiousness of infected individuals 
over time. I also consider the impact of antivirals and Wolbachia- infected mosquitoes on 
transmission. 
My aims in this thesis (and original contribution to the field) were to:  
- Develop mechanistic models describing dengue infection within a human host, linked 
to data, in order to gain greater understanding of dengue infection processes. 
- Therefore, with the model to consider:  
o Heterogeneity between individuals in infection dynamics, 
o Primary and secondary infection dynamics, and their differences,  
o Possible explanations for differences in infection dynamics between serotypes, 
o The impact of hypothetical antivirals. 
- Extend the model using additional data on antibody dynamics, with the aim of a 
gaining deeper understanding of the role of antibody in controlling dengue infection.  
- Gain a greater understanding of the infectiousness of human cases to mosquitoes over 
the course of infection, how this varies between individuals and between serotypes and 
the implications of these results for transmission and for modelling transmission.  
- Gain a greater understanding of the potential impact of Wolbachia infected mosquitoes 
and antivirals on transmission.  
Overall, I hope to add to the body of knowledge about dengue infection processes with a 
fresh approach. I introduce a method which enables us to consider the interaction of the 
different parts of the immune response and virus processes in vivo throughout infection. I 
also aim to consider what can be gained from combining a closer consideration of these virus 
and immune dynamics, with population level dynamics.  
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Chapter 2 : Data, Models and 
Methods 
In Chapter 2, I introduce the models and data used throughout this thesis to consider dengue 
within-host dynamics. The chapter begins with some background on other previous within- 
host models. A simple dengue within- host model is next presented and analytical 
approximations are explored. The relationship between parameter values, model form and 
various model elaborations and the model dynamics is further discussed with use of model 
simulations. In the next section, more elaborate secondary infection models are developed 
and the resulting dynamics considered. The data used in the model-fitting in Chapter 3 are 
presented in section 2.9, with a summary and some descriptive analysis of each dataset. The 
final section describes the methods used throughout this thesis for bringing together models 
and data. 
 Elucidating the dynamics of dengue pathogenesis, as well as being helpful in understanding 
the mechanisms of infection, is important in understanding how antivirals or vaccines may 
modify infection. Mathematical modelling of the interaction between the virus and immune 
response, validated against available quantitative data on viral kinetics, has proved a powerful 
tool for gaining such understanding in influenza and other infections, as described in Chapter 
2. Little modelling of dengue pathogenesis has been undertaken previously however. Nuraini 
et al. used a model similar to that used here to consider viral dynamics (Nuraini et al., 2009), 
but did not examine alternative modes of immune action, the difference between primary and 
secondary disease, and did not fit model output to data.  
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2.1. Within host models  
Modelling of virus dynamics within a host initially came to prominence in the field of Human 
Immunodeficiency Virus (HIV) research (Ho et al., 1995, Perelson et al., 1996) and has been 
since applied to many other infections such as Hepatitis B (HBV) e.g. (Ribeiro et al., 2002) 
and influenza e.g. (Baccam et al., 2006, Beauchemin and Handel, 2011). Within-host 
modelling has been used to consider a variety of virological and immunological questions 
and issues of treatment and control (Nowak and May, 2000). Here I briefly review the field, 
highlighting the areas relevant to my doctoral research. 
In a set of seminal papers Ho, Perelson, Neumann and colleagues (Ho et al., 1995, Perelson et 
al., 1996) examined HIV virus dynamics before and after the initiation of antiviral therapy, 
elucidating important virus properties such as the lifespan of infected cells and virus. The 
work in these papers demonstrated that viral turnover was far more rapid than previously 
thought. To date, HIV (and to a lesser extent SIV) remains the pathogen to which within-host 
modelling has been most applied and developed. More recent work has considered the 
different possible models that could describe the acute HIV infection and long-term 
pathogenesis (Ferguson et al., 1999b, Putter et al., 2000, Fraser et al., 2001, Fraser et al., 
2002, Burg et al., 2009). For example, recent work by Elemans and colleagues (Elemans et 
al., 2011) considered different modes of action of CD8 cellular immune responses in SIV 
infection. This work examined a variety of different mechanisms and, by fitting models to 
data, the authors were able to demonstrate a role of CD8 cells in controlling infection via a 
non-lytic mechanism. Though a chronic infection, the work on HIV was the real take off of 
the field of within host modelling, estimating parameters and understanding processes, which 
my work continues.  
More recently, models of acute infections such as influenza (in humans and mice) have been 
developed (Baccam et al., 2006, Lee et al., 2009, Handel et al., 2010, Saenz et al., 2010, 
Smith and Ribeiro, 2010, Miao et al., 2010). More directly relevant to the study of dengue 
(also an acute infection), influenza models have considered mechanisms limiting infection, 
with models including varying levels of complexity in the immune response represented. 
These have been fitted to nasal wash viral titre time series data from human challenge studies 
(Baccam et al., 2006) or mouse models (Miao et al., 2010), along with various measurements 
of the immune response and its function. . Innate immunity has been a focus of within-host 
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modelling of influenza pathogenesis, with one study concluding that twin peaks of virus titres 
could be generated by including both target cell regeneration and the action of IFN-α 
(Baccam et al., 2006). A role for IFN- α and -β was also hypothesised in a model of equine 
influenza (Saenz et al., 2010). In animal models, it is easier to collect data on immune 
responses, with modelling of infections in mice also showing a role for CD8+ T cells and 
IgM in limiting infection (Miao et al., 2010). The work in this thesis begins by considering a 
general immune response, but in Chapter 4 starts to build up a similar picture of dengue using 
immunological data and different models. There is still work to do before the field is as 
advanced as influenza however.  
Good overviews of influenza within-host modelling are given in papers by Smith and 
Ribeiro, and Beauchemin and Handel (Smith and Ribeiro, 2010, Beauchemin and Handel, 
2011). The study of influenza dynamics in humans has largely been limited to deliberate 
challenge studies e.g. (Baccam et al., 2006). This is because in natural infection, viral titre 
measurements are typically only initiated once symptoms develop. Indeed, most studies of 
acute infections (other than community cohort studies) recruit patients in a healthcare setting, 
meaning recruitment and sampling of patients typically only occurs several days into 
infection, meaning viral titres early in pathogenesis are unavailable. The advantage of 
deliberate challenge studies is that data is available from the early stages of infection. 
However, the observed infection dynamics may differ from those in natural infection. 
Another focus of such modelling work is the action and outcome of antiviral therapy.  In an 
acute infection, virus and infected cells are both cleared by the immune response, meaning no 
‘set-point’ equilibrium is reached (as it is in HIV or HBV infection). As noted by Smith et al., 
the lack of a steady state (and the observed virus increase and decrease) in these acute 
infection systems in the absence of treatment, means dynamics of viral clearance can be 
studied in both the presence and the absence of treatment. This is in comparison to HIV, 
where data on the perturbative impact of antivirals on viral replication was needed to 
understand pre-treatment viral dynamics (Smith et al., 2010). However, the short timescale of 
acute infections such as influenza (and dengue) compared with HIV or HBV means the 
impact of an antiviral on virus dynamics is more difficult to ascertain than for the more 
chronic viral infections. Nevertheless, the impact of antivirals and the evolution of antiviral 
resistance in influenza infection has been a topic for recent research (Handel et al., 2007, 
Beauchemin et al., 2008). 
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Heterogeneity in pathogenesis between individuals is thought to be important in determining 
clinical outcomes of infection and infectiousness. Heterogeneity in foot and mouth disease 
pathogenesis in pigs was captured by variation in the initial virus dose (Howey et al., 2009). 
Work in malaria has also considered heterogeneity in infection for plasmodium chabaudi, a 
rodent parasite (Mideo et al., 2011). Work by Mideo et al. found evidence for differences in 
parasite production rates between strains, and also in the host immune response interaction 
with different strains (Mideo et al., 2008b). In the work that follows in this thesis I will 
consider heterogeneity between patients with dengue infections, and attempt to understand 
the mechanisms that could have created such heterogeneity. 
A large body of more theoretical immunological modelling has also been undertaken. Early 
work by de Boer and others considered, for example, a general theoretical framework for T 
cell antigen presentation and proliferation (Deboer and Perelson, 1995), and more realistic 
descriptions of the removal of virus (De Boer et al., 2001, Ganusov and De Boer, 2008, 
Ganusov et al., 2011). This thesis mainly does not go into such detail on proliferation 
processes, but uses simplifications based on this work. The fitting of such models to data has 
developed considerably in recent years. Qualitative comparison to data and quantitative 
fitting are still both commonly used, though the latter is becoming more prominent, with 
increasingly sophisticated statistical techniques being used e.g. (Putter et al., 2002, Howey et 
al., 2009). I undertake both quantitative fitting using MCMC and also consider qualitative 
model dynamics in the following work.  
While malaria pathogenesis has been well studied in the modelling literature (Day and 
Fowkes, 2011, Metcalf et al., 2011) to date only one model of dengue pathogenesis has been 
published (Nuraini et al., 2009). This undertook a largely equilibrium analysis of the 
replication dynamics of virus and an adaptive immune response and concluded that the ‘virus 
invasion rate’ (the rate determining how easily virus enters uninfected cells) and the growth 
rate of the immune response determine the ‘intensity of infection’ (the highest virus titres 
reached) (Nuraini et al., 2009). However, analysis of the equilibrium of such models is of 
little relevance to pathogenesis, as in reality the system never reaches equilibrium. Rather 
different work (using ensemble models inspired by statistical physics, rather than within-host 
dynamical models) has also considered the interaction between a dengue vaccine and the 
immune response, highlighting the possible importance of multiple injection sites (Zhou and 
Deem, 2006). 
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Experimentally, the lack of realistic animal models of dengue infection has been a major 
challenge in understanding the detailed mechanisms of pathogenesis. This, plus the intrinsic 
difficulties associated with observing virus dynamics in vivo, and the many unanswered 
questions around dengue immunology, means that mathematical models of dengue 
pathogenesis represent a useful tool for identifying key processes and reducing uncertainty.  
2.2. A model of dengue pathogenesis 
2.2.1. Model description and assumptions 
Here, I present a mathematical model of the pathogenesis of dengue infection within an 
individual which describes the interaction between viral dynamics and a simplified 
representation of the host immune response. 
The model describes uninfected target cells (x), infected target cells (y) and free virus 
(virions) (v). Free virus infects target cells via a mass-action process with rate , and infected 
cells produce virions at rate . The model incorporates a simple immune response (z) that 
grows at a rate which is some function of the infected cells, virus and immune response 
levels. The immune response is trying to halt infection by either removing infected cells or 
virus. Virus and cells (infected or not) have a finite lifespan. This basic model is detailed in 
Equation 2-1 and shown graphically in Figure 2-1.  
( )
( , , )
dx
A x xv
dt
dy
xv y zy
dt
dv
y v zx
dt
dz
f v y z
dt
 
  
  
  
  
  

 
Equation 2-1: Basic model system equations.  
Variables of the model are: uninfected target cells (x), infected target cells (y), 
population sizes of free virus (v) and an immune response (z). Parameters of the model 
and their meaning are given in Table 2-1.  
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Using a single state variable for the immune response is clearly a gross oversimplification, 
but in the absence of detailed immunological data to fit the model to, a more complex 
representation cannot currently be robustly parameterised. I discuss extensions to the model 
later in this chapter. 
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Figure 2-1: Graphical representation of the model. Grey virus, Purple cells uninfected 
cells, red infected cells, and pink immune response cells. 
 
Parameters of the model are defined in Table 2-1. Of note is β, which governs the rate of the 
mass-action process by which virus infects uninfected target cells. 
Target cells are produced at a constant rate (A) and have a mean lifespan 1/. Infected cells 
have a mean lifespan in the absence of the immune response of 1/. The mean lifespan of free 
virus in the absence of the immune response is 1/. In adopting the compartmental formalism 
given in equation 1, I am implicitly assuming that the life spans of uninfected cells, free virus 
and infected cells are exponentially distributed.  
The immune response proliferates at a rate specified by the function f, discussed in greater 
detail later. The initial size of the immune effector population is z0. Immunity acts by clearing 
infected cells (again via a mass action process) at rate  (later, I also consider a model variant 
in which the immune response acts by clearing free virus, at rate ε). I assume the target cell 
population is at equilibrium before infection, so x0 = A/ and y0=0, z0 =1, v0 =1. 
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Parameter Meaning 
A Constant target cell production 
γ Cell death rate/day 
β Infection rate of target cells per virion 
α Removal rate of infected cells/day per immune cell 
ε Removal rate of virions/day per immune cell 
δ Infected cell death rate/day 
ω Production rate of virions/day per infected cell 
κ Virion clearance rate/day 
Table 2-1: Parameters of the basic model  
Model equations are given in (Equation 2-1). Symbol and description of each parameter 
are given. 
 
2.2.2. Reproduction number 
The basic reproduction number is the number of infected cells produced by one infected cell, 
or the number of virions produced by one virion, at the start of infection. This expression is 
the product of the average number of virions produced by an infected cell () and the 
average number of cells infected per virion (x0). With the immune response removing 
infected cells, the basic reproduction number of this model system is given by  
   
    
   
  (Nowak and May, 2000) where 0=+z0. Initially, the immune response 
term may be small enough to ignore. Throughout the infection  
   
  
  where =+z. 
Equation 2-2: R0 and R expressions. 
2.3. Approximate analytical solutions 
The model is sufficiently simple to consider analytically. Analytical solutions help consider 
how model parameters govern the different stages of infection, which in turn help understand 
what is necessary for control (both naturally by the immune system and by interventions such 
as antivirals). A full understanding of the trade-offs between parameters in the model is also 
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important for interpreting the results obtained when fitting to data in later sections. I derive 
approximate analytical expressions for the initial growth rate of infected cells and virus, for 
the eventual rate of clearance of virus, and some results concerning the peak virus. Assuming 
the simplest mass-action mixing model, I use f = ηyz as the form of the immune response 
growth function. I also assume the immune response is removing infected cells (α>0, ε=0). 
2.3.1. Early growth 
It is possible to consider the two phases of the viral curve (growth and decay) separately. I 
linearise the model system in each phase, and find solutions for v (virus) and y (infected 
cells). During early growth, the linearised equations (in the absence of immunity) are:  
  
0
dv
y v
dt
dy
v y
dt
 
 
 
 
 
Equation 2-3: Linearised early growth equations.  
Here x is assumed to be constant at the early stage of infection x=x0 = A/γ, and 
z0. Immune response growth is assumed negligible in this period, though the z0 
term could also be ignored if z0 or are small enough. 
 
These can be solved to give: 
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Equation 2-4: Solution to the linearised early growth equations (Equation 2-3). 
Given that 2 is always < 0, in order for there to be growth we need 1>0, which requires 
 (or equivalently, R0>1). 2 decays to zero quickly, and growth is determined by 1. 
The doubling time is given by log 2/1. 
Another approximation for the early growth rate can be derived using the expression linking 
R0, the early growth rate and the generation time: R0=1 +g (Anderson and May, 1992), 
where g is the generation time of infection and is the growth rate. Under the assumption that 
z), (i.e. initially infected cell lifespan is much greater than virus lifespan), 
g=1/(z0). Using the expression for R0 above (Equation 2-2), this gives us 
 = (x0/–  – z0. 
Equation 2-5: Approximation of initial viral growth rate (, assuming initially infected 
cell lifespan is much greater than virus lifespan. 
We use this lambda approximation when considering the secondary infection processes.  
2.3.2. Viral peak 
The viral peak is more difficult to approximate, as the full system contributes to dynamics at 
this point, and the immune response cannot be assumed to be at equilibrium. 
The peak occurs when dv/dt = 0, which gives us v in terms of y, with βx assumed constant 
(only a reasonable assumption if it is assumed that target cells are not greatly depleted by 
infection). Thus we have a system of two equations in only y and z: 
( )
dy x
z y
dt
dz
yz
dt
 
 


 
   
 

 
Equation 2-6: Approximation around the peak of virus.  
Substituting in the early growth solution for y into the dz/dt equation it is possible to get an 
expression for z. Substituting this back into the dy/dt equation one can find a solution for y 
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(and, using v = ωy/κ, a solution for v) at the peak. Unfortunately, this solution says nothing 
about the timing of the peak, and indeed relies on us assuming a value for the time of the 
peak. 
Alternatively, it is possible to find an implicit solution for y and z. Dividing dy/dt by dz/dt 
gives 
( )
( )
x
z y
dy
dz y z
 
 

 
 
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 


 
Solving between initial y and z ( ,o oy z ) and peak y and z ( ,P Py z ), we get a transcendental 
equation for yp = 
0
( ) ln ln ( )
pP
P o P o
o
zy x
y y z z
y z
 
  

  
      
   
. 
Let vp denote the peak titre. Using the fact that at the peak dv/dt = 0, we get y = κv/ω, and can 
hence get a value for vP. However, for this equation to be useful, we still require information 
on the value of zp.  
It is also possible to consider the timing of the peak. We know that at the peak, R=1 so 
x+z) (from Equation 2-2). From this equation, if we assume no target cell 
depletion, the value of z at the peak can be given by 0
1
p
x
z


 
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   
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Rearranging this we get:  
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0
v
y


 . 
For these approximations to be of use there is further work to be done. 
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2.3.3. Decay 
The linearised equations for the decay of virus are: 
dv
y v
dt
dy
v y
dt
 
 
 
 
 
Equation 2-7: Linearised decay equations.  
Here  =δ + αz (z assumed constant), still assuming x is constant. 
 
These equations have solution: 
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Equation 2-8: Decline phase approximation solution. 
 (i.e. solution of Equation 2-7). Subscript P denotes the values of y at which the 
approximation of constant z becomes valid (soon after the peak).  
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4 is always less than 0, but in order for 3 to be less than 0, and therefore for decay to be 
occurring we require ωθ  < ρ  (i.e. R<1). 
2.4. Distinguishable parameters 
In the absence of data on the size of the target cell or immune response populations, not all 
parameters are independent. Substituting x’=x/A, y’=y/A, v’=v, z’=z in the differential 
equations in Equation 2-1. (reducing the dimension of the system) demonstrates that of ,  
and A, only A (Burg et al., 2009) and A can be estimated independently. Similarly only z0 
can be estimated, not  and z0 independently. In addition, estimates of  and  are expected 
to be inversely correlated. 
2.5. Sensitivity of model dynamics to parameter values 
I next explore the sensitivity of the dynamics of the simplest model to parameter assignments, 
and how these parameters interact to determine dynamics. This is useful for understanding 
model drivers and for interpreting the results from fitting the model to data. The immune 
response proliferation form f = ηyz is again used here.  
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Figure 2-2: Sensitivity of model dynamics to parameters.  
Viral dynamics shown for R0 values of 20, 30, 40, 50, 60 and 70 by varying (from top left 
to bottom right) parameters β, κ, A, δ, α and η one at a time given baseline parameter 
values (which result in R035) of β = 3x10
-11
, α=0.1, ω=10000, η=10-5, κ=3.5, δ= 0.14, 
γ=0.14, A=1.4x107. η (which does not affect R0) was varied with the following values: 10
-
6
, 3x10
-6
, 5x10
-6
, 10
-5
, 5x10
-5
,1x10
-4
 and 5x10
-4
.   
Figure 2-2 shows the sensitivity of viral dynamics to model parameters, varying each 
parameter one parameter at a time. Except for η (which does not determine R0), I vary each 
parameter by stepping through the following set of values of R0:  20, 30, 40, 50, 60 and 70.  
As would be expected from the analytical expressions Equation 2-4 and Equation 2-5, we see 
that increasing  (virus entry to cell) or A (target cell recruitment) increases R0 and viral 
growth rate and causes earlier peaking of virus. Increasing  (virus clearance rate) reduces R0 
and viral growth rate, leading to virus peaking later. Increasing η (immunity proliferation 
rate) also moves the peak earlier by achieving earlier control of virus, but with no impact on 
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initial viral growth rates. Variation in  (immune mediated clearance rate of infected cells) 
have a subtle impact: as expected, initial viral growth rates are not substantially affected, but 
increases in this parameter cause immune control of virus replication (and therefore the peak 
of viral load) to occur earlier, but since immune cell populations peak at a lower level, viral 
load decays more slowly thereafter. Model dynamics are relatively insensitive to the value of 
 (infected cell death rate in the absence of immunity), justifying the choice not to fit this 
parameter.   
2.5.1. Elaborating the model 
The model parameters used in this section were obtained by preliminary fitting in Berkeley 
Madonna
TM
 and using the sensitivity analysis presented above. See Section 2.8.3 for more 
discussion of parameter values and which parameters were fit to data in the full model fitting. 
2.5.1.1. Infection process  
The infection process is governed by the target cells, the virus entering the cells and the 
production of more virus by these infected cells. The complexities of virus replication within 
the cell and the processes that are involved in the virus entering the cell could be considered 
in more detail. The cell entry process could be modelled in more detail, for example using 
logistic functions, but that was considered an unnecessary complication for the work here. It 
would be more realistic to have a lag before a newly infected cell can begin producing virus, 
representing the processes that must occur in the cell before new virions can be released 
(Rico-Hesse, 2003). The simplest way is to create another infected cell compartment. There is 
now y1 and y2, infected cells move from y1 to y2 at a rate τ and only y2 can produce virus. 
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Equation 2-9: Differential equations for delay in the virus production of one day (τ=1).  
Example dynamics from this model are shown in Figure 2-3 with a delay of one day. We see 
that similar dynamics can be reproduced in a model with or without a delay. Figure 2-3 
shows dynamics of the model with parameters the delay model ω=1x105 and A=1.4x106 and 
for the non-delay model ω=1x104 and A=1.4x106. These parameter values produce a peak 
time and titre roughly consistent with the data (see later sections) for both models. The delay 
model requires larger virus production than the non-delay to produce similar model 
dynamics. This would imply that if there truly is a delay in the production of virus occurring, 
our model without delay will underestimate the true values of ω and A.  
 
Figure 2-3: Dynamics of the model with a delay in virus production.  
Black lines show log10 (virus) (full line) and log10 (immune) (dashed line) dynamics with 
a delay in virus production. Pink lines show virus and immune dynamics without a 
delay in virus production. Parameters: β= 3x10-10, α= 1, η =1x10-4, κ= 3.5, δ= 0.14, γ= 
0.14, with ω=1x105 and A=1.4x106 for the delay model (black line) and ω=1x104 and 
A=1.4x10
6
 (pink line) for the non-delay
 
model. Delay was taken to be 1 day. 
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A second structural modification which could be made to the model would be to consider 
explicitly populations of different types of target cells. For instance, by including two 
populations of target cells with different infection rates and lifetimes, it is possible for the 
model to produce biphasic decay of viral titre.  
In relation to viral entry into target cells there are two main factors to consider: the proportion 
of virions that are infectious and the rate at which these virions infect cells. Varying 
assumptions about both can be incorporated via parameter value changes, though it is also 
straightforward to explicitly model populations of infectious and non-infectious virus.  
2.5.1.2. Immune response 
I first consider how the immune response proliferates in response to infection, represented in 
Equation 2-1 with the generic function f (). To start, I considered the default proliferation 
function assumed in the results presented so far (i.e. of the mass-action form f (v, y, z) = ηyz), 
where the rate of proliferation scales linearly with infected cell density (see Figure 2-2). In 
this model the immune response peaks at the same time as the virus, the value of the 
replication rate of the immune response as y increases is shown in Figure 2-4.  
 
Figure 2-4: Proliferation rate of y form of the immune response growth as y increases. 
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 I next consider a saturating immune response proliferation rate of the forms  
f (v, y, z) = 1
2
yz
y

 
 (1), or 1
2
yz
z

 
 (2) 
Equation 2-10: Alternative immune proliferation forms 
Work by de Boer and Perelson (Deboer and Perelson, 1995) showed these functional forms to 
be a short-timescale approximation to models which explicitly incorporate antigen 
presentation and immune cell activation. For (1) from Equation 2-10, it is possible for the 
peak of the immune response to occur after the peak of virus (and infected cells). This is not 
possible for (2) from Equation 2-10.  
 
Figure 2-5: Proliferation rate of y/(y) form of the immune response growth as y 
increases. 
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Another way to represent the antigen presentation process is via explicit delays, so the growth 
rate of z at time t is dependent on the viral titre at a previous time point (for example a day 
before). Using delay differential equations, I found that this model produces recognisable 
virus dynamics (i.e. virus increase, peak and decrease) in a much smaller region of parameter 
space, though this is not a reason to reject this model. However, the peak in the immune 
response can, as with the logistic form above, occur later than the virus peak.  
Halstead (Halstead, 2008) groups immune responses as resistance to infection (antibody 
removing virus before it infects cells) and elimination of infection (T cells removing cells 
once infected). The dominant action of immunity - whether removing infected cells or 
removing virus – is also critically important in understanding the dynamics of pathogenesis 
and potential impact of vaccines and/or treatment. I will discuss in Chapter 3 the main 
immune responses for dengue and how they link with the work presented here.  
In the simplified model considered in this chapter, I consider both types of action separately, 
namely the two scenarios: (a) α > 0 and ε = 0, representing only cytotoxic T-cell or antibody-
dependent cell-cytotoxicity, and (b) ε > 0 and α = 0, representing a virus-neutralising 
antibody-type immune action. Work by Baccam et al. (Baccam et al., 2006) on influenza 
concludes that it is not possible to determine the relative contribution of each mode of action 
with only virus titre data.  
In contrast to the scenario when the immune response removes infected cells, if immunity is 
clearing virus, the virus and infected cells can have different decay rates, depending on the 
form of immune response proliferation, strength of the immune response and the lifespan of 
virus and infected cells. There is evidence from monkey models that infected cells may be 
around longer than virus (Marchett.Nj et al., 1973), but this has not yet been quantified in 
human infection.  
2.6. Representing secondary infection  
Significant uncertainty remains regarding how the pathogenesis of secondary infection differs 
from primary (Martina et al., 2009). Multiple theories (namely antigenic sin and antibody 
dependent enhancement) are currently proposed for the infection and immunological 
processes occurring during a secondary dengue infection, as reviewed in Chapter 1. Here, I 
focus on the dynamical implications of these alternative hypotheses, rather than the effect of 
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these on the severity of disease. Since the models of these more complex processes are 
analytically intractable, it is necessary to rely on numerical solutions to explore model 
dynamics.  
 
I will briefly focus on the dynamics of models including these secondary processes compared 
to the dynamics of a primary model (without additional secondary processes) and how these 
dynamics vary for outcomes such as virus increase and decrease and virus peak timing and 
titre. In these simulations I additionally consider the target cell and the dynamics of the 
different immune response populations modelled. In reference to the early infection period I 
consider the  approximation for the early infection growth (Equation 2-5) and R0 (the 
reproduction number) (Equation 2-2). With R0, I discuss whether a primary infection with an 
R0 < 1 (i.e. one in which virus would be unable to grow significantly before being cleared) 
could become established in a secondary case. This is of relevance because there are more 
secondary infections observed in healthcare-based surveillance (for example in the data 
presented later in this chapter). This is could be because secondary infections tend to be more 
severe, meaning more cases seek healthcare. However, there is also the possibility that due to 
these immune processes secondary infection establishes more easily than primary (effectively 
meaning individuals who have been infected once are more susceptible to infection with 
heterologous dengue serotypes than fully naïve individuals).  
2.6.1. Baseline primary model 
The baseline primary model used for comparison to the secondary models is given in 
Equation 2-11, with the parameters in Table 2-2. The model is similar to that presented in 
Equation 2-1, but with a few additions. The variables of the model that are similar to 
Equation 2-1 are: x cells, y infected cells, v virus, and zc2 specific immune response against 
infected cells. The difference between models comes in explicitly modelling the complexes 
of infected cells and immune response ((yzc2)). The infection processes continue as in 
Equation 2-1, with virus entering cells and reproducing, and the immune response attempting 
to stop this process by removing infected cells. The addition of immune response complexes 
means additional processes must be modelled. These are  the formation (at rate c2and 
dissolution of these complexes (at rate c2and the ultimate clearing of complexes (at rate 
ρc2so the infected cells are completely removed).  
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The specific values of the parameter values are not of importance, but were chosen following 
the sensitivity analysis in section 2.5 to recreate the primary acute infection dynamics. The 
immune response parameters must be adjusted as the processes modelled are different (see 
above) and in the current model the immune response is depleted by binding to infected cells 
(not the case in the previous model). Therefore the parameters of the immune response 
growth (c2, attachment of infected cells (c2 complex dissociation (c2and clearance rates 
of complexes (μc2were adjusted so the lifespan of complexes is on the order of days to 
weeks and that the acute primary dynamics were still recreated. These are the parameters of 
the primary immune response. It is then the relative values of the secondary parameters to 
these primary values that are of importance. For each secondary model these are given in the 
following sections. 
Parameter Parameter Meaning Parameter Values 
A Target cell regeneration 1.4x10
6
 
γ Target cell death rate 0.14 
ω Virus production 104 
κ Virus death rate 3.5 
δ Infected cell death rate 0.14 
β Rate virus entry 2x10-10 
αc2 Rate of attachment of specific immune response 1x10
-4
 
ρc2 Rate of dissolution of complexes 0.2 
μc2 Clearance rate of complexes 10 
η (ηyz) Proliferation of specific immune response 3x10-3 
z0 
Initial number of immune cells 
cells/virus 
1 
Table 2-2: Parameters of the baseline primary model  
Model equations given in (Equation 2-11). 
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Equation 2-11: Baseline primary model.  
Variables of the model are: uninfected target cells (x), infected target cells (y), 
population sizes of free virus (v), a specific immune response against infected cells (zc2 )  
and infected cell-immune complexes ((yzc2 )). The function f governs the immune 
response growth, here f = ηyz. Parameter values are given in Table 2-2.  
  
2.6.2. Antigenic sin model 
The first secondary model models antigenic sin. The theory of antigenic sin is that during a 
secondary infection a memory immune response (to the previous serotype) is first activated, 
but is not sufficient to control virus. This memory immune response however blocks the 
binding and/ or proliferation of an effective immune response (Halstead et al., 1983, 
Mongkolsapaya et al., 2003, Midgley et al., 2011). We do not explicitly model the primary 
infection, though this equally could be a tertiary infection, with both the primary and 
secondary infection serotypes influencing the model parameters. Modelling this process 
therefore begins with including two immune cell populations proliferating during secondary 
infection. Assuming both immune responses attempt to clear infected cells these are a 
memory cell response (zc1), and an immune cell specific to the virus serotype seen in the 
secondary infection (zc2). Equation 2-12 gives the equations for the model and Table 2-3 the 
parameters. The virus processes are as in the primary model. The first (memory) immune cell 
population generates antibodies or T cells, starting from a high level, and proliferating at the 
same rate as in a primary infection. These bind with low avidity αc1 to infected cells to create 
infected cell-immune response complexes, which dissociate readily at rate ρc1. The complexes 
are cleared at a low rate μc1. The second (specific) immune cell population generates 
antibodies or T cells from a low initial level. These also proliferate at the same rate as the 
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primary immune response. These however bind with high avidity αc2 to infected cells to 
create infected cell-immune response complexes, which dissociate less readily at rate ρc2. The 
complexes are cleared more quickly at rate μc2. All the parameters governing the specific 
immune response processes are the same as the primary immune response. The memory 
immune response, when bound to infected cells, blocks binding by the second (more 
effective) specific immune cell population (binding at rate memory αc1 < specific αc2). The 
specific immune response is more effective than the memory immune response as it is less 
likely to dissociate from the complexes than the memory response (memory ρc1 < specific 
ρc2), and the complexes are removed more effectively (memory μc1 < specific μc2). This is 
because the specific immune response will be a better “fit” to the virus and more “sticky” 
than the memory, which was generated in response to the different primary infecting 
serotype. The memory immune response begins at a higher level than the specific response 
(memory z0c1 > specific z0c2), as the immune response is already “primed” to produce this 
response. This is one way of modelling the competition between the immune cell 
populations.  
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Parameter Parameter Meaning Parameter Values 
A Target cell regeneration 1.4x10
6
 
γ Target cell death rate 0.14 
ω Virus production 104 
κ Virus death rate 3.5 
δ Infected cell death rate 0.14 
β Rate virus entry 2x10-10 
αc1 Binding avidity of memory immune response to infected cells 1x10
-5
 
αc2 Binding avidity of specific immune response to infected cells 1x10
-4
 
ρc1 Rate of dissolution of complexes 
memory 
1 
ρc2 Rate of dissolution of complexes 
specific 
0.2 
μc1 Clearance rate of complexes memory 1
 
μc2 Clearance rate of complexes specific  10 
ηc1 (ηyz) Proliferation of immune response 
memory (ηyz form) 
3x10
-3
 
 
ηc2 (ηyz) Proliferation of immune response 
specific (ηyz form) 
3x10
-3
 
 
z0c1 Initial size of memory immunity population 10
3
 
z0c2 Initial size of specific immunity population 1 
 
Table 2-3: Parameters used for the secondary antigenic sin model.  
Model equations given in Equation 2-12, where subscript c1 is the memory immune 
response against infected cells and c2 is the specific immune response against infected 
cells.  
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Equation 2-12: Model equations for the antigenic sin model.  
Variables of the model are: uninfected target cells (x), infected target cells (y), 
population sizes of free virus (v), memory immune response against infected cells (zc1), 
specific immune response against infected cells (zc2), infected cell-immune complexes 
((yzc1)) and infected cell-specific immune complexes ((yzc2)). The function f governs the 
immune response growth, here f = ηyz. Parameter values are given in Table 2-3.  
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Figure 2-6: Comparison of antigenic sin model and primary model. 
Immune responses removing infected cells. The figure shows log10 of model outputs, 
with primary model shown for comparison. The immune response proliferation is of the 
form f= ηyz. Thick lines are primary model; dashed lines are secondary antigenic sin 
model. Black: target cells, Red: Virus, Green: Infected target cells, Dark Blue: specific 
immune response, Light Blue: specific immune response- infected cell complexes, and 
(only in secondary model) Orange: memory immune response, Yellow: memory 
immune response-infected cells complexes. Parameters for primary model are given in 
Table 2-2 and the model system in Equation 2-11. Parameters for the secondary 
antigenic sin model are given in Table 2-3, model system in Equation 2-12. 
 
 
Figure 2-6 dashed lines shows the dynamics of the antigenic sin model (Equation 2-12 with 
parameters in Table 2-3) in comparison to the primary model, full lines (Equation 2-11 with 
parameters in Table 2-2). Early dynamics are similar between the two models, the differences 
occurs around the virus peak (red lines), which is slightly later and higher in the primary 
model. The specific immune response, despite proliferating at the same rate as in the primary 
case, reaches lower levels in the secondary model than in the primary, with the memory 
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immune response reaching higher levels than the primary. The specific immune response 
complexes also reach a lower level in the secondary model than in the primary, with the 
memory immune response forming similar numbers of complexes as the primary immune 
response in the primary case. The greatest difference in virus dynamics is then seen in the 
decline rate of virus (and infected cells and complexes). In the primary model all (virus, 
infected cells and complexes) sharply decline as the immune response effectively reduces the 
lifespan of the infected cells (by binding to complexes and then complex clearance). This 
reduction in infected cell lifespan is less in the secondary case, due to the high numbers of 
memory immune response complexes that are not being cleared as effectively as the specific 
immune response complexes, leading to a slower decline rate. The memory immune response 
bound to the infected cells is also stopping the infected cells becoming bound with specific 
immune response and therefore more effectively cleared.   
 
From the model we can see that the antigenic sin process as modelled here has little impact 
on the early dynamics. If we consider this with R0 and the  expressions from Equation 2-2 
and Equation 2-5 we see that the antigenic sin will have an impact on the z0 term (though 
these expressions do not consider the complex-forming processes modelled here). Though a 
change in the z0 term could alter the expressions of early growth and R0, the impact on 
dynamics of the clearance terms early in infection is small compared to the virus replication 
terms (not altered by the antigenic sin processes), and the virus (infected cells) clearance 
z0), is governed by the (at this stage) much larger .   
 
2.6.3. Antibody dependent enhancement model 
The second secondary process modelled is antibody dependent enhancement (ADE). The 
theory of ADE is that the memory antibody response proliferating in a secondary infection 
binds to virus but does not neutralise it. Instead virus is still able to enter cells and indeed 
these complexes may infect cells more readily than virus alone (Dejnirattisai et al., 2010). 
The model of enhancement is given in Equation 2-13 and the parameters in Table 2-4. In this 
model of enhancement, the memory antibody population (zv1) binds to virions to form 
complexes ((vzv1)). Virus in these complexes is still able to infect cells at rate βE, and indeed 
infects cells more easily than free virus (βE > β). This process is added to the virus 
reproduction process shown in Figure 2-7. Within in the model equations this means the virus 
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production process is altered, with the addition of (βE x (vzv1)) to the term governing the rate 
at which target cells become infected. The virus production occurs as in the primary model. 
The virus- memory immune response complexes (vzv1) dissolve at rate v1 so returning virus 
to its unbound state (v), but the complexes can also be cleared (and therefore not able to 
infect cells) at rate μv1.Once again the binding, dissolution and complex removal process is 
explicitly modelled here. To control the infection, a specific immune response (zc2) develops 
(as in a primary infection) which effectively removes infected cells (once again via 
complexes which can dissolve or be cleared). Parameters for the specific immune response 
are as in the primary model. As the memory immune response is binding to virus not infected 
cells, the rates are not directly comparable, but were set so that zv1 proliferates similarly to zc2. 
The clearance of virus-memory immune response complexes was set to be less than infected 
cell- specific immune response complexes, but it could be considered to be the same. The 
virus – memory immune response complexes were set to infect cells at a rate (βE), 10
3
 times 
larger than viruses not in complexes (β). 
 
Figure 2-7: Schematic of the antibody complex process. 
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Table 2-4: Parameters of the antibody dependent enhancement model. 
Detailed in Equation 2-13, where subscript v1 is the memory immune response against 
virus and c2 is the specific immune response against infected cells.  
  
Parameter Parameter Meaning Parameter Values 
A Target cell production rate 1.4x10
6
 
γ Target cell death rate 0.14 
ω Virus production rate per infected cell 104 
κ Virus clearance rate 3.5 
δ Infected cell death rate 0.14 
β Rate virus entry to target cell 2x10-10 
βE Rate of complex entry to target cell 2x10
-10 
/ 2x10
-9
/2x10
-8
/ 
2x10
-7
 
αv1 Rate of attachment of memory immune response to virus 1x10
-5
 
α c2 Rate of attachment of specific immune response 1x10
-4
 
ρv1 Rate of dissolution of virus-memory complexes 1 
ρc2 Rate of dissolution of specific complexes 0.2 
μv1 Clearance rate of virus-memory complexes 1 
μc2 Clearance rate of specific complexes 10 
η v1 (ηvz) Proliferation of memory immune response (ηvz form) 3x10
-4
 
ηc2 (ηyz) Proliferation of specific immune response (ηyz form) 3x10
-3
 
z0v1 Initial size of memory immune population 10
3
 
z0c2 Initial size of specific immune population 1 
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Equation 2-13: Model equations for the enhancement model. 
Variables of the model are: uninfected target cells (x), infected target cells (y), 
population sizes of free virus (v), memory immune response against virus (zv1), specific 
immune response against infected cells (zc2), virus-memory immune complexes ((vzv1)) 
and infected cell-specific immune complexes ((yzc2)). The function f governs the immune 
response growth. Parameter values are given in Table 2-4. 
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Figure 2-8: Comparison of antibody dependent enhancement model and primary model 
βE = 2x10
-7
. Specific immune response removing infected cells: The figure shows log10 of 
model output with primary model shown for comparison. Thick lines primary model, 
dashed lines secondary ADE model. Black: Target Cells, Red: Virus, Green: Infected 
target cells, Dark Blue: specific immune response, Light Blue: specific immune 
response- infected cell complexes, and (only in secondary model), Purple: memory 
immune response to virus, Pink: memory immune response – virus complexes. 
Parameters are given in Table 2-4 model in Equation 2-13. 
 
Figure 2-8 dashed lines shows the dynamics created by the ADE model (Equation 2-13 with 
parameters in Table 2-4) in comparison to the primary model, full lines, (Equation 2-11 with 
parameters in Table 2-2). With this model of enhancement in secondary infection, a faster 
initial increase in virus titres is generated than in primary infection (see red lines). This is due 
to the memory immune response binding with virus and increasing virus entry to the cell 
early in infection. Due to this faster virus increase, the peak also occurs earlier in the 
secondary model. In the current model this peak is lower in the secondary case than in the 
primary, as the immune response controlling infection (by removing infected cells) is 
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proliferating proportional to the infected cells which have also reached much higher levels by 
early in infection and therefore the immune response is at high enough levels to control 
infection, earlier. The virus peak in this secondary model is very sharp.  
 
For E values of 2x10
-7
 to 2x10
-8
 we see the greater rate of virus increase in secondary than 
primary as shown in Figure 2-8. For E values of 2x10
-9 
and 2 x10-
10 
(the latter the same as 
the non-immune complex viruses)
 
, the virus increase rate does not change from the primary 
and secondary infections, but the virus peak is less in the secondary case. This lower peak is 
due to the ADE process additionally removing virus from the blood, and the increased rate of 
virus entry is not sufficiently large to produce a sufficiently greater number of infected cells 
to go on to produce more virus.  
 
If we think about the ADE process with λ and R0 expressions, we see these processes will 
bring about a change in β. This will lead to an increase in both expressions and therefore an 
increased viral growth rate as seen in Figure 2-8, and the possibility of infections establishing 
that could not before (R0<1 to R0>1). 
 
Within the full model dynamics, the high immune response leads to an initial steep decline in 
virus titres in the secondary case (steeper than in the primary case). However the virus (and 
infected cell and immune complexes) decline rate is then slower, as the virus-immune 
complexes are cleared at a slower rate than the infected cells. This need not be the case, 
indeed assuming a greater clearance rate of virus-memory immune cells complexes leads to a 
sharper decline from peak to clearance in the secondary case (this can be justified as there is 
nothing in the theory which determines how strongly these complexes are cleared- unlike in 
the antigenic sin model). 
 
Also of interest is the target cell dynamics in the ADE secondary model. In the primary 
model we were in a regime with no target cell depletion during infection. Generally in the 
primary model if target cell depletion does occur, it happens at the time of the peak. In the 
ADE secondary model however target cell depletion does occur, but not until after the peak 
of infection. This is because of the delay introduced as the virus enters complexes and then 
infects cells (possibly depleting them in the process).  
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It is not clear whether as the virus is non-neutralised in virus-memory immune response 
complexes if the virus in these complexes would still be picked up by PCR or if other 
measurements of these complexes are needed. If both virus and virus in immune complexes is 
counted, then in this model the virus would also reach a higher peak (as well as faster peak) 
in a secondary infection compared to primary.  
2.6.4. Other processes 
Even with the added processes, these models are still simple representations of very elaborate 
processes of a secondary dengue infection, with much uncertainty. The antigenic sin model is 
perhaps more complete, with it being clear that unless in the primary case the immune 
response is having an impact early in infection, antigenic sin will not alter this stage of 
infection. One area of uncertainty however is whether cells bound with memory-response can 
still produce virus (they cannot in the model here). Between the two immune responses 
(memory and specific) there may also be differences in proliferation forms, and the 
competition could be more explicitly modelled with the proliferation linked to binding, or in 
with limits on the total overall immune production rates. The differences between the 
memory and specific immune responses could also be modelled in the levels of occupancy of 
the infected cell required for the complex to be cleared. The immune response binding to 
virus should also be considered, i.e. antigenic sin in neutralising antibody.  
For the ADE model there are many other ways this process could be modelled. In explicitly 
modelling the levels of occupancy it could be modelled such that the memory immune 
response is able to clear the virus but requires higher levels of occupancy than the specific 
immune response in order to do this, and at lower levels of occupancy with the memory 
immune response, enhancement is possible. A model that explicitly models this occupancy 
process would be the next stage in modelling secondary infection. Modelling occupancy will 
also aid in thinking about how exactly these processes work, and the link between what is 
measured and the subsequent immunological processes. An example of this will be with the 
assumption of “sub-neutralising” antibody titres and how these titres via occupancy could 
lead to ADE.  This process could be modelled by moving through occupancy level 
compartments, or could be simplified using a logistic approximation of this process. Further 
work will consider these models and their dynamics in more detail.  
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It has also been shown in vitro that cells infected via ADE produce more virus (Boonnak et 
al., 2008, Kou et al., 2011). This would lead to an increase in the parameter ω in the model, 
which would also lead to an increase in early growth, R0 and λ.  
Another way ADE is hypothesised to work is by non-infectious virions becoming infectious 
when in immune response complexes (Rodenhuis-Zybert et al., 2010a, Voorham et al., 2012). 
This would work in a similar way as the ADE modelled here by increasing . A model in 
which the specific immune response binds to virus should also be considered in further work. 
An additional way in which the ADE process could affect the dynamics would become 
apparent in the model with the specific immune response removing the virus not infected 
cells (as assumed in the previous ADE models). In this case, the virus in memory immune 
response complexes would be “hidden” from the immune response and therefore cannot be 
cleared and is still able to infect cells. The dynamics of this should be explored in further 
work.  
Of course not all parameter regimes were considered, but this work takes the first steps at 
mechanistically considering the processes at work during a secondary dengue infection and 
how these possibly detrimental immune responses fit in with the full infection, remembering 
dengue is still an acute infection, even in secondary infection.  
2.7. Data 
Here I describe the data used in the Chapter 3 to fit the models of virus and immune kinetics 
throughout infection.. The first dataset is hospital based, so the second community based is 
used to assess any bias in these cases due to possible differences in severity between these 
and community cases.   
 Dataset 1  Dataset 2 (Duyen et al., 
2011) 
Setting Hospitalised cases, in a 
clinical trial 
Community cases 
Serotypes DENV1 and DENV2 DENV1, DENV2 and 
DENV3 
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Disease severity DF and DHF unknown 
Table 2-5 : The two datasets presented in this chapter.  
2.7.1. First dataset (Tricou et al., 2010, Tricou et al., 
2011) 
The initial data used to parameterise the simplest model were collected during a clinical trial 
of chloroquine in male adult patients conducted in 2007-8 by OUCRU (Oxford University 
Clinical Research Unit), Ho Chi Minh City, Vietnam (Tricou et al., 2010, Tricou et al., 2011). 
There were no significant differences found between the placebo and treatment groups in the 
study. I therefore include data from both arms in my analysis. Blood samples were taken 
twice daily after hospital admission for a minimum of 5 days. A PCR (polymerase chain 
reaction) TaqMan assay was used to quantify virus in plasma (viral copies per ml of plasma). 
Assays with two different limits of detection used for both DENV1 and DENV2 with limits 
of detection of either 1500 copies/ml or 15000 copies/ml. This leads to measurements below 
the limit of detection at these two different titres. Both “infectious” and “non-infectious” 
virions are measured by the PCR assay. The PCR protocol is described in detail by Simmons 
and colleagues (Simmons et al., 2007). 
Patients in the trial were classified as either primary or secondary infections by both their 
antibody titres at arrival in hospital and at the end of infection. The IgG and IgM levels at 
these times were compared with the standard chart from Thailand using the ratio of IgG and 
IgM during and after infection, as described in (Innis et al., 1989). Though perhaps these 
classifications need revisiting currently this is the most commonly used method for 
discerning primary and secondary infections. NS1 levels were also measured, though I do not 
include these in the model fitting as it is not clear what the role of NS1 is in pathogenesis or 
disease (Avirutnan et al., 2006). Patient disease severity is classified in the original paper 
using the standard WHO measures for DF and DHF(WHO, 1997) after review of case notes 
(Tricou et al., 2011). 
There is individual patient data on cases of DENV1 primary DF (n=14), secondary DF 
(n=91) and secondary DHF (n=32). Figure 2-10 summarises the data. There were insufficient 
numbers of DENV1 primary DHF patients in the dataset to use (n=4). For DENV2, there 
were secondary DF (n=24) and secondary DHF (n=21) cases (Figure 2-11). There were also 
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insufficient numbers of DENV2 primary DF to use (n=5). At hospitalisation, for each 
individual, the time since reported symptom onset was recorded. Viral load measurements 
were taken twice daily from arrival in hospital until discharge.  
For the DENV1 primary DF patients, the mean time of first measurement since symptom 
onset is 2.02 days (s.d. = 0.50) (distribution in black in Figure 2-9), and mean of the highest 
(log10) viral load measurement is 9.30 copies / ml of plasma (s.d. = 0.75). 
For DENV1 secondary DF patients, the mean time of first measurement since symptom onset 
is 1.79 days (s.d. = 0.56) (distribution in blue in Figure 2-9) and mean of the highest (log10) 
viral load measurement is 9.30 copies / ml of plasma (s.d. = 1.05). For DENV1 secondary 
DHF patients, the mean time of first measurement since symptom onset is 2.00 days (s.d. = 
0.46) (distribution in red in Figure 2-9) and mean of the highest (log10) viral load 
measurement is 9.10 copies/ml of plasma (s.d. = 1.60). There are appears to be greater 
variability in the virus dynamics in the secondary cases. 
In DENV2 secondary DHF patients, the mean time of first measurement since symptom onset 
is 1.88 days (s.d. =0.55) and mean of the highest (log10) viral load measurement is 8.85 
copies / ml of plasma (s.d. = 1.03), and in secondary DENV2 DF patients, the mean time of 
first measurement since symptom onset is 2.23 days (s.d. = 0.69) and mean of the highest 
(log10) viral load measurement is 7.48 copies / ml of plasma (s.d. = 1.70).  
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Figure 2-9: DENV1 day after symptoms of first measurement. Black primary DF, blue 
secondary DF, red secondary DHF. 
 
The highest recorded viral titre measurement is not necessarily the true peak, given the 
possibly late stage of infection at which the first viral sample is taken. For DENV1, of the 
primary DF cases 8 of 14 showed a viral load increase from the first measurement, compared 
with only 21 of the 91 secondary DF patients and only 10 of 32 of the secondary DHF 
patients. For the secondary DENV2 patients this happens for only 3 of 24, and 5 of 21 DHF. 
The lack of early measurements obviously has implications for model fitting, as there is a 
substantial period of virus growth for which we have little data. There are more 
measurements that fall below the assay limit of detection for secondary DENV1 cases, a 
difference previously noted (Tricou et al., 2011). Also noted by Tricou et al., the peak (when 
observed) is earlier in secondary infections compared with primary (Tricou et al., 2011).  
I will briefly summarise other findings in the Tricou et al. (2011) paper which are relevant to 
my work. For DENV1 it was noted that primary cases had a longer infection than secondary 
(p <0.00001). Also of note, DHF cases had higher virus titres than DF at enrolment, 
regardless of serological status (primary or secondary classification). Virus peaks titres (when 
observed) were not, however, significantly different between disease severities or between 
primary or secondary infection. For DENV1 and all serotypes together, a faster maximum 
daily virus decrease rate was observed in secondary cases compared to primary (p<0.00001). 
Statistical comparisons between primary and secondary subgroups for the other serotypes 
were not possible due to small numbers. It was noted that DENV1 had significantly higher 
virus at multiple time points when compared to DENV2 or DENV3.  
The analysis in the Tricou et al. 2011 paper drew comparisons between the average virus 
titres of people grouped by primary/secondary disease and virus serotype and generally used 
day 3 to compare titres. In contrast, the analysis I conduct allows for individual 
heterogeneity, so individuals are considered separately. I also consider in this way differences 
between groups. In addition I consider possible mechanisms for the differences between 
groups observed and summarised above.  
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Figure 2-10: Measured viral titres (viral copies/ml of plasma) over time in a) Primary DF, b) Secondary DF and c) Secondary DHF 
DENV1 patients (Tricou et al., 2011).  
Each colour is a different individual. Unfilled circles are measurements below the assay limit of detection.  
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Figure 2-11: Measured viral titres (viral copies/ml of plasma) over time in a) Secondary 
DF and b) Secondary DHF DENV2 patients (Tricou et al., 2011).  
Each colour is a different individual. Unfilled circles are measurements below the assay 
limit of detection. 
 
2.7.2. Validation dataset (Duyen et al., 2011) 
The second dataset I consider consists of similar longitudinal measurements of viral load in 
children from a community setting in Vietnam, collected from June 2006 until March 2008. 
Once again this dataset was previously analysed at an aggregated level (Duyen et al., 2011).  
This second dataset is used for comparison with the first dataset for both individual and group 
parameter estimates, and to validate any differences in these parameters between primary and 
secondary groups. It is also used to undertake more powerful comparisons between serotypes 
(there being more cases of DENV2 and DENV3 in the second dataset).  
Unfortunately, this dataset does not contain disease severity classifications. As the data were 
collected from cases in the community, we may expect severity to be less than in hospitalised 
patients, though we have no evidence for this. Virus measurements in the second dataset were 
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taken using a different PCR assay to that used in the first dataset. The assay used in the 
second dataset has a lower limit of detection (100 viral copies/ ml of plasma for DENV1, 
DENV2 and DENV3), which means there are detectable virus measurements at lower levels. 
Again, both “infectious” and “non-infectious” virions are captured. The data are shown in 
Figure 2-12, Figure 2-13 and Figure 2-14. 
In the second dataset samples are only taken once a day and we do not have exact timings for 
these. I assume these are taken at the same time every day and, as in the first dataset, use the 
reported time since symptom onset as the time variable. I use the data from individuals with 5 
or more measurements (regardless of whether these are above or below limit of detection). 
The primary/ secondary classification was undertaken in a similar way for the second dataset. 
Individuals with a negative ELISA at first measurement, with no increase in IgG by first 
follow up measurement were classified as primary cases. Individuals with a positive ELISA 
measurement to start, or an increase in IgG greater than that in IgM were classified as 
secondary cases (Duyen et al., 2011). The final difference between the two datasets is that the 
second dataset is comprised of children, not adults. It is not clear what impact this has on 
virus dynamics, but a recent paper found significant differences in some clinical measures 
and symptoms between adults and children (Dinh The et al., 2012). 
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Figure 2-12: Measured viral titres (viral copies/ml of plasma) over time in a) Primary 
and b) Secondary DENV1 patients (Duyen et al., 2011).  
Each colour is a different individual. Unfilled circles are measurements below the assay 
limit of detection. 
 
Figure 2-13: Measured viral titres (viral copies/ml of plasma) over time in a) Primary 
and b) Secondary DENV2 patients (Duyen et al., 2011).  
Each colour is a different individual. Unfilled circles are measurements below the assay 
limit of detection. 
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Figure 2-14: Measured viral titres (viral copies/ml of plasma) over time in a) Primary 
and b) Secondary DENV3 patients (Duyen et al., 2011).  
Each colour is a different individual. Unfilled circles are measurements below the assay 
limit of detection. 
 
In this dataset there are 31 primary and 26 secondary DENV1 patients, 7 primary and 22 
secondary DENV2 cases and 12 primary and 7 secondary DENV3 cases used. Remembering 
that the measurements are daily (not twice daily), 10 (of 31) primary and 9 (of 26) secondary 
DENV1 cases increase from first measurement. 0 (of 7) primary and 7 (of 22) secondary 
DENV2 cases increase from first measurement. 6 (of 12) primary and 3 (of 7) secondary 
DENV3 cases increase from first measurement.  
I summarise the analyses undertaken in the Duyen et al. 2011 paper that are relevant for my 
work that follows. The study noted for DENV1, significantly greater virus levels (taken on 
illness day 3) (p<0.02) in primary compared to secondary cases, as well as a longer time until 
resolution, with a median of 7 days to viral clearance in primary compared to 5 days in 
secondary, p< 0.001), similar to the first dataset. The mean highest viral load measurement 
was also greater in primary than secondary, with 8.78 compared to 7.83 log10 copies/mL, p= 
0.006), both less than the corresponding measurements for the first dataset. Using once again 
the measure of virus titres on illness day 3, it was noted than DENV1 primary titres were 
significantly higher than DENV2 or DENV3 primary titres (p<0.01). For DENV2 and 
DENV3 no significant results were found when comparing primary with secondary cases, 
possibly because the sample sizes were small. There was however a suggestion that the 
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highest virus titres were greater in secondary cases for both DENV2 and DENV3. Other 
summary measures can be found in the source paper (Duyen et al., 2011). 
 
2.8. Model fitting 
Throughout this thesis I aim where possible to fit mechanistic models to data from clinical 
cases.  
2.8.1. Likelihoods 
Virus measurements were included in the likelihood on a log scale. A log scale was used 
because of the PCR amplification, and because of the large range of values (from 10
2
 to 10
8
). 
Using the log scale means the largest values do not have an inflated contribution to the 
likelihood. Using PCR measurements it is necessary to include the measurement error. For 
other viruses, PCR measurement error has taken a standard deviation of 1 log. I assume the 
error is normally distributed.  
For measurements below the limit of detection, the full information about these data points is 
that the titre at this point is at, or below, a certain threshold. In the likelihood the cumulative 
distribution function (cdf) is therefore used. Combining measurements above and below the 
limit of detection, the full expression for the likelihood is given by Equation 2-14. 
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Equation 2-14: Full likelihood expression for the two datasets presented in this chapter.
ϕ is the Gaussian (normal) probability density function (pdf),  is the cdf of the normal 
distribution, n is the number of observations for that individual, dvi is the ith viral load 
measurement and vi is the model virus prediction at the time of this ith measurement. 
LDv is the limit of detection and σv is the error in viral load measurement. The indicator 
function, civ equals 0 if Div > LD and equals 1 if not. The log of this function is taken and 
the loglikelihoods are summed over all individuals.  
 
I take the natural logarithm of these likelihood expressions, and assuming independence 
between individuals sum over all individuals. The log likelihood is then used to fit the model 
and estimate the unknown parameters as described in Chapter 2. 
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2.8.2. Model comparison 
In order to compare model fits I use the Bayesian Information Criterion (BIC) (Schwarz, 
1978). BIC is a measure of the goodness of fit of a model which also takes into account the 
number of parameters in the model, with a penalty for a greater number of parameters. The 
BIC is defined as 2log logBIC L k n   , where L is the likelihood, k the number of 
parameters and n the number of data points. The log likelihoods alone were also compared 
between models, in a non-Bayesian way. I also qualitatively assessed the fits of the models, 
particularly whether the peak titres were fitted and whether a peak was imputed in those 
patients for whom a peak is not observed.  
2.8.3. Prior distributions and assumed parameter values 
In the Bayesian framework for parameter estimation it is possible to incorporate prior 
distributions for parameters. These prior distributions represent beliefs regarding parameter 
values, prior to model fitting. In our case, there was little information on many model 
parameters, so uninformative improper uniform priors were usually used. The current 
framework however allows for any additional information to be easily incorporated (e.g. from 
humanised mice models or vaccine challenge studies) as it becomes available. I briefly 
summarise the data relevant for use in prior distributions and in providing ranges for fixed 
parameters, and how and why this data was ultimately used.  
As individuals are experiencing natural infections, the time of infection is unknown, and data 
are reported as a function of time since symptom onset. The model begins at the time of 
infection, so it is necessary to estimate the time of infection (or with this data, equivalently 
the incubation period). Using data from previous infection experiments (Simmons, 1931, 
Sabin, 1952, Nishiura and Halstead, 2007), I assigned a normal prior distribution to the 
incubation period with a mean of 5.7 days and standard deviation of 3 days. The symptoms 
were defined as fever onset in this study. In the virus titre data I have symptoms onset is self 
reported, and may not be fever. However fever is thought to be the first sign of a dengue 
infection so this may be a fair assumption to make. 
For ω, the virus production rate, there is also in-vitro work, characterising the virus output 
over time from both monocytes and dendritic cells (Cologna and Rico-Hesse, 2003) for 
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different genotypes of DENV2. I use data from this 2003 study to guide the estimate for ω 
when it is fixed.  
Due to the uncertainty surrounding the target cells of dengue in vivo, multiple prior 
distributions could be included. Of the dengue target cells suggested, monocytes (Kou et al., 
2008) target cell number estimates would be in the order of 0.1 – 0.8 x109 cells/L of blood 
(Kenneth, 2001). However for macrophages (Jessie et al., 2004), a cell with a large reservoir 
in tissues, the number of cells would be greater. In the model fitting I fixed the number of 
target cells at various parameter values (consistent roughly with a plasma (monocyte) or 
tissue based (macrophage) cell) and considered the likelihoods of the models with these 
different numbers of target cells.  
A monocyte’s life span is estimated at around 3 days (Whitelaw and Bell, 1966), and 
macrophages may survive weeks to months (Kenneth, 2001) though the lifespan may reduce 
when activated (Sompayrac, 2003). Uninfected target cells were fixed to have a lifespan of a 
week (γ = 0.14). In the model with immune response clearing infected cells, an excess death 
rate of infected cells proved difficult to resolve given the much larger impact of immune-
related clearance of infected cells. Therefore I also set the non-immune mediated death rate 
of infected cells to the same as non-infected cells (δ= γ = 0.14) with all cell lysis due to the 
modelled immune response. The same was necessary for the lifespan of virus in the absence 
of immune response when model assumed the immune response was removing virus.  
The parameters, and whether they were estimated, plus their values if fixed, are summarised 
in Table 2-6. All prior distributions, except the incubation period, were vague improper 
uniform priors.  
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Parameter Meaning Value/Estimated 
A Constant target cell production/ml/day 1.4x10
5
/1.4x10
6
/1.4x10
7
 
γ Cell death rate/day 1/7 per day 
β Infection rate of target cells per virion estimated 
α Removal rate of infected cells/day per 
immune cell 
estimated 
ε Removal rate of virus/day per immune 
cell 
estimated 
δ Infected cell death rate/day 1/7 per day 
ω Production rate of virions/day per 
infected cell 
1x10
4 
κ Virion clearance rate/day estimated 
s Parameters governing the immune 
response proliferation 
estimated 
IP Incubation period estimated 
z0 Initial population size of immune 
effector population 
1 
 
v0 Initial inoculum of virus 1 
 
Table 2-6: Parameters of the basic model their meaning, whether they are estimated 
and their values if fixed.  
Equations given in (Equation 2-1), model is run per ml of plasma.  
 
2.8.4. Parameter variation 
In fitting the model to the data, I consider three levels of parameter estimation. The first level 
is patient specific, where each individual has a different estimate for the same patient specific 
model parameter (e.g. if α was estimated at this level, for 10 individuals there would be 10 α 
parameter estimates). The second level is group specific, where there is one estimate of the 
group specific model parameter for every individual of the same group (e.g. if α was 
estimated at this level and the groups were primary and secondary there would be one 
primary and one secondary parameter estimate of α). The third level is overall where all 
individuals in the dataset have the same parameter estimate for this parameter. The reasons 
for including these parameter estimation levels are three-fold. Firstly, we hope to “learn” 
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from those individuals for whom we have more information in the early stage. Secondly, 
estimating all parameters independently for each individual would lead to over-fitting, given 
the limited data available for each patient. Keeping some parameters constant across 
individuals gives fewer parameters to estimate overall and therefore improves inferential 
power (Ferguson et al., 1999b, Putter et al., 2002). Thirdly, varying parameters between 
individuals or groups is useful for understanding which processes are driving observed 
heterogeneity in virus dynamics between these individuals or groups.  
It makes biological sense to assume that “virus parameters” such as the production rate of 
virions () and virus clearance rate () are similar between individuals infected with the 
same serotype. These parameters are therefore kept as group specific or overall parameters in 
all models. There may be differences in virus parameters between strains within serotypes 
(Cologna and Rico-Hesse, 2003), but these were not considered here. 
Those parameters relating to the immune response (“immune parameters”), immune 
proliferation (), or immune efficacy (), the incubation period (linked with the initial virus 
inoculum (v0)) and infection of target cells () might be argued to vary between people. For 
example, differences in HLA may lead to different efficacies of immune response 
proliferation, but also in the effectiveness of the immune response at clearing infection 
(Stephens et al., 2002). Virus is thought to enter cells via receptor mediated endocytosis (van 
der Schaar et al., 2008), a process which might occur at different efficacies in different 
people. The viral inoculum may differ between people depending on the level of virus in a 
mosquito when it bites (Acosta et al., 2008), and whether the mosquito is interrupted during 
feeding.  
Different combinations of the patient specific parameters were tested (e.g. the α, IP model, 
where α (rate of removal of infected cells by the immune response) and the incubation period 
are patient specific), with the parameters not patient specific, as group specific or overall 
parameters. The models with these different combinations of patient level parameters were 
compared using the log likelihood and the BIC.  
I fit the model separately to the different patient groups considered (primary DF, secondary 
DF and secondary DHF), and also to all groups together. In order to compare patient specific 
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parameters between groups, I compared combined posterior distributions for each group  to 
take into account the distribution of these parameter estimates around the median values.  
2.8.5. Monte Carlo Markov Chain (MCMC) 
implementation 
In a Bayesian setting for model fitting we require a joint distribution of both the data and the 
parameters (θ) for inference (Gilks et al., 2000). The joint distribution is given by 
 (      )   (    | ) ( ).  
Using Bayes Theorem it is possible to determine the distribution of   given the data, the 
posterior distribution (π), where P (θ) is the prior.  
    ( |    )  
 ( ) (    | )
∫ ( ) (    | )   
 
Equation 2-15: Formula for Posterior Distribution. 
Implementing this parameter fitting uses the following steps. Firstly, prior distributions are 
assumed. From a given starting point, using MCMC, a new parameter value is suggested or 
“proposed” from a given proposal distribution, q. So,         where    is the new 
proposed parameter value,    is the previous parameter value, and X is a random value from 
q. I used the Metropolis - Hastings algorithm (Gilks et al., 2000) to generate samples from the 
proposal distribution. A proposal value was generated from the normal distribution, with a 
specified variance. The variance (or step-size) was altered to attain an acceptance rate of 
between 15 and 50%, with the ideal being 23% (Gilks et al., 2000). The variances were tuned 
by hand for each parameter. The values of the variances used here were between 0.01 and 
0.1.This new parameter value is subsequently accepted or rejected with a certain probability 
of acceptance. This probability of acceptance (Equation 2-16) depends on the likelihoods of 
the model run with the proposed and previous parameter values, the probability of both 
parameter values under the prior distribution of this parameter and both parameter values’ 
probability under the proposal distribution. The acceptance probability is given by Equation 
2-16. 
  (     )     (  
 (  ) (  |  )
 (  ) (  |  )
).  
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Equation 2-16: The acceptance probability.  
π is the posterior distribution, θ1 is the previous parameter and θ2 is the new “proposed” 
parameter, q is the proposal distribution.  
 
As the acceptance probability only contains the ratio of  (  |    ) and  (  |    ) 
(Equation 2-15 and Equation 2-16), it is not necessary to integrate over all parameter space, 
making the calculation more straightforward. If the acceptance probability is below a 
randomly generated uniform value between 0 and 1,    is accepted and will make up part of 
our final chain (φ). Otherwise    is rejected and    retained. The process is repeated multiple 
times, i.e. multiple “runs” are performed.  
For each parameter, the final chain of these accepted parameters (φ), from the multiple runs, 
is taken to represent the posterior distribution (π) of each parameter. The posterior 
distribution can then be considered as the belief about each parameter after the model fitting. 
In order for posterior distributions (π) to be generated, the final chain (φ) must be stationary 
and the MCMC chains must have converged. 
At each run a different parameter of the model was chosen to update (β, α etc.). If the chosen 
parameter was patient specific, a new parameter was generated for each individual, and these 
parameters were individually accepted or rejected. If the chosen parameter was a group 
specific parameter, the joint likelihood was calculated for all individuals in the group and the 
parameter was accepted or rejected for the whole group. If the chosen parameter was an 
overall parameter, the joint likelihood was calculated for all individuals and the parameter 
was accepted or rejected for all individuals.  
Convergence was assessed by visual inspection of the trace plots. After a burn in of around 
300000 updates (more for the antibody models in Chapter 4), the chain was sampled every 
100
th
 update to characterise the posterior distribution. This further thinning was performed to 
reduce autocorrelation (Gilks et al., 2000). 
The MCMC, likelihood and accept/reject step were coded in R (R Development Core Team, 
2012). Due to the computational requirements of solving the dynamical model millions of 
times, after initially coding the model in R using the deSolve package (Soetaert et al., 2010) I 
coded the model in C, which was compiled into a dll file to be called by the R script. The C 
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implementation was approximately 10 fold faster than the original R code, though 
computational time was still an issue in undertaking inference for the more complex models.  
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Chapter 3 : Model 
parameterisation with virus 
titre data 
In this chapter I present the results from models fit to the virus titre datasets presented in 
Chapter 2. I first present results for fitting the model to DENV1 patients from the first 
dataset, including some model diagnostics and sensitivity analysis. These results show 
estimated parameter values of the model, with individual variation created by variation in the 
immune response parameters. Differences between primary and secondary cases were either 
in virus parameters or in the immune response parameters (consistent with the two theories of 
antibody dependent enhancement or antigenic sin for secondary infections). I next present 
validation of these parameter values by fitting the model to DENV1 patients from the second 
dataset. Thirdly, I present results for the other serotypes in this dataset (DENV2 and 
DENV3), with a variety of differences noted in parameter estimates between the serotypes. 
Finally, I present results considering a hypothetical antiviral. Of the different antivirals tested 
that which blocks virus production has the best impact, though the result for an antiviral 
blocking virus production is still negative across all individuals, as many are caught too late 
in infection for an antiviral to have a large impact.The phrase “complex interplay”, appears 
regularly in the dengue literature, e.g. (Dejnirattisai et al., 2008). This phrase highlights how 
the immune system and virus interact in a non-straightforward way during a dengue infection 
to control and enhance infection and symptoms. This chapter uses the within-host models 
outlined in Chapters 2 to characterise the dynamics of pathogenesis in primary and secondary 
dengue cases, using sequential viral load data from a number of studies.  . I estimate the 
parameters characterising viral kinetics and the dynamics and impact of the immune 
response. 
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3.1. Methods  
3.1.1. Model used in this chapter 
Given the limited data first available, I use the simplest model described in Chapter 2, which 
has four state variables: the population sizes of free virus (v), uninfected target cells (x), 
infected target cells (y) and an adaptive immune response (z). Free virus infects target cells 
via a mass-action process with rate , and infected cells produce more virus at rate . Using a 
single state variable for the immune response is clearly a gross simplification, but in the 
absence of detailed immunological data to fit the model to, a more complex representation 
cannot be robustly parameterised. The model is defined by the ordinary differential equations 
in Equation 1. The parameters of the model used in this chapter, and their values if fixed, are 
given in Table 2-6.  
dx
A x xv
dt
dy
xv y zy
dt
dv
y v
dt
dz
yz
dt
 
  
 

  
  
 

 
 
Equation 3-1: Model describing the infection and immune processes.  
Variables of the model are: uninfected target cells (x), infected target cells (y), 
population sizes of free virus (v) and an adaptive immune response (z). Parameters of 
the model are given in Table 2-6. 
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3.1.2. Data and model fitting 
The two datasets used here are described in detail in Chapter 2. In this chapter firstly results 
are presented from model fitting with the first dataset, mainly for DENV1 cases, but with 
some DENV2 (only secondary cases). I then present results fitting the model to the second 
dataset, to validate my results. As the second dataset has a greater number DENV2 cases 
(primary as well as secondary) and some DENV3, it allowed further exploration of serotype 
variation. The model was fit to the data as described in Chapter 2, using the prior 
distributions as also described in Chapter 2. For each dataset I fit the primary and secondary 
and disease severity groups separately with different numbers of parameters varying as 
patient specific and the remainder of the parameters group specific. I next fit to all groups 
within a serotype together with different numbers of parameters varying as patient and group 
specific and the remainder of the parameters as overall parameters. Different numbers of 
target cells were considered to see which provided the best fit to the data. When comparing 
patient specific parameters between groups the posterior distributions for each parameter for 
all patients were summed together to make a “combined” posterior distribution and plotted 
(both as described in Chapter 2). Models are compared using the log likelihoods and the BIC 
(Bayesian Information Criterion) as described in Chapter 2. 
3.1.3. Modelling antiviral drugs 
Within the model outlined above, I considered antivirals that either: a) reduce the virus entry 
to the cell, b) stop the cell producing virus, or c) increase the virus clearance rate. I modelled 
scenarios in which an antiviral was administered immediately on arrival to hospital, with the 
antiviral becoming active immediately. I did not model the pharmacokinetics 
pharmacodynamics (PKPD) of the drug, but for simplicity assumed a constant action of the 
antiviral. Practically, to consider the hypothetical antiviral in the model, I did the following. 
For each individual, the best fit model parameter posterior distributions were sampled from 
for all parameters and for each individual with each parameter set sample the next steps 
undertaken: 
1. Model was run up until the time of arrival to hospital. 
2.  Model with the antiviral action included was run from time of 
arrival to hospital.  
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The model outputs from stage 1 at the time of arrival to hospital were used as initial 
conditions for stage 2.  
I compared directly each individual without antiviral, to itself with the antiviral for the 
following summary measures: 1, the percentage change in area under the virus curve, 2, log10 
change in virus peak titre or 3, the change in time until virus resolution. I consider the model 
dynamics and these summary measures for the primary DF, secondary DF and secondary 
DHF groups. These measures were then averaged across patients within each group. Multiple 
outcome measures were used as it is not clear which is the ultimate desired impact on virus 
dynamics of a dengue antiviral (Nguyen et al., 2012). This is because the link between virus 
dynamics and symptoms is not clear, therefore it is not obvious what characteristics of the 
virus dynamics an antiviral should ideally change.  
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3.2. Results 
3.2.1. DENV1 model fit and parameter values 
Table 3-1 lists the model fits undertaken, which vary by the data subset fitted to, the assumed 
production rate of target cells, and which parameters were fitted on a patient or group specific 
basis (other fitted parameters were fit as common to all patients). Table 3-1 also displays the 
median posterior log likelihoods and BIC for each model fit. The virus production rate per 
infected cell, , was always fixed as common to all patients. 
The model with α, η, IP fitted as patient specific fitted best to both each of the individual 
patient groups (first 3 blocks of Table 3-1) and to fits to all patients at once (last block of 
Table 2-1) (with a similar likelihood with β at group level for the fit to all patients altogether, 
but with values of β not estimated as different between groups). Table 3-2 shows the 
parameter estimates obtained for a selection of the best fitting models listed in Table 3-1.The 
fits of the α, η, IP as patient specific model fit to each patient group separately (assuming a 
common production rate of target cells of 1.4x10
6
) are shown for 5 representative patients 
from each group in Figure 3-1. These same patients are used in figures throughout the thesis 
(Chapter 3 and 5). The model fits the viral titre data well. Imputed immune response and 
target cell dynamics are also shown. 
For the groups fit separately, the best model by BIC varies from group to group. For primary 
DF, the incubation period alone as patient specific is the best, and the addition of other 
parameters not justifiable on statistical grounds, though they do improve the fit. For 
secondary DF the incubation period and immune efficacy (α) as patient specific is the best 
model, with η and the incubation period not far behind. For secondary DHF the incubation 
period only as patient specific is once again best by BIC. However, in the α, IP patient 
specific and IP patient specific models the fit to the data is fairly poor and the difference in 
peak titres between individuals is not recreated.  
I examined the sensitivity of model fit to the assumed production rate of target cells (and thus 
the pre-infection equilibrium number of target cells), and found that increasing this rate from 
the lowest considered value to the middle value improved the fit to all patient data (see Table 
3-1). For the secondary cases the fit is further improved by the using the highest number of 
target cells, indeed, we see with the greatest number of target cells, the fitted viral load curves 
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are able to reach all the peaks titres (see Figure 3-2), compared with the model fit with fewer 
target cells where in some cases the virus peaks are missed (see Figure 3-1).  
Figure 3-3 shows the fit for the model with the best BIC of those fitted to all patients at once 
(with η fitted as a group specific parameter, α, IP as patient specific, third from bottom row 
of Table 3-1). In this figure, smaller intervals are seen for the model around the data, 
compared to Figure 3-1 and Figure 3-2. This is due to the smaller number of parameters 
being estimated. Also of note here is that due to estimating η as a group specific rather than a 
patient specific parameter, in those patients who do not increase from the first measurement, 
this first measurement does not have to be the peak virus titre. This means that a peak of virus 
is inferred in some cases as coming earlier in infection than the time at which the data 
measurements start. This is discussed in greater detail in later sections.   
The fits, likelihoods and parameter values presented above are discussed in the following 
sections with emphasis on the between patient and between group variation found in 
parameter estimates.  
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DENV1 patient 
data fitted 
Patient specific 
fitted parameters 
Value of A (target 
cell production, 
/ml/day) 
Median 
log likelihood 
BIC 
 
 
PRIMARY DF 
(15 patients) 
IP 1.4x10
6
 -130 357 
α, IP 1.4x106 -114 468 
η, IP 1.4x106 -104 376 
β, η, IP 1.4x106 -104 447 
α ,η, IP 1.4x106 -84 407 
α, η, IP 1.4x105 -103 447 
α, η, IP 1.4x107 -87 414 
 
 
SECONDARY DF 
(91 patients) 
IP 1.4x10
6
 -2234 5736 
α, IP 1.4x106 -643 2554 
η, IP 1.4x106 -684 2635 
β, η, IP 1.4x106 -1041 3966 
α, η, IP 1.4x106 -488 2860 
α, η, IP 1.4x105 -713 3309 
α, η, IP 1.4x107 -399 2683 
 
 
SECONDARY 
DHF 
(32 patients) 
IP 1.4x10
6
 -222 656 
α, IP 1.4x106 -187 768 
η, IP 1.4x106 -180 753 
β, η, IP 1.4x106 -198 971 
α, η, IP 1.4x106 -157 889 
α, η, IP 1.4x105 -299 1173 
α, η, IP 1.4x107 -151 876 
 
 
 
All groups 
(138 patients) 
α, η, IP 1.4x106 -696 4420 
η, IP + α as group 
specific 
1.4x10
6
 -999 4045 
α IP + η as group 
specific 
1.4x10
6
 -906 3859 
α, η, IP + β as 
group specific 
1.4x10
6
 -695 4427 
α, η, IP+ β as 
group specific 
Primary: 1.4x10
6
 
Secondary: 1.4x10
7
 
-675 4381 
Table 3-1: Table of median posterior distributions log likelihood values and BICs for 
the different models and patient groups considered.  
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Figure 3-1: Model fit for best fit model (by likelihood: α, η, IP fitted as patient specific) 
fitted to all patients groups separately, assuming A=1.4x10
6
/ml/day. 
(See Table 3-1). Results shown for representative selected patients. Viral load shown as 
black dots (filled: above detection limit; unfilled: below the limit of detection). Black 
lines: fitted median viral dynamics, Grey lines: sample from posterior for virus 
dynamics, Pink lines: sample from posterior for immune response dynamics, Purple 
lines: sample from posterior of target (uninfected) cell dynamics. First row: primary DF 
patients; second row: secondary DF patients; third row secondary DHF patients. 
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Figure 3-2: As Figure 3-1, but assuming A=1.4x10
7
/ml/day.  
Best fit model (by likelihood α, η, IP fitted as patient specific) fitted to all patients 
groups separately (see Table 3-1). Results shown for representative selected patients. 
Viral load shown as black dots (filled: above detection limit; unfilled: below the limit of 
detection). Black lines: fitted median viral dynamics, Grey lines: sample from posterior 
for virus dynamics, Pink lines: sample from posterior for immune response dynamics, 
Purple lines: sample from posterior of target (uninfected) cell dynamics. First row: 
primary DF patients; second row: secondary DF patients; third row secondary DHF 
patients. 
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Figure 3-3: Model fit for groups fit altogether α, IP patient specific, η group specific, 
assuming A=1.4x10
6
/ml/day.  
Results shown for representative selected patients. Viral load shown as black dots 
(filled: above detection limit; unfilled: below the limit of detection). Black lines: fitted 
median viral dynamics, Grey lines: sample from posterior for virus dynamics, Pink 
lines: sample from posterior for immune response dynamics, Purple lines: sample from 
posterior of target (uninfected) cell dynamics. First row: primary DF patients; second 
row: secondary DF patients; third row secondary DHF patients. 
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Model Paramete
r 
Primary DF Secondary DF Secondary DHF 
Best Likelihood  
α, η, IP patient 
specific,  
A=1.4x10
6
 
Β 2.81 
(2.38, 3.49) x10
-
10
 
3.48 
(3.47, 4.11)x10
-
10
 
3.72 
(3.40, 4.15)x10
-10
 
Α 0.34 
(0.25, 0.69) 
0.0047, 1.19 
0.22 
(0.056, 0.48) 
7.61x10
-6
, 2.2 
0.13 
(0.043, 0.35) 
1.07x10
-5
, 2.21 
Η 2.65 x10-6 
(1.77 x10
-6
, 
8.34x10
-6
) 
4.71x01
-7
, 
2.26x10
-4
 
5.90x10
-6
 
(8.85x10-7, 
1.11x10
-5
) 
4.95x10
-7
, 0.64 
2.06x10
-6
 
(8.56 x10
-7
, 
2.57x10
-5
) 
4.91 x10
-7
, 0.039 
IP 5.18 
(4.70, 5.80) 
3.98, 7.27 
5.32 
(4.65, 6.00) 
3.03, 7.82 
5.35 
(4.86, 5.80) 
3.83, 6.31 
Κ 5.01 
(4.40, 5.67) 
8.13 
(7.33, 8.80) 
7.64 
(7.03, 8.47) 
α, IP patient 
specific,  
A=1.4x10
6
 
Β 6.00 
(4.89, 8.41) x10
-
10
 
4.34 
(3.97, 5.01) x10
-
10
 
5.09 
(4.58, 5.70) x10
-10
 
Α 0.39 
(0.093, 1.40) 
9.62x10
-7
, 1.6 
0.22 
(0.0132, 1.05) 
7.67 x10
-9
, 1.43 
0.13 
(1.90 x10
-6,
 1.15) 
7.96 x10
-7 
1.28
 
Η 5.75 x10-7 
(5.03x10
-7
, 
6.45x10
-7
) 
8.55 x10
-7 
(7.96x10
-7
,
  
9.12 
x10
-7
) 
7.96 x10
-7 
(7.41x10
-7
, 
8.65x10
-7
) 
IP 5.00 
(3.82, 6.95) 
3.72, 8.44 
5.91 
(4.59, 8.13) 
(4.36, 10.1) 
4.98 
(3.65, 8.01) 
(4.21, 8.69) 
Κ 11.0 
(8.56, 17.8) 
8.35 
(7.72, 9.27) 
9.03 
(8.14, 10.2) 
 Table 3-2: Parameter estimates for a selection of model fits, groups fit separately. 
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Models shown are the model fitting α, η and IP at patient specific for the fits to each 
patient group separately, and the four variants of the models which fit to all patients 
listed in the last block of Table 3-1. I summarise patient specific parameter estimates 
with the median, inter-quartile range and maximum/minimum of the distribution of 
median parameter estimates obtained across all fitted patients. Medians and 95% 
credible intervals are shown for the common and group specific parameters. 
 
 
Model Paramete
r 
Primary DF Secondary DF Secondary DHF 
η, IP patient 
specific,  
α group 
specific, 
A=1.4x10
6
 
Β 2.08 
(1.99, 2.18) x10
-10
 
Α 0.085 
(0.029, 0.17) 
3.71x10
-35
 
(9.61x10-45, 
2.57x10-27) 
3.26x10
-16
 
(2.58x10-21, 
5.21x10-12) 
Η 3.62x10-6 
(1.68x10
-6
, 
1.42x10
-4
) 
4.59x10
-7
, 
3.30x10-4 
2.44x10
-6
 
(2.41x10
-5
, 
0.00046) 
3.5x10
-6
, 60 
4.01x10
-5
 
(9.11x10
-6
, 
0.00065) 
2.02x10
-6
, 0.97 
IP 5.77 
(5.44, 6.44) 
4.80, 8.50 
5.59 
(4.77, 6.37) 
1.42, 8.45 
5.92 
(4.97, 6.90) 
2.27, 7.74 
Κ 4.43 
(4.33, 4.53) 
α, η, IP patient 
specific,  
β group specific, 
A=1.4x10
6
 
Β 4.12 
(3.67 4.82) x10
-
10
 
3.6 
(3.38, 3.79) x10
-
10
 
3.7 
(3.38, 4.07) x10
-10
 
Α 0.97 
(0.67, 0.98) 
0.002, 1.5 
0.18 
(0.05, 0.44) 
1.19x10
-5
, 2.11 
0.13 
(0.04, 0.40) 
1.46x10
-5
, 2.20 
Η 1.178x10-6 
(8.07x10
-7
, 
2.88x10
-6
) 
4.09x10
-7
, 
9.32x10
-5
 
5.55x10
-6
 
(9.25x10
-7
, 
0.00012)  
5.09x10
-7
, 0. 65 
2.1x10
-6
 
(8.73x10
-7
, 
2.71x10
-5
) 
4.91x10
-7
, 0.04 
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IP 5.25 
(4.70, 6.00) 
4.37, 7.39 
5.38 
(4.62, 6.09) 
3.05, 7.68 
5.44 
(4.99,.585) 
3.75, 6.61 
Κ 7.74 
(7.33, 8.11) 
Table 3-3:  Parameter estimates for a selection of model fits, all patients fit together. 
Models shown are the model fitting α, η and IP at patient specific for the fits to each 
patient group separately, and the four variants of the models which fit to all patients 
listed in the last block of Table 3-1. I summarise patient specific parameter estimates 
with the median, inter-quartile range and maximum/minimum of the distribution of 
median parameter estimates obtained across all fitted patients. Medians and 95% 
credible intervals are shown for the common and group specific parameters. 
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3.2.2. MCMC diagnostics 
  
Figure 3-4:MCMC traces for DENV1 Primary DF Person 1, the model with α, η, IP 
patient specific (after a burn in of 300, 000 runs these were thinned so 1 in 100 runs was 
taken to form the posterior distributions).  
MCMC traces for: β, α, η, IP, log likelihood and κ shown.  
 
Figure 3-4 shows parameter traces for primary DENV1 patient 1 α, η, IP patient specific 
model and acceptance rates for this model for all primary DENV1 cases are shown in Table 
3-4. The parameter β converges with more difficulty (as assessed visually), but it converges 
best in the model shown where it is a group level parameter, as shown here. I judged all the 
MCMC to have converged by eye, and the acceptance rates to be within the acceptable range 
(Gilks et al., 2000).  
Patient β α η IP κ 
1  
 
 
 
 
 
 
42 
 
23 20 5  
 
 
 
 
 
 
23 
 
2 12 18 5 
3 10 16 5 
4 11 14 5 
5 15 19 5 
6 25 17 5 
7 38 20 5 
8 59 6 6 
9 12 22 6 
10 25 19 5 
11 5 17 4 
12 37 19 4 
13 38 25 8 
14 42 22 7 
15 16 19 5 
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Table 3-4: Acceptance rates for the primary patients with the α, η, IP fit as patient 
specific model.  
3.2.3. Individual heterogeneity DENV1 
Patient-to-patient variation in η (immune response growth rate), and incubation period (IP) is 
largely sufficient to recreate the differences observed between patients (particularly in the 
magnitude and timing of peak viral titre). This is in agreement with the results from Error! 
Reference source not found.. The addition of variation in the parameter α improves the 
model fit further, but variation in α and the incubation period alone were not able to recreate 
differences in peak titre and timing. It was always necessary to fit the incubation period of 
each patient, presumably due to differences in the timing of symptoms or perhaps variation 
caused by initial viral inoculum.  
In order to correlate parameter values with the dynamics observed, the parameter values of 
the primary patients whose dynamics are plotted in Figure 3-1, are presented in Table 3-5. 
The fourth and fifth patients have the lowest peaks and the highest η values. Patient 2 has the 
highest incubation period, (not obvious from the figure) and patient 3 has low η and a low α, 
leading to a high late peak and a slow virus decline rate. These are in fitting with the 
dynamics observed with parameter variation in Chapter 2. 
Table 3-5: η, α and IP values for each individual for the primary cases for the α, η, IP 
patient specific model. 
Parameter medians and 95% credible intervals are shown. Model dynamics with these 
parameters are shown in first row Figure 3-1.  
Parameter Patient 1 Patient 2 Patient 3 Patient 4 Patient 5 
η 
5.00x10
-6
 
(2.22x 10
-6
, 
1.13x10
-5
) 
1.09x10
-6
 
(5.32x10
-7
, 
2.75x10
-6
) 
4.71 x10
-7
 
(3.81x10
-7
, 
5.90x10
-7
) 
4.51x10
-5
 
(1.90x10
-5
, 
1.02 x10
-4
) 
2.26x10
-4
 
(1.10x10
-5
, 
9.7x10
-4
) 
IP 
4.78 
(3.70, 5.73) 
7.04 
(5.41, 8.48) 
4.84 
(3.88, 5.68) 
5.33 
(4.01, 6.96) 
4.12 
(2.83, 6.41) 
α 
0.349 
(0.0319, 
0.894) 
0.835 
(0.237, 1.51) 
0.00467 
(1.08x10
-4
, 
0.108) 
0.871 
(0.183, 1.73) 
0.301 
(9.80x10
-3
, 
1.13) 
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Figure 3-5: Correlations and posterior distributions for individual 1 DENV1 primary 
DF for the α, η, IP patient specific model. 
The posterior distributions are given on the diagonal, with the correlation coefficients 
above the diagonal.  
 
Correlations between parameter estimates provide information about the dependencies in 
model processes and the limitations on what it is possible to estimate. Figure 3-5 shows the 
correlations for one primary DF patient; similar patterns are seen for other primary DF and 
secondary DF and DHF patients. The main correlations are between β and κ, as these 
parameters trade-off in determining the initial viral growth rate, a period for which we have 
little data (respective correlation coefficients (r): primary 0.65, secondary 0.89). For the 
patient specific parameters, there is correlation between α and IP (mean correlation across all 
primary DF patients 0.42 with the correlations consistently positive, for secondary DF 
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patients mean correlation is 0.45). There is also a negative correlation between η and IP, (-
0.23 for primary DF cases, -0.42 for secondary DF), though the relationship is not 
consistently negative across patients.  
As it is currently only possible to sample patients as they arrive at hospital or healthcare 
centre, data on the early part of infection dynamics is not available. This is particularly 
noticeable in the secondary group where the majority of patients have decreasing virus titres 
by the time they arrive in hospital. Inferring the early infection is mainly performed by setting 
the initial virus titre, and estimating the incubation period (using an informative prior 
distribution), and by estimating some parameters as group specific or overall parameters. 
With the immune response growth parameter (η) not varying between patients (see Figure 3-3 
where it is group specific), it is possible to estimate an imputed peak for all patients in which 
one is not observed, which infers different early infection dynamics to the α, η, IP patient 
specific model. 
3.2.4. Comparing primary and secondary cases 
It is informative to compare parameter estimates between primary and secondary case patient 
groups. Parameter estimates for all the models discussed below are shown in Table 3-2.  
In the model fits to groups separately with α, η, IP fitted as patient specific, differences in 
parameter estimates between primary and secondary groups were observed in β (virus entry 
to cell) and κ (virus clearance rate). The estimated values for both parameters were greater in 
the secondary cases compared with primary (see Table 3-2 and the posterior distributions 
plotted in row 1 Figure 3-6). These parameters are correlated as shown in Figure 3-5.  
When fitting all patient groups at once, and estimating α, η, IP as patient specific, β as group 
specific and  as global, the variation in β seen in the separate fits to each patient group 
disappears, and variation in the immune response parameters dominates. We see differences 
in α estimates for primary DF vs. secondary DF and secondary DHF but not for secondary 
DF vs. secondary DHF. For the parameter η, there is limited evidence for a consistent 
difference: not between primary DF vs. secondary DHF or secondary DF vs. secondary DHF, 
but between primary DF vs. secondary DF. The IP estimates are different for primary DF 
compared to  secondary DHF but not  for the other between group comparisons. These 
parameters can be observed in the combined posterior distributions shown in Figure 3-6.  
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The model fitted with α and IP as patient specific and η as group specific shows some 
differences in estimates of and IP between groups both when fitted to all patients together 
(the model with the best BIC, see Figure 3-3), and when fitted to the different patient groups 
separately (for both see Table 3-2), but the fit of this model is relatively poor (both 
quantitatively and qualitatively). In the fit with the groups altogether, comparing the joint 
posterior distributions, the parameter estimates for are  different between primary DF vs. 
secondary DHF  secondary DF patient groups. The parameter estimates for η are different 
between primary DF and each of secondary DF and DHF (see Table 3-2) and the combined 
posterior plots. Similar differences are seen in the model fit to each groups separately. It is of 
interest that this model parameterisation (which imputes a virus peak prior to the start of 
observations for many of the patients for which data is only available on the post-peak 
decline) still predicts differences between the primary and secondary cases in the immune 
response parameters. This would suggest that the differences estimated between primary and 
secondary are not simply because of the greater amount of missing data for secondary cases 
and the necessary assumptions made in this period by the α, η, IP patient specific model. In 
many of the models fitted the primary DF and secondary DHF the estimates of η are similar 
(see results above and e.g. see Figure 3-6), and differences are in the estimated IP. 
The greatest production rate of target cell (A) fits provide a better fit for secondary DF cases 
than the intermediate number of target cells (log likelihood greatest: -399, intermediate: -488, 
see Table 3-1). The goodness of fit for the intermediate and greatest number of target cells is 
similar for the primary cases ((log likelihood greatest: -87, intermediate: -84, see Table 3-1) 
and secondary DHF (log likelihood greatest: -151, intermediate: -154, see Table 3-1). 
Following this result, if the secondary cases are allowed to have a higher production rate of 
target cells than the primary cases the variation in η between groups is removed but variation 
in α remains (see Table 3-2). In the secondary cases we also see greater variation in the 
patient specific parameters and resulting dynamics than for primary (see Figure 3-1, Figure 
3-6 and Table 3-2).  
In the original paper analysing the dataset fitted to here, a difference was noted in the early 
viraemia of DHF compared with DF patients (Tricou et al., 2011). However, I found no 
differences between the DF and DHF groups in the parameters estimated for most model 
variants. The exception was when  was fitted as a group specific parameter (third model of 
Table 3), but the estimates of  for both secondary DF and secondary DHF groups are 
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unrealistically small for this model variant (and the fit poor – see Table 3-1). In the posterior 
parameter distributions shown in Figure 3-6 there are no differences between secondary DF 
and secondary DHF for DENV1.  
To summarise, there are two distinct ways in which we can fit differences between primary 
and the secondary cases. The first is with differences in β and κ (“virus parameters”) possibly 
consistent with ADE, and the second with differences in the “immune response parameters” 
possibly consistent with antigenic sin (both with and without different numbers of target 
cells).  
 
Figure 3-6: Posterior Densities for Primary DF, Secondary DF, and Secondary DHF for 
DENV1 first dataset. 
Posterior Densities for Primary DF (red), Secondary DF (black) Secondary DHF (blue), 
or when parameter are common, distributions for all groups shown in black. For 
individual parameters the posterior distributions shown are the joint distributions 
across all patients. Parameters in columns left to right: β, κ, log10 (α), log10 (η), IP. 
Results shown for model fitting parameters α, η and IP as patient specific and assuming 
A=1.4x10
6
 (fits shown in Figure 3-1). The top row shows results for the model fitted to 
patient groups separately (so β, κ group specific), and the bottom row shows results for 
the model fitted to all patients with β, κ common between groups. 
 
3.2.5. Sensitivity to assumptions regarding immunity 
In order to assess how robust the results were to model assumptions, and how robust the 
results were to which of the non-distinguishable parameters were estimated, I performed 
multiple sensitivity analyses. As it is not possible to distinguish between immune response 
proliferation and action models and there is evidence for different forms of both, it is 
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important to assess sensitivity to these assumptions in particular. First, I present results from 
considering a different immune proliferation form (ηz here compared to ηyz which is used in 
the previous results). I also attempted to fit models of the form: ηyz/ (const+ z) or  
ηyz/ (const+ y) (see Equation 2-10), but due to the lack of data on the immune response, both 
these models just converged to the simpler ηyz or ηz models during fitting. 
 
Second, I consider other forms of immune action. As discussed in previous models of acute 
infection (Baccam et al., 2006), it is difficult if not impossible to distinguish between a model 
in which the immune response clears virus and a model in which immune response clears 
infected cells if only viral load data are available. The results presented above assume that the 
immune response is clearing infected cells; i.e. a CD8+ response or an antibody dependent 
cell cytotoxic response. In addition, in order to be able to estimate immune clearance 
parameters with the available data, it was also necessary to fix the lifespan of infected cells in 
the absence of an immune response. Here I consider the scenario of the immune response 
clearing virus directly. Given estimated viral clearance rates are high even in the absence of 
an adaptive immune response, the additional impact of an immune response clearing virus is 
to reduce the viral half-life to minutes. In order for the model to reproduce observed viral 
load decay rates in this scenario therefore requires a relatively short infected cell lifespan 
(even in the absence of an immune response) of around 3h. This estimated lifespan is short in 
comparison to estimates for cells infected with other viruses (Baccam et al., 2006). This value 
is probably unrealistically low for most target cells, suggesting the more realistic model of 
immune action is infected cell clearance (my default assumption above). However, in the 
absence of other evidence I present model results for the alternative scenario below.  
Third, I present results from allowing the initial size of the immune population (z0) to vary 
between patients or patient groups rather than the effectiveness of the immune response (α). 
These two parameters are non-distinguishable if only viral load data are available (see 
Chapter 2), so in exploring this model variant I fix α arbitrarily to 1.  
I also considered estimating the initial viral dose (v0) rather than the incubation period. 
However, without a strong prior on v0, v0 estimates became unreasonably large, so it was 
preferable to estimate the incubation period, fixing v0 whilst remaining aware that some of the 
variation in the incubation period is likely to arise from the initial virus dose.   
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3.2.5.1. Model fits using ηz form of immune proliferation  
In this model fit the immune response proliferates at a constant rate throughout infection. 
Though after infection this is of course not realistic (as the immune response would continue 
to proliferate forever), during infection (the period we are considering) this may well 
approximate the process of immune stimulus and then proliferation of the "correct" immune 
response cells. Qualitatively, this model does not fit as well as that with the ηyz form of 
proliferation (Figure 3-7). We see in this figure that in the ηz case the virus dynamics can 
have a (possibly more realistic) more rounded shape.  
When the patient groups are fit separately (dynamics shown in Figure 3-7), β and κ estimates 
were larger in secondary infections than in primary (non-overlapping credible intervals), 
consistent with results presented above for the default proliferation model. In the model for 
groups fit altogether, differences in estimates of α were seen between primary DF vs. 
secondary DF and secondary DHF. Estimates of η were different between primary DF and 
secondary DHF and between primary DF and secondary DF. Incubation period estimates 
differed between all three patient groups for this model. Aside from the differences in the 
incubation period estimates, these parameters are consistent with the immune differences 
between primary and secondary cases as seen for the default model. 
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Figure 3-7: Model fit with α, η, IP fitted as patient specific fitted to all patients, with the 
ηz form of the immune response proliferation assuming A=1.4x106/ml/day, groups fit 
separately.  
Results shown for representative selected patients. Viral load shown as black dots 
(filled: above detection limit; unfilled: below the limit of detection). Black lines: fitted 
median viral dynamics, Grey lines: sample from posterior for virus dynamics, Pink 
lines: sample from posterior for immune response dynamics, Purple lines: sample from 
posterior of target (uninfected) cell dynamics. First row: primary DF patients; second 
row: secondary DF patients; third row secondary DHF patients. 
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3.2.5.2. Sensitivity to immune response action  
For the model fit to all patients with an immune response which removes virus, I saw 
differences in estimates of α between primary DF and both secondary DF and secondary 
DHF,, consistent with earlier results. The model fit is shown in Figure 3-8). Overall, 
parameter estimates and between-group differences were broadly similar in pattern to the 
model assuming the immune response removes infected cells. When the model was fit to the 
three patient groups separately, estimates of infected cell lifespan (estimated here because the 
infected cells are not targeted by the immune response) as well as β were higher in secondary 
DF and DHF groups than the primary DF (non-overlapping credible intervals). From Figure 
3-8 we can see that a greater number of target cells may be needed in this model to fit the 
data.  
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Figure 3-8: Model fit with α, η, IP fitted as patient specific fitted to all patients, with the 
ηyz form of the immune response proliferation, but with immune response removing 
virus, assuming A=1.4x10
6
/ml/day, groups fit separately.  
Results shown for representative selected patients. Viral load shown as black dots 
(filled: above detection limit; unfilled: below the limit of detection). Black lines: fitted 
median viral dynamics, Grey lines: sample from posterior for virus dynamics, Pink 
lines: sample from posterior for immune response dynamics, Purple lines: sample from 
posterior for target (uninfected) cell dynamics. First row: primary DF patients; second 
row: secondary DF patients; third row secondary DHF patients. 
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3.2.5.3. Sensitivity to estimating z0 rather than α 
When estimating z0 rather than α, the model fits and parameter estimates of other parameters 
were comparable with the default model. In fitting the groups together, parameter estimates 
of z0 were different between the primary DF and secondary DF and secondary DHF groups. 
There were different estimates of  between the primary DF group the secondary DF group. 
Incubation period estimates were different between primary DF and secondary DHF, but not 
for the other comparisons. Overall for this model, we see the distinct difference in z0 between 
primary and secondary cases we saw for α in the default models, but the between group 
differences in estimates of IP and η become less clear-cut.  
However, the fact that we estimate a lower initial number of immune cells (z0) in secondary 
compared with primary cases does not appear consistent with a memory response (even 
allowing for antigenic sin), providing some support for the default assumptions that 
primary/secondary cases differences manifest in immune action (i.e. α the efficacy of the 
immune response).  
3.2.6. DENV1 validation with second dataset 
With the caveats described in Chapter 2, it is a useful exercise to compare the parameter 
values estimated by fitting the model to a different dataset (the second dataset described in 
Chapter 2) with those presented above (Table 3-2). Due to the lack of disease severity 
classification for the second dataset, I compare the parameter estimates for DENV1 primary 
(DF and DHF together) and secondary (DF and DHF together) cases between the two 
datasets. For this I use the model with the highest likelihood for the first dataset (α, η and IP 
as patient specific parameters). In this second dataset there are 31 primary and 26 secondary 
DENV1 patients.  
Firstly, I fit the primary and secondary groups separately, where the model provides a good 
fit to the data. For primary DF and DHF, common parameters have similar estimates in both 
datasets. For the first dataset, I estimate β = 2.82x10-10 (2.34 x10-10, 3.42 x10-10) and κ = 5.17 
(4.64, 6.02), while for the second dataset, β = 2.90 x10-10 (2.40 x10-10, 3.14 x10-10) and κ = 
5.50 (4.96, 6.21) – remarkably similar. Estimates of IP and α are also very similar for both 
datasets, but there were differences in estimates of η, with the estimated values being larger 
for the second dataset. Corresponding posterior distributions are shown in Figure 3-9.  
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For secondary cases, the global parameter estimates were also similar between the datasets 
but there was a suggestion of estimates of κ and α being larger and β being smaller for the 
second dataset (see Figure 3-9). As we can see in Figure 3-9, credible intervals were wider 
for the second dataset, probably due to its smaller size. 
 
Figure 3-9: Posterior distributions for parameter estimates for the two datasets. 
Primary (top row) and secondary (bottom row) cases were fitted separately. Results for 
the original and validation dataset are shown in black and blue respectively. As before, 
for individual parameters the combined posteriors are shown. From left to right 
posterior estimates for β, κ, and log10 (α), log10 (η) and IP are shown, for the model 
variant fitting α, η and IP as patient specific. 
 
 
For the second dataset (unlike the first), there was no need for target cells production rates to 
be increased above A=1.4x10
6
 to reproduce all the observed maxima of viral load in the 
secondary cases.  
Differences between parameter estimates for primary and secondary cases in immune 
parameters were broadly comparable for the two dataset. For the second dataset, estimates of 
η were larger and α smaller in secondary cases compared to the primary cases. These 
differences remained when both primary and secondary cases were fit together. Differences 
were not observed between primary and secondary cases in κ and β for the second dataset 
(possibly because of the large credible intervals for the second dataset). 
Overall, the second dataset therefore provides reasonable validation for the parameter values 
estimated from the first (larger) dataset for both primary and secondary cases, but only 
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supports differences in the immune response parameters, not the virus parameters between 
primary and secondary cases. 
 
3.2.7. Estimates for other serotypes  
I now present results for fitting the model to data for cases of DENV2 and DENV3 from both 
datasets. I fitted the model separately to DENV2 secondary DF and to DENV2 DHF cases in 
the first dataset. Parameter value estimates are given in Table 3-6 and the model fit is shown 
in Figure 3-10.  
 Model Parameter Secondary DF Secondary DHF 
Model 
Fitting 
Groups 
Separately: 
α, η, IP-
patient 
specific, 
A=1.4x10
6
 
β 3.94 
(3.05, 4.71)  
x10
-10
 
4.29
 
(3.89, 5.34)
 
x10
-10
 
α 0.536  
(0.235,
 
1.40) 
4.08 x10
-3
, 2.82 
0.401 
(0.304, 0.571) 
6.81 x10
-3
, 1.07 
η 3.54 x10-5 
(3.43 x10
-4
, 1.26 
x10
-2
) 
5.84 x10
-7
, 0.224 
1.52 x10
-6
 
(8.18 x10
-6
, 4.15 
x10
-5
) 
6.59 x10
-7
, 2.56 x10
-
2
 
IP 4.43 
(4.11, 5.75) 
1.89, 6.39 
5.78 
(5.17, 6.23) 
4.30, 7.78 
κ 7.39 (6.80, 9.17) 10.4 (8.97, 11.8) 
 
Table 3-6: Parameter estimates for DENV2, model fitting α, η, IP as patient specific.  
 
There are no differences between the two secondary DENV2 groups (though suggestions of a 
larger κ for DENV2 secondary DHF). Comparing DENV1 to DENV2, though there were 
wider credible intervals on the estimates of  and κ for DENV2 (with particular problem with 
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 for DENV2 secondary DF, see Figure 3-11), the estimates were not different from those for 
DENV1 (though in Figure 3-11 κ DENV2 secondary DHF looks different to the estimates for 
the others groups). For the patient- specific parameters there are differences for all parameters 
between DENV1 and DENV2 DF cases. There are onlydifferences in α parameter estimates 
for DENV1 DHF vs. DENV2 DHF (once again a greater spread on the posterior distributions 
for DENV2 than DENV1 (see Figure 3-11)).  
 
 
Figure 3-10: DENV2 model fit.  
Results shown for selected representative patients from first dataset. Viral load shown 
as black dots (filled: above detection limit; unfilled: below the limit of detection). Black 
lines: fitted median viral dynamics, Grey lines: sample from posterior for virus 
dynamics, Orange lines: sample from posterior for immune response dynamics, Blue 
lines: sample from posterior of target (uninfected) cell dynamics. First row: Secondary 
DF. Second row: Secondary DHF.  
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Figure 3-11: Estimated parameter posterior distributions for fits to DENV1 secondary 
DF, secondary DHF and DENV2 secondary DF and secondary DHF from the first 
dataset.  
DENV1 secondary DF (black), secondary DHF (blue) and DENV2 secondary DF 
(orange) and secondary DHF (green). For patient specific parameters, joint posteriors 
across all patients are shown. From left to right posterior estimates of , κ, log10 (α), 
log10 (η) and IP are shown for the model variant fitting α, η and IP as patient specific.  
 
The second dataset had greater representation of non-DENV1 cases than the first dataset 
(though the groups are still small), containing 7 primary and 22 secondary DENV2 cases and 
12 primary and 7 secondary DENV3 cases. I therefore fitted the model to primary and 
secondary cases, each serotype separately for this dataset (Figure 3-12 and Figure 3-13), 
fitting α, η and IP as patient specific and other parameters as group-level.  
For secondary cases, patient specific parameters were not significantly different between the 
3 serotypes (Figure 3-12). There were however differences (by non-overlapping credible 
intervals) in  estimates between DENV1 and DENV2, and between DENV1 and DENV3 
(though due to the small sample sizes the posteriors are not entirely satisfactory). 
Qualitatively, estimates of κ appeared different for all three serotypes (Figure 3-12), but were 
only significant comparing DENV2 and DENV3.  
Figure 3-13 shows the corresponding posterior distribution estimates for primary DENV1, 
DENV2 and DENV3 cases from the second patient dataset. Comparing DENV2 and DENV3 
the onlydifference was in estimates of η. Comparing DENV1 and DENV2 there were 
differences in estimates of κ (DENV1: 5.50 (4.96, 6.21), DENV2: 2.97 (2.34, 4.10)) and all 
the individual parameters.There were no differences between estimates of any parameters for 
DENV1 and DENV3.  
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Figure 3-12: Estimated parameter posterior distributions for fits to secondary DENV1, 
DENV2 and DENV3 from the second dataset.  
DENV1 secondary (black), DENV2 secondary (orange) and DENV3 secondary (purple). 
For patient specific parameters, joint posteriors across all patients are shown. From left 
to right posterior estimates of , κ, log10 (α), log10 (η) and IP are shown for the model 
variant fitting α, η and IP as patient specific.  
 
 
Figure 3-13: Estimated parameter posterior distributions for fits to primary DENV1, 
DENV2 and DENV3 from the second dataset.  
DENV1 primary (black), DENV2 primary (orange) and DENV3 primary (purple). For 
patient specific parameters, joint posteriors across all patients are shown. From left to 
right posterior estimates of , κ, log10 (α), log10 (η) and IP are shown for the model 
variant fitting α, η and IP as patient specific.  
 
Comparing primary and secondary cases within serotypes, DENV2 shows patterns similar to 
DENV1 in the immune response efficacy and proliferation parameter estimates (differences 
in  between primary and secondary for DENV2). This is however coupled with 
differences in κ (primary: 5.50 (4.96, 6.27), secondary: 8.99 (7.95, 11.10), but not in β. There 
are no differences between primary and secondary for DENV3 in the immune response 
parameters, estimates of β are different (non-overlapping credible intervals) between primary 
and secondary (primary 2.28x10
-10
 (2.86 x10
-10
, 3.28 x10
-10
), secondary: 3.90 x10
-10
 (4.49 
x10
-10
, 4.85 x10
-10
), but estimates of κ are not different.  
The groups were also fit together assuming the same virus parameters for primary and 
secondary. In this fit, much of this significant variation in estimated parameter values 
between primary and secondary disappears. In this case, for DENV2 there are differences 
between the primary and the secondary cases in only α, and for DENV3 only in the 
incubation period For all serotypes in the second dataset it was not necessary to have a 
greater target cell production in secondary cases than in primary in order to reach all virus 
peaks.  
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3.2.8. Modelling antiviral drugs 
Using the parameter estimates from best fit model (by likelihood) fitted to all the patients in 
the first dataset, I here examine the potential impact of antiviral treatment on viral dynamics. 
This is assessed by comparing each individual to itself with and without treatment, using 
multiple outcome measures and then averaging (taking the mean and the normal standard 
deviations to get confidence intervals) across patients. Three types of antiviral action are 
modelled: blocking virus production (modelled by reducing ω), blocking virus entry to the 
cell (modelled by reducing ), and increasing viral clearance (modelled by increasing ). For 
blocking virus production (modelled by reducing ω) and blocking virus entry to the cell 
(modelled by reducing ) the antiviral was either 90% or 100% effective and viral clearance 
(modelled by increasing ) was increased x10 or x100. 
Results of this analysis for DENV1 cases are shown in Table 3-7. The results show that an 
antiviral blocking virus production (ω=0, 100% effective) decreases the area under the viral 
load curve slightly more than a drug which blocks virus entry to the cell (=0, 100% 
effective), but this is not statistically significant. Blocking virus production will have a 
greater impact because by doing this, all virus production is immediately halted. If virus entry 
to the cell is blocked, cells already infected can continue to produce virus. For both actions a 
90% effective antiviral was not significantly better than no treatment for any of the outcome 
measures. 
The only consistent result across primary, secondary and disease severity groups was a 
reduction in the time until virus is undetectable for an antiviral that halts virus production. 
There was also a significant change in the AUC for primary DF with an antiviral that 
increases virus removal (x10 or x100) and significant reduction in the peak virus for 
secondary DF and DHF with this antiviral action (but only x100). In Figure 3-14 the outcome 
of the model with the antiviral blocking all virus production is shown for the sample of 
patients. In this figure and in Table 3-7 a greater impact of the antiviral in the primary 
compared to the secondary cases can be seen. The greater impact in primary cases is due to 
the primary cases generally arriving at an early stage in the virus dynamics.  
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Though we see many patients having a positive outcome in this figure, the ones that do not 
have a positive outcome make most of the overall results non-significant (as discussed 
above). A non- positive outcome can mean two things. Firstly it can mean the change in 
dynamics with the antiviral compared to without is so small that dynamics with and without 
cannot be distinguished. Generally this happens with the late arrival to hospital in infection 
by which time the virus dynamics are controlled by the clearance parameters (αyz, κ and δ) 
not the virus production parameters (β and ω). Secondly, a negative outcome can result (i.e. 
the time until virus clearance is greater with an antiviral than without). This negative outcome 
can occur when the immune response is cut off at a lower level because the antiviral keeps 
virus (and infected cell) titres lower and therefore reduces the immune response proliferation 
(as this is proportional to infected cell titres with the proliferation form ηyz)). This in turn 
leads to a slower virus decline, as the virus decline is proportional to the infected cell decline, 
which is governed by the immune response (αyz) (see Figure 3-15). In contrast, assuming the 
ηz form of the immune proliferation form would lead to no differences in the level of immune 
response with or without an antiviral (as the immune response develops regardless of the 
level of virus/ infected cells), and thus no difference in the rate of decline of viral load. We 
see in Figure 3-15 and Figure 3-14 that the antiviral can also reduce the target cell depletion 
in some cases. The levels of target cell depletion with an antiviral will be the same in the 
models with both immune response proliferation forms. 
For DENV2 in the first dataset similar results are obtained, with many positive impacts upon 
individual dynamics, but once averaged the results become non-significant.  
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Mode of action Reducing virus entry to cell Reducing virus production Increase virus clearance 
Efficacy of treatment 100% 90% 100% 90% 100 x 
increase 
10 x increase 
Average % 
change in AUC 
Primary 
DF 
-40 
(-101, 20) 
-33 
(-80, 13) 
-61 
(129, 7) 
-57 
(-123, 7) 
-68 
(-127, -10) 
-65 
(-122, -8.7) 
Sec DF -24 
(-71, 22) 
-19 
(-58, 20) 
-48 
(-118,21) 
-45 
(-110,20) 
-54 
(-120, 11) 
-52 
(-117, 13) 
Sec 
DHF 
-19 
(-52, 13) 
-14 
(-39, 11) 
-49 
(-113, 14) 
-45 
(104, 12) 
-55 
(-115, 3.8) 
-51 
(-107, 5.0) 
Average 
difference in 
log10 peak virus 
Primary 
DF 
-0.37 
(-1.1, 0.39) 
-0.3 
(-0.99, 0.27) 
-0.43 
(-1.29, 0.43) 
-0.46 
(-1.27, 0.35) 
-0.67 
(-1.48, 0.14) 
-0.48 
(-1.3, 0.33) 
Sec DF -0.23 
(-0.89, 0.42) 
-0.3 
(-0.86, 0.23) 
-0.26 
(-0.99, 0.45) 
-0.38 
(-1.03, 0.29) 
-0.72 
(-1.4, -0.05) 
-0.40 
(-1.1, 0.26) 
Sec 
DHF 
-0.17 
(-0.64, 0.29) 
-0.20 
(-0.5, 0.1) 
-0.21 
(-0.76, 0.33) 
-0.27 
(-0.76, 0.21) 
-0.59 
(-1.1, -0.11) 
-0.30 
(-0.79, 0.18) 
Change in time 
until virus 
undetectable 
 
Primary 
DF 
-1.4 
(- 8.2,5.4) 
-0.74 
(-8.4, 5.5) 
-5.2 
(-8.0, -2.4) 
-2.3 
(-7.2, 2.6) 
-3.6 
(-9.8, 2.4) 
-2.7 
(-9.7, 4.22) 
Sec DF 0.87 
(-6.5, 8.2) 
0.97 
(-6.0, 8.0) 
-2.5 
(-4.8, -0.29) 
-0.06 
(-5.6, 5.5) 
-0.56 
(-7.0, 5.9) 
-1.9 
(-7.6, 3.6) 
Sec 
DHF 
0.7 
(-5.5, 7) 
0.29 
(-4.4, 5.0) 
-2.1 
(-3.9, -0.29) 
-0.23 
(-4.7, 4.2) 
-0.57 
(-6.5, 1.68) 
-0.43 
(-5.5, 4.6) 
 
Table 3-7: Summary measures for modelled impact of antiviral treatment. 
Antiviral initiated immediately after onset of symptoms and impact considered on viral load profiles of primary DF, secondary (sec) DF 
and secondary (sec) DHF DENV1 cases for different scenarios for antiviral efficacy. Comparing median outcomes of the best fit model 
(by likelihood), with and without the antiviral. Undetectable is <1500 copies/ml. 
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Figure 3-14: Impact on model dynamics of antiviral that 100% blocks virus production.  
Antiviral shown: antiviral that stops all virus production (reduces ω to 0). The same 
representative patients are shown. There are 5 primary DF cases (row1), 5 secondary 
DF cases (row2), and 5 secondary DHF cases (row3). Without antiviral: Grey: sample 
from posterior for virus dynamics, Purple target cells and pink immune response. With 
antiviral: Black virus, orange target cells and green immune response: Sample from 
posterior for virus dynamics: Underlying model parameters were those from the best 
fitting (likelihood) groups separately virus removing infected cells model α, η, IP 
varying.  
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Figure 3-15: Impact on model dynamics of antiviral that 100% blocks virus entry to 
cell.  
Antiviral shown: antiviral that stops virus entering cell (reduces β to 0). The same 
representative patients are shown. There are 5 primary DF cases (row1), 5 secondary 
DF cases (row2), and 5 secondary DHF cases (row3). Without antiviral: Grey: sample 
from posterior for virus dynamics, Purple target cells and pink immune response. With 
antiviral: Black virus, orange target cells and green immune response: Sample from 
posterior for virus dynamics: Underlying model parameters were those from the best 
fitting (likelihood) groups separately virus removing infected cells model α, η, IP 
varying.  
  
132 
 
3.3. Discussion 
3.3.1. Parameter values 
Though the work presented here is the first to consider a model of dengue dynamics fit to 
data, so there is no direct comparison for parameter values estimated, there is limited 
information from in vitro dengue experiments (as outlined in Chapter 2) and some 
information from other viruses. For virus production (ω) and the target cell production rates 
(A) parameters, data introduced in Chapter 2 was used to fix values. Virus entry to the cell (β) 
and virus lifespan (κ) however were estimated, so it is possible to compare the estimates of 
these parameters to the data discussed in Chapter 2. The lifespan of the virions appears 
consistent with estimates of the lifespan of other RNA viruses (Baccam et al., 2006). The 
values of proportion of “infectious” virions from the van der Schaar et al. papers (van der 
Schaar et al., 2007, van der Schaar et al., 2008) of 1:2.6x10
3
 to 1:7.2x10
4
 are consistent with 
estimated β parameter values in this work (β on the order of 1x10-10 and this parameters also 
includes the rate of virus entry to the cell). The immune response parameter values are 
specific to the model system and have not, to my knowledge, been measured in vivo or in 
vitro before, so there is no information available with which to compare the estimated values.  
Similar estimates of the majority of parameters were obtained from model-fitting to both 
datasets for DENV1. This provides us with some confidence in the estimates. The different 
magnitude of estimates for the immune response proliferation parameter (η) in the two 
datasets however still requires some exploration. The second dataset has lower virus peaks on 
average than the first (see Chapter 2), so it is probably this driving the differences in η. A 
greater η would be consistent with a more robust immune response in children.  
Three different production rates of target cells (A) were considered, and for all cases in the 
first dataset, the fit was worst with the lowest A (Table 3-1), better with the intermediate 
number, and for secondary even better with the highest number of cells. Though we are not 
looking at precise types of cells, the larger number of cells may suggest a tissue based target 
cell infected in vivo, with plasma not able to support such a large number of cells. As ω 
(virus production) and the number of target cells are non-distinguishable, the larger estimate 
of A could actually be due to greater virus production (ω). However the values chosen for ω 
are relative to in vitro measurements (Cologna and Rico-Hesse, 2003) and already fairly large 
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in comparison to other infections such as influenza (Baccam et al., 2006). There does not 
appear to be much target cell depletion controlling infection, with no greater than 10% of 
target cells depleted at the peak of infection, however interaction with the virus production 
parameter and the cell lifespan and regeneration, may impair our ability to fully understand 
the phenomenon of target cell depletion currently.  
3.3.2. Individual heterogeneity 
I used the mathematical model, fit to data to test whether heterogeneity between patients in 
the immune response parameters was able to recreate the variation observed in virus 
dynamics between patients. To recreate the virus dynamics variation seen between patients 
(the majority of which is seen in timing and magnitude of peak titres) it was necessary to vary 
the immune response proliferation (η) along with the incubation period between patients. 
This provides evidence for a role for the immune response in shaping the virus dynamics. 
There was no additional benefit in varying the rate of virus entry to cell (β). This should be 
interpreted with caution however due to the difficulty in estimating the early period where β 
dominates. The importance of η in shaping the virus outcome confirms theoretical results by 
Nuraini et al. (Nuraini et al., 2009) and results seen in Chapter 2, section 2.5. Biologically 
this makes sense, as heterogeneity in the immune response for dengue has been noted in other 
studies of in vivo response e.g.(Innis et al., 1989). Variation could be due to HLA type or 
other genetic factors (Loke et al., 2001, Khor et al., 2011, Malavige et al., 2011), information 
we do not have for the patients here. There is evidence for variation in antibody levels over 
time from primary infection, as shown in (Prince and Matud, 2011) which would be 
consistent with differences in the secondary infection immune response between patients. 
Estimated variation in the incubation period is probably a mixture of variation in the 
incubation period and variation in the initial virus inoculum (v0). The parameter v0 impacts 
the stage of the curve observed, but not the slope of that curve. 
A significant differential between individuals that we do not have data on is the resulting 
target cells dynamics. In some individuals there is a large amount of target cell limitation- 
shaping the dynamics and leading to more rounded virus peak. In others, target cells stay 
fairly constant throughout infection and do not impact the virus dynamics.  
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3.3.3. Primary and secondary infection 
The majority of the primary vs. secondary comparison was undertaken for DENV1, though 
some consideration of the other serotypes was possible in the second dataset. As observed by 
Tricou et al. (Tricou et al., 2011), the dynamics of primary vs. secondary cases for DENV1 
infection in first dataset were suggestive of a “quicker” infection (one in which virus both 
peaks and then clears more rapidly) in secondary cases, with possibly a higher peak (though 
the peak is often not measurable) and a sharper virus decline compared to primary cases. This 
quicker infection is also noted in the second dataset (Duyen et al., 2011). All the parameter 
variations estimated and described for models fit to the DENV1 cases in the current chapter 
capture in some way these dynamics. I will discuss the interpretation of these below, 
considering whether these are consistent with the theories of antibody dependent 
enhancement (ADE) or antigenic sin for secondary infection. These results were fairly 
consistent across model variation in the immune response proliferation and action.  
The first regime that fit the data was greater β (virus entry to the cell) and κ (virus clearance 
rate) in secondary cases, only observed in the first dataset (see Figure 3-16). The greater β in 
secondary cases could be explained in two ways. Firstly, the virus in complexes in a 
secondary infection is facilitated into cells and can therefore infect them at a greater rate 
(Dejnirattisai et al., 2010), as modelled in Chapter 2. Secondly, that virions that were 
previously non-infectious have become infectious within complexes (Rodenhuis-Zybert et al., 
2010a, Rodenhuis-Zybert et al., 2011), as discussed in Chapter 2.The differences in κ could 
be due to the removal of virus more quickly from the blood as a result of this increased entry 
into cells (I do not explicitly model this process). The greater κ in secondary cases could also 
be explained by some other quick responding immune response removing virus more 
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effectively from early in a secondary infection. 
 
Figure 3-16: ADE parameters model fit schematic.  
 
The other parameter regime for differences between primary and secondary cases, differences 
in the “immune response” parameters, provides some evidence for antigenic sin. Differences 
in immune efficacy and proliferation would be consistent with the antigenic sin hypothesis, 
where the secondary immune response is thought to be less efficacious (governed by 
parameter α) against the current infecting strain, but which could proliferate (governed by 
parameter η) more quickly in a secondary infection than in primary (Halstead et al., 1983, 
Mongkolsapaya et al., 2003). This process is represented in Figure 3-17. This difference in α 
is observed in both datasets, with the differences in η less clear for both secondary DF and 
DHF. Immune efficacy and the initial number of immune cells are non-distinguishable in the 
model, so the estimates could mean a larger number of immune cells in primary infection 
compared to secondary. However, as presented in Section 3.2.5.3 a greater number of 
immune cells in primary than in secondary would be counterintuitive. Considering the 
dynamics of the simple model used here, as in Chapter 2, it is shown that an increase in 
immune response growth cannot increase the peak titre, only keep it the same (with a 
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decrease in efficacy) or decrease it (see Error! Reference source not found.). However a 
faster immune proliferation and a less effective immune response can lead to a sharper virus 
decrease (as observed in the data for secondary cases). It is probably this sharper virus 
decrease and the “quicker” secondary infection which is driving these immune response 
differences in parameter estimates between primary and secondary, as the peak is often 
unobserved in secondary. The argument against the difference in early data alone driving 
results comes from the α, IP patient specific model. In this model a peak can be, and is, 
imputed in cases where it is not observed, the differences in the immune response parameters 
remain. The parameters of this model are still possibly consistent with antigenic sin.  
 
Figure 3-17: Antigenic sin parameters model fit schematic. 
Having discussed the results of fitting the simple model to data, I would like to consider how 
these results, and more generally the previous thinking around secondary infections, fit in 
with the dynamics of the more complex secondary models considered in Chapter 2. The 
difference between the ADE and the antigenic sin from the more elaborate models in Chapter 
2, is in the size and timing of the virus peak. In the antigenic sin model it was not possible to 
create a faster peak in secondary than in primary infection (assuming the immune response is 
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not acting early in infection) and, in the parameter regime modelled, the secondary peak was 
slightly lower. ADE was able to create a faster peak, but this was not higher in the parameter 
regime considered in Chapter 2 (unless the virus in complexes was still picked up PCR). A 
higher peak may be possible with ADE, depending on the controlling immune responses. It is 
not clear if we are seeing higher peaks in secondary cases in our data and how reliably this 
has been observed in previous datasets. Understanding what happens in the early infection 
will help us understand if either or a combination of these processes is occurring (discussed 
further in the Next section). With regard to the virus decline, the antigenic sin model in 
Chapter 2 actually produced a slower virus decline in the secondary infection, not what we 
see in the data. The difference between the antigenic sin models (in Chapter 2 and the simpler 
model used in this chapter) requires further thought, though is I think to do with the 
assumptions about initial immune response population sizes and proliferation rates. The ADE 
model was able to produce faster virus declines, dependent on the parameters of the virus-
immune complex clearance rate (the rate being governed by the slowest of these processes).  
The greater number of target cells being a better fit for the secondary cases (for the first 
dataset) would be consistent with virus being able to infect additional different cells in a 
secondary infection. For example, this could be ADE facilitating entry into Fcγ receptor cells 
that the virus could not enter before (Rothman and Ennis, 1999)). An alternative explanation 
could be increased virus production in a secondary case, as in work by Kou et al. and 
Boonnak et al. (Boonnak et al., 2008, Kou et al., 2011), as these parameters (target cells and 
virus production) were non-distinguishable in this model (see Chapter 2). 
There was most data for DENV1, so much of the work focused on DENV1 serotype, but I 
also considered the primary vs. secondary relationship for DENV2 and DENV3. The primary 
vs. secondary results are less clear for the different serotypes. For DENV2, it does seem these 
immune response parameters (consistent with antigenic sin as in DENV1) could be consistent 
with the data (but there are also differences in κ (virus lifespan)). For DENV3, we only see β 
differences between primary and secondary, or incubation period differences if β was fixed 
between groups. There could be differences between serotypes in the primary vs. secondary 
differences (which is discussed in more depth later) or it could be that we do not have enough 
data here yet to discern what is happening for DENV2 and DENV3. 
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3.3.4. Disease severity 
In most models we do not observe any differences in parameters between secondary DF and 
DHF. This is a different result to the work by Tricou et al. where differences in early virus 
titres were found between DF and HDF cases (Tricou et al., 2011).  The differences between 
the results could be due to considering infection dynamics on an individual level as here, not 
aggregated as in the previous work, or due to the fact I do not consider primary and 
secondary cases together. The lack of difference could be due to the disease severity 
classification (which has now been revised, and consideration of datasets with the new 
classification could be of interest), or due to disease severity being determined by something 
not modelled here, for example cytokine storms (Pang et al., 2007), and the relationship 
between disease severity and virus dynamics not straightforward. There may be a use in 
considering a model such as this for prediction of severe disease, but this was not the aim of 
my work. 
3.3.5. Serotypes 
I aimed here to mechanistically consider the differences noted in virus dynamics between 
serotypes (Duyen et al., 2011, Tricou et al., 2011). Once broken down into primary/ 
secondary and serotypes, some of the groups in the datasets become quite small (with not 
enough primary DENV2 in first dataset to consider). though this means we cannot do all 
comparisons, the fact that we do not see primary DENV2 cases in hospital despite there 
obviously being DENV2 transmission is interesting in itself. In the primary group (second 
dataset), the main result is that differences are estimated between serotypes in not just the 
“intrinsic” virus parameters, but also in the immune response parameters (i.e. how the virus 
interacts with the immune system). There are consistent differences between DENV1 and 
DENV2 for the immune response parameters, and suggestions of differences in these 
parameters between DENV1 and DENV3. There are no immune response parameter 
differences between the serotypes for secondary cases in the second dataset, with some for 
secondary DF in first dataset. For the second dataset secondary cases there were differences 
in the virus parameter estimates between serotypes.  
It is hard to reach a conclusion from the results presented here, but there is a suggestion from 
the second dataset that we see immune response differences between parameters in primary 
cases, but not in secondary (though we do see immune response differences in the first 
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dataset between DENV1 and DENV2 secondary DF cases). If the results in the second 
dataset stand up, it could be that for a secondary case, the primary infecting serotype is more 
important than the current infecting serotype. In other words the primary infecting serotypes 
determines the virus dynamics in a secondary infection, perhaps by determining the 
“strength” of the immune response. We of course do not have information on the primary 
infecting serotype. It could also be that the sample sizes here are too small to determine any 
effect in the secondary case, or possibly the model is not capturing the important processes 
that differ between serotypes. It is important to remember that some serotypes may be more 
alike than others (Halstead, 2008), as noted here with more similar parameters between 
DENV1 and DENV3, than DENV1 and DENV2. We also must remember that we could be 
seeing different parts of the virus curve for the different serotypes and it could be this that is 
driving the results.  
This is the first attempt to consider what mechanistically could be causing differences in virus 
and immune dynamics between serotypes. There is some evidence of differences between 
serotypes in causing symptoms (Halsey et al., 2012) (which could be mediated by the 
immune response). There has been study of the immune response elicited after infection and 
how the immune response interacts with subsequent different serotypes (Valdes et al., 2000, 
Brehm et al., 2004, Bashyam et al., 2006). Some work has also dissected the response to the 
infecting serotypes, for example work by Valdes and colleagues (Valdes et al., 2000). It 
appears however that often studies both in vitro and using clinical cases are undertaken with 
virus or antibodies to only one serotype, or with cases of only one serotype. Repeated 
experiments with difference serotypes would be of great use, and could validate the 
parameter values and serotype differences estimated here.  
3.3.6. Antiviral use 
The work here on antivirals is intended to raise a few points in the use of antivirals and 
modelling dengue in the way presented here.  
The main issue concerns what should be the ultimate outcome measure for testing an 
antiviral, which is not yet clear (Simmons et al., 2012b). The aim ultimately would be to 
reduce disease or severe disease, but currently as we do not fully understand what is causing 
either, the steps to achieve a reduction are not clear, and virus measures can be used as 
proxies. The different antiviral actions were better for different outcome measures, but in the 
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results presented there did not seem to be a clear pattern emerging, except that blocking virus 
production (Figure 3-14 and Table 3-7) was favourable to blocking virus entry to the cell 
(Figure 3-15 and Table 3-7), and the earlier in infection dynamics treatment is administered 
(preferably as the virus is still increasing) the better. That the effective antiviral depends on 
time through infection at which it is administered is a real problem for dengue where patients 
are arriving in hospital at different points in their virus dynamics. In particular in this regard, 
secondary cases seem to arrive to hospital at a later stage in their virus dynamics (not 
symptoms), as well as possibly DENV2 arriving later compared to DENV1. There are 
similarities to work on influenza by Lee et al. (Lee et al., 2009), where they find drugs to 
limit infection or replication must be given within 2 days of infection to be effective. The 
other problem with timing is that non- positive results with the antiviral could lead to the 
conclusion that an antiviral is not doing what it is hoped it will, despite the fact it is 
effectively blocking virus replication, and therefore could be of use in early infection. The 
variation in patients’ dynamics also makes it more difficult to discern whether an antiviral is 
having an impact. In this analysis I overcome this problem by comparing an individual to 
itself with and without the antiviral, something that is obviously not possible in reality.  
In some cases I predict a longer virus infection with a less steep virus decline with an 
antiviral than without, which intuitively would be a bad thing. However, this longer virus 
duration happens because of a lower level of immune repose predicted. High levels of 
immune activation have been linked with severe symptoms (Dejnirattisai et al., 2008). So 
immune response reaching a lower level overall may be a good thing, though of course we 
cannot tell if that is the case from the work here. Whether the less steep virus decline happens 
depends on the action of the antiviral, and also the action of the immune response. In 
addition, though we cannot comment on symptoms in this simulation, target cell depletion 
have also been implicated in causing symptoms for other infections (Dobrovolny et al., 
2010), so it is worth considering target cells and immune response when considering 
antivirals just targeting virus, as the work here suggests that antivirals could be predicted to 
also have an impact on these.  
These results also highlight what we need to know about immune response to decide on 
effective antiviral actions. The form of the model, in particular assumptions about the 
immune response proliferation, and parameter estimates are important in understanding 
which antiviral actions are best, and how effective an antiviral would need to be to control 
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virus replication. The fact there is variation in predicted outcome of treatment on virus 
dynamics depending on model assumptions about the immune response means the reverse is 
also true; the virus dynamics with an effective antiviral could tell us more about what is 
controlling the virus and how the effective immune response is proliferating. Though there 
may be added complications with the immune response changing because of the antibody, 
data from a therapeutic antibody, given early in infection, that clears infection rapidly (a very 
effective antiviral), as developed in work by Shrestha and colleagues (Shrestha et al., 2010), 
could help in understanding the immune mechanisms dominating infection.  
3.3.7. Limitations 
The most obvious limitation in this chapter is the lack of early data and the necessity to make 
v0 /incubation period assumptions and have a strong prior distribution on the incubation 
period. Of course this is a huge over simplification, but the positives of working with natural 
infection data from humans are great and animal models are lacking for dengue. By 
considering different models with common parameters I explore how it is possible to impute 
the early stage of infection, and will discuss in later sections how best to get at the important 
early infection period in the future.  
Though of course there is more work to be done with data in early infection. There a few 
points to be made. Firstly, the fact that this data is missing more greatly in secondary cases is 
a difference in the dynamics and something that needs to be explained. The work in this and 
the previous chapters has begun to think in more detail about this and other characteristics of 
the virus dynamics, and will I hope stimulate further research in this area.  
In some cases, the immune response may be having an impact early in infection (and 
therefore causing variation in initial virus growth). This could well be occurring for 
secondary infection where memory immune response could be activated very quickly, but in 
primary infection this doesn’t seem to be justifiable. Further work will assess the impact of 
the immune response early infection assumed in the model.   
Another limitation is that the data here is hospitalised infections, and those seeking other 
medical care, which is probably the tip of the iceberg of all infections. I discuss how to get 
data on other less severe or sub-clinical infections in later sections. There are also only 
measures of virus in the blood and this may be missing differential virus load in various 
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organs as seen in monkey (Marchett.Nj et al., 1973) or autopsy studies (Rosen et al., 1999) 
(though of course these are severe cases who die). I also only have measures or both 
infectious and non-infectious virions, with this possibly varying during infection and between 
serotypes and disease severity. I also do not have measures of virus in immune- complexes as 
in (Moi et al., 2011a), or infected cells throughout infection. Therefore infected cells are 
assumed to follow the same dynamics as the virus, which has been shown to not be the case 
in monkeys (Marchett.Nj et al., 1973). Infected cells could be measured by flow cytometry 
and has been discussed with the Screaton group.  
By using just viral load measurements we are not seeing the full picture of what occurs in 
infection (Lloyd, 2001), however I think this does not mean that important insight cannot be 
gained from the work, particularly in comparing between primary and secondary infection. 
The addition of further other measurements and what we can learn from this are discussed in 
the next chapter. I discuss these and other limitations in the next section as I aim to think 
about how we can clarify these with future work.  
3.3.8. Next 
There are many ways the work presented here could be developed in the future. Where it 
goes next will depend on which are decided on as the important questions to answer, and 
what data is available or is possible to collect.  
The logical, and I think most useful, next step for data collection will be immunological data 
to go along with virological data. I describe my work in starting to measure and model 
immunological data in the following chapter, and will discuss where to go next with that at 
the end of Chapter 4. The next chapter does not focus on the primary vs. secondary questions, 
so I will discuss the next steps in considering primary vs. secondary infection here.  
In the work presented in this thesis I used parameter values as proxies for the secondary 
processes, with some qualitative work looking at how different models of the processes 
would fit in. These more complex secondary models, explicitly modelling the secondary 
immune processes fit to data would be a useful next step in fitting together the early, possibly 
detrimental, immune response and its outcomes, along with the virus clearance that ultimately 
occurs. Measuring the efficacy of the immune response in vivo, along with the magnitude of 
the virus titres, fitted to these models will ultimately help understand the processes occurring.  
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Here I have validated the parameter estimation with a second dataset. Use of this framework 
with additional datasets from other transmission settings would be of great use, and would aid 
the understanding of the factors that influence what is observed on both an individual and an 
epidemiological level.  
An issue that has repeatedly come up in the current chapter, and will continue to be 
mentioned in the rest of this thesis is the unobserved early infection period. Of course virus 
measures in the early period would be of use, but also of great use would be measures of the 
immune response (and its efficacy). Human challenge models seem to be a very good way of 
getting information about this period. The early human challenge models were performed in 
an era before detailed antibody or T cell measures could be taken (though recorded 
measurements of leukocytes throughout infection may be of use) (Simmons, 1931, Sabin, 
1952). In some early vaccine trials (Eckels et al., 1984, McKee et al., 1987, Innis et al., 
1988), experimental infection was seen, as noted by Tricou et al. (Tricou et al., 2011), and 
these may be of use. Most recently human challenge studies have been considered in the 
context of vaccine studies, with infection of patients with vaccine derived strains (Gunther et 
al., 2011). This study concluded a role for IFN – γ in the acute phase of illness. In human 
challenge models, there may however be issues about how an individual is infected. 
Inoculation is favourable as the amount of virus can be controlled, but infection with a 
mosquito more accurately represents a natural infection, due to virus titre and possible 
modulation of infection by mosquito saliva (Ader et al., 2004). However, data gained with 
infection by either route could be of great use. Ethical considerations are of course very 
important here. Human challenge studies may also be of use in considering whether an 
antiviral is effectively blocking infection in vivo, as in these studies the antiviral could be 
administered early in infection or even prophylactically. The ideal study design without 
deliberately infecting individuals would be a cluster study. In this study design the idea 
would be to sample around cases.  This would mean sampling contacts of cases, possibly in 
households (Beckett et al., 2005) or in other social groups (Stoddard et al., 2013), depending 
on how transmission is thought to occur . In this design it would be possible to obtain 
measurements from cases early in infection and would make it possible to observe natural 
infection as well as a range of disease sevierties. It would not be straightforward to derive 
sample sizes for such a study, but model simulation studies could be used, taking into account 
the variation of virus titres observed. These studies are discussed in more detail in Chapter 5. 
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Using animal models it would also be possible to obtain measurements in the early period, 
though it is not clear how representative animal models are of human dengue infection. 
Humanised mouse models are under development (Mota and Rico-Hesse, 2009, Mota and 
Rico-Hesse, 2011, Cox et al., 2012). These models may be a good way forward and would 
also be open to manipulation with different types of cells, which could help with the question 
of which cells are infected in vivo. Experimental infection of monkeys may also be a rich 
data source, e.g. (Barban et al., 2012) Data from animal models could either be fit to or be of 
use for information for prior distributions.  
Other extensions to the work would be to consider data from less severe cases, even ideally 
(though possible unattainably) asymptomatic cases (of which more in Chapter 5).  
Focusing on the virus dynamics, it would be possible to think about sequence diversity and 
evolution. Though evolution may be more important in a long-term infection, there are 
possibilities in the consideration of dengue evolution with within host models which could be 
combined with early quasi species data by Thai and colleagues (Thai et al., 2012), and may 
give addition insight into the virus parameters and possibly even the early stage of infection.  
3.3.9. Summary 
In summary, I have fitted a model to virus titre data from primary and secondary dengue 
cases, estimated the parameters of the dengue infection process and found parameter 
differences between primary and secondary infections, consistent with the theories of ADE or 
antigenic sin. The weight of the evidence across model formulations and datasets for DENV1 
is pointing towards antigenic sin, but without ruling out ADE as also having an impact in 
early infection. The results for the other serotypes were more mixed. 
To recreate differences between serotypes, both intrinsic virus and immune response 
parameter differences were possible. The picture for the secondary differences was less clear 
than for the primary, perhaps suggesting that the primary infecting serotype (which is 
unknown) has a role to play here too.  
 I considered the impact of an antiviral within the dengue infection system, showing that an 
effective antiviral can impact the virus dynamics, but the earlier this is given the better. The 
work also shows there may be issues in assessing the efficacy of an antiviral due to many 
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patients arriving late into their virus profile, and because of variation between patients. More 
work is needed to understand which is the best outcome to use for assessing if an antiviral is 
effective at controlling replication and how an antiviral will be of best use for treatment.  
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Chapter 4 : Modelling antibody 
role in virus clearance 
In this chapter I mainly focus on the role of antibody in controlling infection though, with a 
brief consideration of enhancement. I use unique data giving sequential viral and antibody 
titre measurements for a number of hospitalised dengue patients. I find a model consistent 
with antibody for a role in the control of infection, but there are caveats as I will discuss 
further below. The model proliferation form consistent with the antibody data is also found 
and discussed.  
To assess the role of antibody in controlling infection, in the following section I describe data 
on antibody dynamics throughout infection, and use statistical and mathematical modelling to 
analyse these data. I also consider what it is possible to learn about the functional form of 
antibody proliferation. I consider different models of the action of antibody and differences 
between serotypes and individuals.  
4.1. Methods 
4.1.1. Data 
The data comprises of dengue virus and IgM and IgG measurements twice daily and anti-E 
IgG once daily taken from multiple dengue patients for at least 5 days from their arrival in 
hospital. This final dataset has been published as a clinical trial (Nguyen et al., 2012). The 
clinical trial was undertaken to assess the safety and impact on dengue virus dynamics of 
balapavir, a drug used to treat Hepatitis C. Unfortunately, no significant difference was noted 
between the treatment and the placebo groups, so individuals from the two arms are grouped 
together in my analysis. Similar to the first dataset, the trial was undertaken on hospitalised 
adult dengue patients, with twice daily blood samples taken. The data is presented in Figure 
4-1 and Figure 4-2. A different PCR assay was used for this dataset than for the previous 
datasets in this thesis, with a lower limit of detection of 357 viral copies/ml of plasma for 
DENV1 and 72 viral copies/ml of plasma for DENV2. In addition to the published data, 
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antibody titre measurements were taken throughout infection. I thank Than Ha Quyen and 
Duong Thi Hue Kien
 
for their work in producing these antibody titres. 
IgG and IgM antibodies were measured using an ELISA assay as described above and in 
(Cardosa et al., 2002, Hang et al., 2009, Chau et al., 2009), with the resulting titres an optical 
density. This ELISA does not measure the antibody to a specific epitope, but the overall 
binding of the antibody, and does not give an antibody per ml measurement by an overall 
antibody titre in units. For DENV1 anti-E DENV1 protein IgG antibody titres were 
determined once per day also by ELISA, though this time using serial dilutions, and the 
outcome relative to the dilution that resulted in 0.3 optical density, as described in (Chau et 
al., 2009). Therefore the resulting titres are on a different scale to the IgG and IgM. Anti-E 
IgG has a lower limit of detection at 10 units. Due to the larger range of the anti-E values and 
the dilution outcome, these titres were presented and used in the likelihood expression, on a 
log scale. A summary of the characteristics of the dataset is given in Table 4-1 and the data 
presented in Figure 4-1. It is of interest to note that in some patients the titres of IgG and IgM 
antibody are still low at the time virus starts to decline. In addition, all primary infections and 
some secondary infections still had undetectable levels of anti-E IgG antibody at the end of 
infection. However, this heterogeneity enables us to consider what is controlling infection, 
and how that may differ between patients. A peak in virus (an increase from the first 
measurement) was observed in 12 out of the 32 DENV1 patients, and in 7 out of the 21 
DENV2 patients. Using the antibody titres, individuals could be classed as primary or 
secondary infections. When using the antibody titres this classification must be used with 
care and I discuss this in later sections. Of the DENV1 cases, 5 would be classified as 
primary, the remainder secondary, and all the DENV2 cases are secondary. 
 DENV1 DENV2 
No. of patients 32 21 
No. of measurements per person 
virus IgG, IgM (mean, s.d.) 
11.4, 0.5 11.4, 0.5 
No. of measurements per person anti-E IgG 5 0 
Day symptoms at first measurement 
(mean, median, s.d.) 
1.6, 1.7, 
0.35 
1.5, 1.6, 
0.30 
% Secondary 84 100 
Virus decrease rate log10 
(mean, median, s.d.) 
-1.2, -1.3, 
0.70 
-1.5, -1.4, 
0.40 
Virus titre at start of decrease log10 
(mean, median, s.d.) 
9.0, 9.3, 
1.2 
8.2, 8.1, 
0.9 
Day of virus decrease start (symptoms) 4.2, 4.3, 3.9, 3.7, 
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(mean, median, s.d.) 1.4 1.5 
IgM at start of decrease 
(mean, median, s.d.) 
3.8, 2.4, 
3.7 
4.1, 2.3, 
4.9 
IgG at start of decrease 
(mean, median, s.d.) 
1.7, 0.9, 
2.8 
4.5, 1.6, 
11.6 
Anti-E IgG at start of decrease 
(mean, median, s.d.) 
127, 10, 
420 
- 
 
Table 4-1: Summary of data characteristics. 
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Figure 4-1: Measured viral and antibody titres over time for DENV1 patients.  
The left hand axis shows log10 viral copies/ml of plasma in black and log10 anti-E titres 
in green. The right hand axis shows IgG titres in red and IgM titres in purple (both on a 
linear scale). Each box is a different individual. Unfilled marker symbols show 
measurements below the assay limit of detection for virus and anti-E IgG and above the 
upper limit of reliable (linear) quantification for IgG and IgM (Nguyen et al., 2012). 
 
Figure 4-2: Measured viral and antibody titres over time for DENV2 patients.  
The left hand axis shows log10 viral copies/ml of plasma in black. The right hand axis 
shows IgG titres in red and IgM titres in purple. Each box is a different individual. 
Unfilled symbols show measurements below the assay limit of detection for virus and 
above the upper limit of reliable (linear) quantification for IgG and IgM (Nguyen et al., 
2012). 
 
4.1.2. Correlations 
I used Spearman’s rank correlation to examine correlations between antibody and virus 
dynamics, as this statistics is insensitive to outliers. I explore the following relationships:  
Rate of decrease of log10 virus vs.  
1. increase in antibody during time of virus decrease 
2. antibody titre at start of virus decline 
3. ratio of log10 viral titre to antibody titre at time of start of viral decline  
4. ratio of viral titre to antibody titre at time of start of viral decline  
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I undertake these analyses separately for IgG and IgM for both DENV1 and 2 and anti-E IgG 
for DENV1. I use log10 virus titres of the virus due to the exponential decrease and the large 
differences in values. Using this however means we cannot consider any possible one-to-one 
relationship between antibody and virus.  
If a “peak” in virus was observed, the highest virus titre point was taken as the start of virus 
decline. Otherwise the start of decline was taken as the point from which there was greater 
than 1 log10 decrease in virus titre in one day as in (Tricou et al., 2011). There is no 
difference seen in the rate of virus decline or antibody titres at the start of decline between 
patients with and without a peak, though it is not possible to be sure a reasonable surrogate 
of the peak is captured. The decline rate was calculated over the period until the final 
measurement or until the virus titres fell below the limit of detection, whichever was first 
using
   10 10log v  log
( )
p E
p E
v
t t
 
 
 
 
, where vp is the virus titre at peak, vE virus limit of detection 
or the final measurement used, tp time of peak, tE time of undetectable virus or final 
measurement. Person 15 did not ever have a greater than 1 log10 decrease in virus titre in one 
day so was excluded from the analysis.  
For IgG and IgM, the antibody increase was taken until the antibody goes above 25 units (so 
tE is time until antibody above 25, the upper limit of reliable (linear) quantification, with the 
virus decline rate in the same period (so vE is the corresponding virus at time tE). For anti-E 
IgG the antibody increase was measured up until the final virus measurements used.  
For those patients in which there were measurements before the peak of virus, I considered 
the relationship between time from symptom onset to virus decline and antibody increase up 
to the start of virus decline. I also attempted to see if there was a sharp increase in antibody 
just before the virus decline, using the ratio of antibody from one day to the next, at and after 
the peak: i.e. I tested using the Mann Whitney test whether there was a different between: 
( ) ( 1)
and
( 1) ( )
Ab p Ab p
Ab p Ab p


, where p is the day of peak virus titre Ab is the antibody 
measurement.  
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In order to correct for multiple testing, I use the Bonferroni correction (simple and 
conservative) of α= ἀ /n, where ἀ is the previous significance level, n the number of 
comparisons undertaken and α the new significance level.  
 
4.1.3. Dynamical models 
I adapted the models used in Chapter 3 to fit to viral dynamics alone, to also fit to the 
antibody data presented above. As the primary and secondary classification is reached by the 
antibody titres and in this work I am fitting to the antibody titres, I was loath to group cases 
by this classification. Initial model fitting with the groups altogether determined that IgM 
could fit both primary and secondary cases, but for the IgG certain patients were not being fit 
(and the parameter values here were causing the MCMC to crash overall). On inspection 
these individuals that the model would not fit were those individuals who would be classed as 
primary cases. I therefore only fit the IgG data to the secondary cases. Two immune 
processes were considered: (a) proliferation of the immune response and (b) the clearance of 
infection by antibody. Three forms of immune proliferation function were fitted: 
 f (y, v, z)= (η1yz / (η2 + z)),  
 f (y, v, z)= (η1yz / (η2 + y)),  
 f (y, v, z)= ηyz    (the original form used for most of Chapter 3)  
As in the last chapter, I consider antibody clearing either infected cells or virus (α >0 or ε>0). 
I mainly took the immune response parameters and the incubation period (η1, η2, SF, z0 and 
IP) as patient specific parameters. In the between patient-heterogeneity section I considered 
different combinations of the immune response parameters as patient specific. 
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4.1.4. Fitting to data 
The parameters of the model and their values are given in Table 4-2. 
Parameter Meaning Value/Estimated 
A Constant target cell production/ml/day 1.4x10
6
 
 Cell death rate/day 1/7 per day 
 Infection rate of target cells per virion estimated 
 Removal rate of infected cells/day per immune cell 1 
 Infected cell death rate/day 1/7 per day 
 Production rate of virions/day per infected cell 1x10
4 
 Virion clearance rate/day estimated 
1 Proliferation rate of immune cells/day per infected 
cell 
estimated 
2 Threshold parameter for the immune response 
proliferation- in logistic growth model 
estimated 
SF Scaling factor of immune response estimated 
z0 Initial population size of immune effector 
population 
estimated 
v0 Initial inoculum of virus 1/ml 
Table 4-2: The parameters of the model and values if fixed.  
The parameters z0, 1, 2 and SF and the incubation period are replicated for each 
patient. The parameter z0 is estimated, with α fixed.  
 
 
Slightly differently from the work in Chapter 3, I estimate z0 here, not α, and use a scaling 
factor (SF) for the antibody measurements to translate them into ‘true’ antibody titres. The 
model output antibody titre is multiplied by this scaling factor parameter to produce antibody 
‘measurements’ comparable with the data, and is therefore used in the likelihood only. This 
factor is necessary as the ELISA assay used to quantify antibody does not give precise 
concentrations of antibodies per ml of plasma. The model fitting was undertaken as described 
in Chapter 2, with the addition of a term in the likelihood corresponding to antibody 
measurements. Error in IgG and IgM measurements was assumed to be on a linear (non-log) 
scale but on the log scale for anti-E measurements, due to the dilution technique and the very 
large measurements towards the end of infection otherwise dominating the likelihood. For the 
IgG and the IgM measurements, there is the additional complication of what is essentially an 
upper limit of detection, LDa. Above the limit of LDa =25, we cannot assume the measured 
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value is linearly proportional to true antibody concentration. For measurements above LDa I 
therefore use the probability that the observation is above LDa in the likelihood. Error was 
assumed to be = 1. The full likelihood is given by Equation 4-1.  
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Equation 4-1: Full likelihood expression for the antibody dataset IgG and IgM 
measurements.  
ϕ is the Gaussian (normal) probability density function (pdf),   is the cdf of the normal 
distribution, n is the number of observations for that individual, Div is the ith viral load 
measurement and xiv is the model virus prediction at the time of the ith measurement. 
LDv is the limit of detection and σv is the error in viral load measurement. The indicator 
function, civ equals 0 if Div > LDv and equals 1 if not (as previously defined in Chapter 
2). In addition, Dia is the ith antibody measurement and xia is the model antibody output 
at the time of the ith measurement and SF the scaling factor. LDa is the upper limit of 
detection for the antibody measurements and σa is the error in the antibody 
measurements. The indicator function, cai = 1 if antibody measure i is above the limit of 
detection (LDa), and = 0 if not.  
 
The anti-E measurements have a lower limit of detection, and I use the same method here as 
for the handling the lower limit of detection of virus. This gives the likelihood for the virus 
and anti-E measurements as in Equation 4-2.  
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Equation 4-2: Full likelihood expression for the antibody dataset anti-E measurements. 
  is the Gaussian (normal) probability density function (pdf),   is the cdf of the 
normal distribution, n is the number of observations for that individual, Div is the ith 
viral load measurement and xiv is the model virus prediction at the time of the ith 
measurement. LDv is the limit of detection and σv is the error in viral load measurement. 
The indicator function, civ equals 0 if Div > LD and equals 1 if not (as previously defined 
in Chapter 2 and above). DiE is the ith anti-E antibody measurement and xiE is the model 
anti-E antibody output at time of the ith measurement, SF the scaling factor. LDE is the 
lower limit of detection for the anti-E antibody measurements and σE
2 
is the standard 
deviation for the anti-E antibody. The indicator function, cEi = 1 if antibody measure i is 
below the limit of detection (LDE), and = 0 if not. 
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I take the natural logarithm of these expressions, and assuming independence between 
individuals sum over all individuals. The log likelihood is then used to fit the model and 
estimate the unknown parameters as described in Chapter 2. 
4.2. Results 
4.2.1. Correlations 
I performed 24 tests so the significance level is 0.05/24 = 0.0021. The one significant result 
was a positive correlation for DENV1 data between the increase of IgM and the virus decline 
rate this is also the strongest correlation. There is also a negative correlation with IgG 
increase and virus decline rate, thought this is not signifciant. 
Serotype Antibody 
Measure 
1 2 3 4 
DENV1 IgG 
 
-0.43 
p= 0.015 
-0.23 
p=0.19 
0.04 
p=0.82 
0.21 
p=0.26 
 IgM 
 
0.67 
p= <0.0001 
-0.15 
p= 0.39 
0.03 
p=0.7 
0.13 
p=0.46 
 anti-E 
 
-1, 
p= 0.3 
-0.16, 
 p= 0.36 
-0.22,  
p= 0.21 
-0.01,  
p= 0.95 
DENV2 IgG 
 
-0.36 
p-:0.15 
0.13 
p=0.56 
-0.02 
p=0.93 
0.20 
p=0.28 
 IgM 
 
-0.13  
p=0.54 
-0.29 
p=0.19 
0.06 
p=0.78 
0.19 
p=0.39 
 
Table 4-3: Spearman rank correlations (rho) and significance (p) values for rate of log10 
virus decrease. 
 Rate of log10 virus decrease vs. 1) increase in antibody during time of virus decrease, 2) 
antibody at time of virus decrease, 3) ratio of virus to antibody at time of decrease, 4) 
ratio of log10 viral titre to antibody titre at time of start of viral decline. Results for IgG, 
IgM for both DENV1 and 2, and for anti-E IgG for DENV1. 
 
In considering the period before infection, I look at whether there is anything that indicates 
the virus decline is about to start. For the ratio of antibody from one point to the next before, 
and at, the start of virus decline, for DENV1 IgM there is a small and not quite statistically 
significant (with the multiple testing correction) increase from before to at the time of virus 
decline commencement across people (p 0.025). There is a mean of 1.29 (s.d. 0.38) before the 
start of the virus decline compared to 1.67 (s.d 0.79) at the peak. The same increase is not 
seen for IgG (1.21 vs. 1.3, p 0.65), nor for DENV2 IgG (p 0.25). The result is however 
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borderline significant for DENV2 IgM (p 0.054) where there are only 7 patients in the 
DENV2 sub-group. These results may provide a pointer towards the antibody as measured by 
the IgM having an impact at the start of the virus decline, though of course it is not possible 
to show causality. Due to having the measurements every other day, I was unable to consider 
the anti-E IgG on such a fine scale. 
4.2.2. Dynamical model fit 
For the following sections (until the heterogeneity section) immune response parameters and 
the incubation period (η1, η2, SF, z0 and IP) are patient specific.  
I consider a few different forms for the function determining immune proliferation. I found 
that that the ηyz used as the default assumption in Chapters 2 and 3 did not fit the IgG and 
IgM data well. This is also obvious from a visual inspection of the data showing that antibody 
does not sharply increase and peak as the virus peaks. We therefore require a different form 
from ηyz or η1yz/(η2 + z) as Chapter 2 shows that these two forms can only produce an 
antibody peak at close to the same time virus peaks. I therefore adopted the form η1yz/(η2 + 
y), which reduces to ηyz and ηz in edge cases (the coefficient of the functional form as y 
increases is depicted in Figure 2-5). This functional form fits the data much better ( 
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
, Error! Reference source not found., Error! Reference source not found. and Error! 
Reference source not found.). Resulting parameter estimates are given in Error! Reference 
source not found. and Error! Reference source not found.. The chosen functional form 
assumes there is a threshold density of infected cells, above which antibody proliferates 
exponentially, this proliferation saturates at high infected cell densities. For some patients, 
the estimated threshold is low, so effectively pure exponential (ηz) proliferation is seen from 
the start. Conversely, for the anti-E data the ηyz form fitted best with the model fit unable to 
resolve all the parameters of the η1yz/(η2 + y) model. Results presented in this chapter 
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therefore use the η1yz/ (η2 + y) form of immune response proliferation for IgG and IgM and 
ηyz for the anti-E IgG. 
Antibody is thought to work by either contributing to cell death (ADCC), or by neutralising 
virus. In the previous chapters, I found little to help distinguish between these two models. 
Assuming immunity removes virus produced parameter estimates less consistent with the 
expected infected cell lifespan, and differences in whether the infected cell dynamics 
followed those of the virus, but the viral titre data could be fitted equally well with either 
assumption. However, given I am modelling antibody responses specifically in this chapter, 
one might expect virus removal/ neutralisation to be the dominant mode of action of 
immunity ((Pierson and Diamond, 2008).  
It is perhaps unexpected that, in the fitting presented below I find more evidence supporting 
the ADCC hypothesis – the parameter estimates are more plausible, and the model fit is better 
(though there could be more work to do on fitting the virus removal model and the possible 
differences in target cell numbers between the models). For DENV1 IgM all patients, the log 
likelihood is -859 assuming antibody removes virus (with the infected cells having a lifespan 
in the absence of immune response of ~7 hours), and -798 assuming antibody removes 
infected cells. The log likelihoods for DENV2 were -1633 and -1138 assuming antibody 
clears virus or infected cells respectively. Therefore, I present results which assume antibody 
clears infected cells for the rest of this chapter.  
 In figures  
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
 
 
170 
 
 
Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
, Error! Reference source not found., Error! Reference source not found., Error! 
Reference source not found. and Error! Reference source not found. I present fits of the 
mechanistic dynamical model to the data for the different serotype groups and antibody types 
for the immune response removing infected cells, the (η1yz / (η2 + y)) immune response 
proliferation form for IgG and IgM and ηyz for the anti-E IgG, and parameters η1, η2, z0 and 
IP as patient specific, the other parameters fitted per group. The parameter estimates for these 
models are shown in Error! Reference source not found., Error! Reference source not 
found. and Error! Reference source not found.. IgG are shown for secondary only as the 
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model was unable to fit the primary cases due to there being no IgG increase during the time 
of infection (as discussed above). Model output from parameters sampled from the posterior 
distributions is shown in grey (virus), blue (target cells), light purple (IgM) and pink (IgG). 
Model output with the median parameters is shown in the bolder lines (black (virus), purple 
(IgM) and red (IgG)).  
From the fits obtained, it can be seen that it is possible to find a model consistent with either 
IgG or IgM antibody being responsible for controlling infection, though the fit to the anti-E 
IgG data is less convincing for antibody against this epitope playing the dominant role. But 
like the work in Chapter 3, there is great uncertainty as to system dynamics early in infection, 
due to the lack of measurements. Comparing directly between antibodies is difficult due to 
the different values, scales, and upper and lower limits of detection of the measurements. 
Qualitatively, IgM seems to fit slightly better (even for DENV2 where all are secondary 
cases) ( 
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
 
Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
 and Error! Reference source not found.), though for the secondary cases IgG 
measurements also fit well. Unless the measured levels of IgG are actually changing over 
time in a primary infection (but not picked up by the measurements) then something else 
must be controlling infection. Are there different processes occurring in primary or secondary 
infection or would it make more sense that IgM is at work in controlling infection in both 
primary and secondary disease? The better fit for IgM could imply that IgM has a more active 
role than IgG. However, IgM could fit better due to the measured IgG values also containing 
antibody towards a different serotype, meaning not all measured antibody would have the 
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impact I am assuming in the model. Though the scaling factor should go some way to 
incorporate the possibility of “non-useful” antibody being captured, it is not considered in the 
model that the scaling factor could change during infection. The anti-E IgG measurements for 
DENV1 is serotype-specific too, and these also provide a fairly good fit, though with much 
greater uncertainty than the other measurements and with some patients not fitting at all. 
The most important time period for the antibody fit is the area around the virus peak. In some 
cases, the model fits well, but in others the model needs an increase in the antibody level to 
control the virus where such an increase is not observed in the data. 
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-104-11: MCMC traces for DENV1 patient 1 IgM model fit diagnostics. 
MCMC traces for: log likelihood, β, z0, η1, IP, κ, SF, η2 shown. MCMC shown are 
thinned with every 100
th
 run shown. Model fit of DENV1 virus and IgM measurement, 
parameters η1, η2, SF, z0 and IP as patient specific, the other parameters fitted per 
group. Last 2000 runs of those shown here were taken for the posterior distributions.  
 
Figure 4-124-13: MCMC traces for DENV2 patient 1 IgM model fit diagnostics. 
MCMC traces for: log likelihood, β, z0, η1, IP, κ, SF, η2 shown. MCMC shown are 
thinned with every 100th run shown. Parameters z0, η1, η2, SF and IP as patient specific, 
the other parameters fitted per group. Last 2000 runs of those shown here were taken 
for the posterior distributions. 
 
loglikelihood β η1 
IP κ η2 SF 
α 
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It was more difficult to achieve good MCMC mixing and convergence with this model and 
dataset than in Chapter 3, as with additional datasets and parameters comes added 
complexity, and the necessity to complete more MCMC runs. I show diagnostic MCMC 
traces for the fit to virus and IgM data for one patient of each serotype Figure 4-104-11 and 
Figure 4-124-13 (MCMC update acceptance rates were generally acceptable (typically 20-
30% and always above 5%). 
The main parameter there are difficulties with is β. Note in the correlation figure that the 
estimate of β is correlated with the scaling factor of the antibody. In limiting the number of 
parameters to be estimated, mixing and convergence were achieved more easily with fewer 
patient specific parameters. For DENV2 model fitting, β was fixed. Possible extensions will 
include using the estimates of β from the previous chapter as prior distributions for the work 
in this chapter.  
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4.2.2.1. Between-patient heterogeneity 
In considering patient heterogeneity I concentrate on the IgM dynamics for both DENV1 and 
DENV2 (now estimating  too). As well as considering the parameter estimates as they vary 
between patients, it is possible to consider different models with different combinations of 
parameters at “patient specific” as in Chapter 3. It is not possible in the current chapter to 
consider primary vs. secondary infections due to the small number of primary infections.  
Patient specific 
Parameters 
Log likelihood BIC 
z0, η1, η2, SF, IP -789 2653 
z0, η1, η2, SF, IP -1138 3129 
SF, z0, IP -866 2397 
SF,z0, IP -1093 2603 
η1, η2, IP -979 2622 
η1, η2, IP -1286 2990 
Table 4-7: Posterior median log likelihoods and BIC of the fit of different models with 
varying combinations of parameters fitted as patient specific.  
In the model fit figures ( 
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
, Error! Reference source not found., Error! Reference source not found. and Error! 
Reference source not found.) the model with η1, η2, SF, z0 and IP as patient specific 
parameters are shown. Retaining the variation in the incubation period for all models, I 
consider here whether the majority of variation is coming either from the initial number of 
immune cells and the scaling factor (so some measure of the immune efficacy/ proportion of 
the immune response responsible for clearance), or the parameters governing the immune 
response proliferation, (so differences coming in how the immune response develops, not in 
how efficacious it is), with the log likelihoods and BIC given in Table 4-7. Interestingly in 
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both DENV1 and DENV2 the best BIC (with the likelihoods not far off the full variation 
model) was obtained with the scaling factor and the initial immune cells number varying 
between patients. In the z0, SF, IP model it is possible to capture both variations in the 
antibody titres and in the virus titres, including peak. It appears that although there is 
variation in the antibody titres, the variation does not translate to variation in the parameters 
governing the response proliferation. In the previous chapter, most of the heterogeneity 
between individuals could be recreated in the models with variation in the immune response 
proliferation, and not the immune response efficacy (α not z0 estimated in the previous 
chapter as they were not distinguishable). This previous result is different to what I estimate 
here with the different immune response proliferation form and additional data. 
In another way to consider patient variation I return to the full model and consider the 
patients and their parameter estimates and model outcomes. An interesting question is 
whether there are patients that are “faster responders”, i.e. develop an antibody response more 
quickly. With the parameterisation of the immune response proliferation here, “faster 
responders” do not come out immediately. However to consider this question I evaluate (η1y/ 
(η2 + y)) the coefficient of z in the immune response growth equation. The maximum value of 
the coefficient of z does not vary greatly amongst people, but the maximum is reached at 
slightly different times (3 - 5.5 days after infection).  
I considered the estimates of each model parameter against some discrete model outcomes: 
maximum virus titre, minimum target cell number and the final level of modelled immune 
response (something it is not possible to consider with the data due to the non-linearity of IgG 
and IgM measurements beyond 25). Here there are (borderline) significant correlations 
between z0 and both the maximum value of virus (-0.38, p= 0.05) and the minimum of target 
cells (0.48, p= 0.005), once again highlighting the importance of z0 in controlling dynamics in 
the current model. There is also a significant correlation between the estimates of the scaling 
factor and the minimum of target cells (0.45, p=0.009) but no significant correlations with the 
other outcomes. Between the estimates of the incubation period and both virus peak and 
target cells there is a correlation (with the greater the incubation period the greater the peak, 
correlation coefficient 0.45, p= 0.009) and also between the incubation period estimates and 
the target cell depletion (-0.59, p= 0.0009). The first could be due to the lack of imputation of 
peaks in the model fit, and the second due to the correlation between higher peaks and target 
cells depletion (-0.81, p<0.0001). There is borderline significance between η1 and both virus 
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peak (0.32, p= 0.06 and the final level of immune response (0.33, p= 0.7), but not with the 
target cell depletion.  
Though not a rigorous analysis of the dataset there are a few patients it is worth looking at 
qualitatively. Patient 8 DENV1 in  
 
Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
 has titres of IgG and IgM, that in this patient do not control infection, but which are high 
enough to do so in others. Looking more closely there are differences in patient 8’s anti-E 
IgG, with anti-E IgG becoming detectable as virus begins to decrease. The current model 
does not seem to be able to reproduce the peak titres at the right time, and the duration of 
time at peak observed in the data, in patient 8 either. A longer time at peak could be caused 
by target cell depletion. Considering the secondary models in Chapter 2 it seems possible that 
an enhancement model could also create the observed longer period at the peak, with the 
enhancement and clearance processes briefly at equilibrium. 
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Patient 15 in  
 
Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
, who is excluded from the statistical analysis because they never have greater than 1 log10 
virus decrease in a day, has the lowest virus titres and among the highest antibody at start of 
measurements (though the high antibody measurements could be due to time into the 
infection). The model fit for patient 15 is peculiar with the ηyz form of the immune 
proliferation a good fit, and highest measurements taken as the peak in order to capture the 
slower virus decline. It is possible also to impute a peak before the measurements begin 
though it is then more difficult to capture the virus decline rate. Finally, there are a few 
individuals in which there appears to be a two phase decline (something which is not seen in 
232 
 
datasets from Chapter 3 due to the higher limit of detection). This two phase decline is not 
captured by the model. In Section 4.3, I will discuss how it would be possible to extend the 
model to consider these. 
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4.3.  Discussion 
Using sequential virus and antibody measurements I aimed in this chapter to explore the 
relationship between virus and antibody response dynamics during dengue infection.  
My analysis provides some evidence for a role of IgM and IgG antibody in shaping the 
observed virus dynamics. For DENV1 infected patients (the majority of the dataset), I find a 
correlation between the rate of increase in IgM during infection and the virus decline rate. 
More convincingly, the mechanistic models I fit to the patient data can successfully 
reproduce observed viral dynamics with an immune response with dynamics which match 
observed antibody dynamics well. However, the fit is not perfect: for some patients, the fit to 
the antibody levels around the peak of virus is poor, with the model predicting changes in 
antibody around the virus peak that are not seen in the data (see for example, patient 4 in  
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Figure 4-3: Model fit of DENV1 virus and IgM measurements (primary and secondary 
patients).  
Each plot shows an individual patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Mauve, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (purple shows IgM, black show virus). 
Parameter estimates are shown in Error! Reference source not found..  
 
Figure 4-4: Model fit of DENV1 virus and IgG measurement secondary patients only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Pink, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (red shows IgG, black shows virus). 
Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-5: Model fit of DENV1 virus and anti-E IgG measurement secondary patients 
only. 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group. Orange, grey and blue curves show samples 
from the posterior distributions of antibody, virus and target cell trajectories, 
respectively. Median fits are shown as bold lines (brown shows anti-E IgG, black shows 
virus). Parameter estimates are shown in Error! Reference source not found.. 
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Figure 4-6: Model fit of DENV2 virus and IgM measurements (all patients, all secondary only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated. Mauve, grey and blue 
curves show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (purple shows IgM, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
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Figure 4-7: Model fit of DENV2 virus and IgG measurements (all patients, secondary 
only). 
Each plot shows a separate patient. Parameters z0, η1, η2, IP and SF fitted as patient 
specific, other parameters fitted per group, not estimated.. Pink, grey and blue curves 
show samples from the posterior distributions of antibody, virus and target cell 
trajectories, respectively. Median fits are shown as bold lines (red shows IgG, black 
shows virus). Parameter estimates are shown in Error! Reference source not found..  
 
 
In some cases there is a possible biphasic virus decline, not captured by the current model 
though such dynamics could be readily captured by including different target cells (with 
different lifespans) or perhaps multiple immune responses playing a role.  
The imputed target cell dynamics vary between models, but significant depletion of target 
cells is predicted for many DENV1 and some DENV2. This implies that not just the antibody 
control is playing a role in the virus dynamics at this point. Links have been suggested 
between target cell depletion and disease severity for other diseases such as influenza 
(Dobrovolny et al., 2010). For this data, we see that patients with greater drops in target cells 
also seem to spend longer at or around the peak virus titres, which may mediate more severe 
symptoms.  
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My aim in the current chapter was not parameter estimation, but in fitting to the data it is 
possible to estimate parameters. I show parameter estimates for the (η1yz / (η2 + y)), model 
fit, with the antibody acting by removing infected cells, with parameters z0, η1, η2, IP and SF 
as patient specific. 
Serotype Parameter Parameter Estimates 
DENV1 β 4.27x 10
-10
 (4.04 x 10
-10
, 4.62 x 10
-10
) 
 z0 1.29 x 10
-1
 (4.58 x 10
-2
, 3.70 x 10
-1
)  
                        2.52 x 10
-5
, 4.65         
 η1  1.15  (0.925, 1.37 )      
0.485, 2.04* 
 IP 3.90 (3.30, 4.76) 
2.31, 7.07 
 κ 3.94 (3.84, 4.10) 
 SF 0.299 (0.167, 0.473)    
1.25x10
-2
, 2.94  
 η2 6.92 (1.97, 65.4) 
3.73 x 10
-4
, 1.52x10
5  
**
 
DENV2 β 2x10
-10
 
 z0 2.53x10
-2
(9.85x10
-3
, 0.102) 
 2.37x10
-4
, 0.261 
 η1 0.986 (0.799, 1.20) 
 0.541, 1.90 
 IP 6.87 (5.98, 7.64) 
 4.74, 9.73 
 κ 4.04 (3.91, 4.18) 
 SF 0.256 (0.159, 0.499) 
 0.06.41x10
-2
, 0.888 
 η2 0.713 (0.104, 12.3) 
 4.06x10
-4
, 4.68x10
3
 
* 3.38 x 10
188
   , **3.06 x 10
189
    Values for patient 15 (see below) 
Table 4-4: IgM parameter estimates for the models fitting each serotype separately.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
 
 
Serotype Parameter Parameter Estimates 
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DENV1 β 3.04 x 10
-10
 (2.89 x 10
-10
, 3.31 x 10
-10
) 
 z0 1.17x10
-2
 (3.26x10
-3
, 0.036 ) 
2.11 x 10
-4
, 1.94 
 η1 1.48 (1.37, 1.69) 
1.04, 3.87 x 10
127
 
 IP 4.52 (3.89, 5.18 ) 
1.61, 6.13 
 κ 3.97 (3.84, 4.15) 
 SF 0.103 (0.0278, 0.436 ) 
6.31 x 10
-3
, 3.04 
 η2 18.4 (0.0330, 185)  
5.24 x 10
-7
 9.99 x 10
130
 
DENV2 β 2x10
-10
 
 z0 2.34x10
-2
 (4.24x10
-3
 , 0.112) 
 2.02x10
-3
 0.407  
 η1 1.37 (1.28, 1.60) 
1.11, 4.85x10
6
 
 IP 4.33 (3.77, 4.91) 
3.24, 6.57 
 κ 4.10 (4.00, 4.24) 
 SF 6.83x10
-2
 (3.16x10
-2
 , 0.177) 
 1.66x10
-2
, 0.654 
 η2 0.280 (1.05x10
-2
, 1.97) 
1 4.85x10-
-4
 2.58x10
11
 
 
Table 4-5: IgG parameter estimates for the models fitting each serotype separately, 
secondary only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
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Serotype Parameter Parameter Estimates 
DENV1 β 2.87 x10
-10
 (2.46 x10
-10
, 3.23 x10
-10
) 
 z0  0.249 (6.86 x10
-2
, 7.37 x10
-1
)  
2.31 x10
-6
, 1.90 
 η 4.44 x10
-6
 (1.59 x10
-6
, 2.81 x10
-5
) 
5.57 x10
-7
, 4.79 x10
-2
 
 IP 6.18 (5.61, 6.80) 
4.03, 7.73 
 κ 6.14 (5.57, 6.63) 
 SF 112 (12.6, 399) 
0.156, 4.32 x10
4
  
 
Table 4-6: Anti--E IgG parameter estimates DENV1 secondary cases only.  
For immune response parameters and the incubation period which are patient specific 
parameters, median (IQR) and min and max are reported. For the group-level 
parameters, β and κ the median and (95% CI) are reported. Parameters z0, η1, η2, IP and 
SF were fitted as patient specific and others as common to all patients in the fitted group. 
 
 
 
In Error! Reference source not found., the starred values correspond to patient 15, where 
the ηyz form of immune response proliferation fits just as well as the saturating form for both 
IgG and IgM, meaning and estimates of η1 and η2 can be arbitrarily large (so long as η2 is 
much greater than y). Patient 15 is discussed in detail later. This is again true for the IgG fits 
(Error! Reference source not found.) to patient 15, but since similar estimates are obtained 
for other additional patients when fitting IgG, we leave these estimates in the table. 
Comparing these parameter estimates to those from the previous chapter, values of β and κ 
are similar. The immune response parameter estimates however, have changed considerably, 
due to the different functional form of immune proliferation are being used. There is also a 
suggestion of shorter incubation period estimates in the current fits compared with those 
presented in Chapter 3.  
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Figure 4-8: Correlations in parameter estimates: DENV1 Patient 1 IgM and viral titre 
data (primary and secondary patients).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
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Figure 4-9: Correlations in parameter estimates: DENV2 Patient 1 IgM and viral titre 
data (all patients, all secondary).  
Parameters z0, η1, η2, IP and SF as patient specific, and other parameters fitted per 
group. Parameter estimates for patient 1 shown. Trace correlations plotted in the lower 
diagonal, correlation coefficient shown in the upper diagonal. Univariate posterior 
densities for each parameter are shown on the diagonal.  
 
 
), and in some individuals dips in the target cell numbers also shape the dynamics to some 
extent.  
My model predicts that relatively low levels of IgG or IgM antibody are sufficient for 
controlling infection. However, given we would expect antibody concentrations increase by 
many orders of magnitude following infection and that our measurement of antibody has 
errors which are approximately constant on a linear scale (as compared with viral load, where 
errors are constant on a log scale), this result is perhaps unsurprising. It does however imply 
that antibody concentrations substantially overshoot the levels needed to control infection.   
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Scaling factor- variation in efficacy of the antibody measures- further work will look more 
closely at the scaling factor as a common variable. Initial analysis has shown this to fit best 
for DENV2, but currently less well for DENV1. Further, on-going, work will explore this 
scaling factor in more depth in order to more greatly understand its impact on model fit and 
the relevant interpretation of these results.  
I found a qualitatively better fit for IgM than IgG (given the datasets being fitted are different 
in the two cases, it is not possible to compare likelihoods), but it is not clear whether the 
better fit tells us something about the actual antibody role or what the antibody measurements 
are quantifying. Fitting to both IgG and IgM will be undertaken in future. IgM could measure 
more specific antibody than IgG. IgG could be measuring a more mixed group of antibodies 
to different serotypes (all captured by ELISA) as it is more associated with the memory 
immune response. It is interesting that we do not see much difference in the IgG and IgM 
dynamics for secondary infections, contrary to what has been previously seen (Innis et al., 
1989). It is not clear to me why this would be, though may be to do with assays used or on 
considering averages across the groups opposed to individual dynamics. 
Delving more deeply into the different types and specificity of the antibody measures, we 
also considered anti-E protein IgG measurements. The model fit fairly well to this antibody 
measure though not as well across all patients as to the previous IgM and IgG and the model 
fit had greater uncertainty. The different methods used to take the anti-E measurements mean 
they have different errors from the overall IgG and IgM measurements. Anti-E measurements 
have a lower limit of detection, but no upper limit of detection. The model is less able to fit 
the observed timing of the increase in anti-E, though I am unsure if this is related to the lower 
measurement limit of detection (as there is no information to inform the proliferation 
parameters below this level), or because anti-E IgG is not the relevant antibody population, as 
has been noted in vitro work (Wahala et al., 2009, Williams et al., 2012). In the dataset there 
were also anti-E domain 3 IgG measurements which were not analysed in the work presented 
here, but could be of use in future work. 
Initial descriptive analysis shows a great variation in antibody titres at the time of virus 
decrease and throughout infection, with certain titres able to control the virus in some 
patients, but not in others. Considering this heterogeneity between patients with the model, I 
find that infection variation can be recreated by variation in the initial level of antibody and 
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what proportion of antibody is actually effective, not by variation in the parameters governing 
how the antibody proliferates. Measures of serotype specific antibody throughout infection 
will be of use to test this prediction. There is some evidence for only a small proportion of 
antibody raised against dengue infection actually being effective (de Alwis et al., 2011), and 
variation in this proportion between patients could result from heterogeneity in previous 
infection history. This also could account for variation in the initial level of effective 
antibody, due to differences in the timing and serotypes of prior primary infection between 
the secondary cases, as discussed in the introduction (Prince and Matud, 2011).  
More generally, this research is only of use in tandem with experimental work. Even if 
dynamically there is evidence for a role in antibody in either clearing virus or infected cells, 
if this is immunologically not possible, then both need to be further questioned. Similarly, if 
the immunological processes shown as possible to occur do not fit with the mechanistic full 
picture of the infection dynamics, then more work is needed in either the measurement of the 
immunological measures or to explore additional mechanisms.  
Within the model formulation there were some details that warranted further exploration. 
Understanding the form of the immune response proliferation is important in understanding 
the impact of something such as an antiviral, which may halt not only the virus reproduction 
cycle but also the immune response proliferation (as highlighted in the previous chapter). I 
used simplified functional forms of these processes, not an explicit model of B-cell dynamics. 
The initially assumed simple form for proliferation (ηyz) (as used in Chapter 3) was not a 
good fit to these antibody data, and a more complex saturating form was needed. This more 
complex form approximates the effects of mechanistically considering antibody speciation 
and proliferation (Deboer and Perelson, 1995). This form has a threshold, η2, of infected cell 
density above which antibody proliferates at a constant (exponential) rate. This threshold 
affects the action of antivirals (see Chapter 3), as if η2 is very small antibody proliferation 
rates depend only weakly on infected cell levels, leading to the rate of decline of virus being 
similar with or without antiviral use However, if η2 is larger, antivirals can modify the rate of 
immune response proliferation and thus viral titre declines.  
I also compared models of antibody action (clearing virus or by clearing infected cells). 
While both models fit qualitatively well, the parameter estimates and log likelihoods indicate 
that infected cell removal is the dominant mechanism, but there is more work to be done. 
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There is in-vitro evidence for both ADCC (Garcia et al., 2006) and virus neutralisation 
(Pierson and Diamond, 2008). The antibody measures here give us more information about 
the ability of the measured antibody to bind to virus (especially the anti-E titres); measuring 
the ability of sera to neutralise or the cell cytotoxicity ability of sera will be of use. 
Considering the decline phase, there is also evidence for a two phase decline in some 
patients. Not currently captured by the model, extensions of the model which may capture 
this could be different target cells populations, or more than one immune response clearing 
virus, infected cells or complexes at different rates.  
As mentioned previously, the relationship between symptoms and immune-virus dynamics 
has not been fully elucidated. There is some evidence for a correlation between T- cell 
responses and disease severity (Mongkolsapaya et al., 2003, Mongkolsapaya et al., 2006), 
possibly mediated by cytokine storms. Other work gives some evidence that the ability of 
antibody to kill cells (ADCC) varies between disease severity groups (Garcia et al., 2006). 
There is also some evidence for a “stronger immune response” (cytokine storm) in more 
severe dengue infections (Pang et al., 2007, Rothman, 2011). The cluster study design 
discussed later in this section (also see Chapter 3) would be of use to collect data from mild 
dengue cases to compare the immune response and virus dynamics between severity groups. 
In this dataset most of the patients were classified as having a secondary infection. When 
studying antibody response it is important to be careful as the primary/secondary 
classification is often made using antibody measurements (Innis et al., 1989), so there is a 
risk of tautology in discussing differences in antibody responses between primary and 
secondary infections. Epidemiological confirmation of primary or secondary (or indeed 
tertiary) infection (obtainable within closely monitored cohorts) would be of use. Though it is 
not possible to consider primary vs. secondary infection dynamics with this dataset, with 
more information it would be possible to consider whether different processes are occurring 
in the clearance phase of primary compared to secondary infection, as well as the early 
infection phase. 
The theme of understanding the early infection stage runs through this PhD. Of the ways of 
understanding these early stages all the methods described in Chapter 3 would still be of use 
in the study of controlling infection human challenge studies (Gunther et al., 2011) or cluster 
studies (Beckett et al., 2005) or recalling blood donors found to be infected with dengue. 
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These would mean being able to capture the dynamics before and at peak in more individuals. 
Extensions to the current work will continue to think about the whole infection, combining 
multiple data types and times of measurement. For example, the models presented in Chapter 
2, thinking explicitly about secondary infections, could be fitted to additional data on 
antibody neutralising and enhancing activity from early infection or antibody directed 
towards specific serotypes. Such data is seen in (Endy et al., 2004, Chau et al., 2008). 
Explicitly early in infection, we could consider if we see antibody capable of neutralisation 
and enhancement, what are the levels of these and how do the competing processes interact? 
Other extensions to the model could consider in more detail the antibody binding process. It 
is thought that antibody works on a binding threshold basis (Dowd and Pierson, 2011), and 
these thresholds could be modelled. An increasing area of research in regard to antibody 
neutralisation is the stoichiometry and physical shape of the virus and how the shape relates 
to antibody binding (Dowd et al., 2011, Midgley et al., 2012), with probable binding in 
multiple sites needed for neutralisation and with variation in the “stickiness” of antibodies. 
Models incorporating binding sites (a simple version is given in chapter 2) would be of use in 
determining what processes are necessary for neutralisation, and how the neutralisation 
process changes between primary and secondary infection. It was unfortunately not possible 
with the dataset used in this chapter to compare primary and secondary infection, but 
ultimately work with models and data such as these could inform our understanding of 
competition between antibody populations for binding sites, and the mechanism and impact 
of cross-immunity and antibody dependent enhancement. However, it would be advantageous 
for antibody titres to be reliably quantified at much lower concentrations than were possible 
for the measurements I considered in this chapter.  
Another theme running throughout this thesis is how models allow data at different scales to 
be combined. The research presented so far in this thesis has focussed on linking the 
molecular/cellular scale to that of a single host, to understand the dynamics of pathogenesis. 
The next level up is the population of hosts, where we are interested in the transmission 
dynamics of epidemics and how immune memory modifies those dynamics. Understanding 
the dynamics of how an epidemic modifies the distribution of antibody titres across a human 
population would be valuable here, but information is currently limited. Cohort studies with 
frequent antibody titres measurements (and more frequent sampling during and after 
infection) would be of use, as in the Nicaraguan cohort for example (OhAinle et al., 2011). 
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This would also help test the prediction the work here that variation in infection dynamics 
between individuals is in part governed by the size of the relevant immune cell population 
early in infection. As in the Thai cohorts (Laoprasopwattana et al., 2004) and the birth 
cohorts (Chau et al., 2008, Chau et al., 2009) multiple measurements of antibody titres 
throughout the time before infection are of great use in understanding antibody dynamics. 
Coupled with detailed information from infection (as in the dataset used here) these would be 
of even greater use, and would aid understanding of the relative importance of previous 
exposure to different serotypes, and how this interacts with subsequent immune response 
during infection 
Interesting technically will be the combination of multiple types of data. In the work 
presented in this chapter, combining the different data types was fairly straightforward and 
the likelihoods are easy to derive. As more immune response measurements (e.g. T cell 
activation or measurements of the innate immune response) become available, likelihoods 
will become more complex. Care will particularly have to be taken with the antibody 
measurements, which could have overlapping groups, i.e. the same thing measured in 
different ways. As with the work here, what is actually measured by an assay is imperative 
for how this will fit in with the modelling work and what we can learn from fitting models to 
it. In addition to the different approaches to quantifying antibody, measurements of other 
types of immune responses would be of use. Though I have developed a model consistent 
with antibody controlling infection, T-cells proliferate similarly during infection and may 
play a significant role in clearance of infected cells, particularly in secondary infection. It 
would also be of use to understand the dynamics of immune complexes throughout infection, 
as possible in some way in work by Moi et al, (Moi et al., 2011a). An interesting further field 
of study would the extent to which interferon (IFN) modifies viral pathogenesis, possibly 
acting by blocking virus entering the cell (Gunther et al., 2011, Kurane et al., 1993, Liu et al., 
2007, Shresta et al., 2004), for which data is available for this dataset. 
Though the model will be refined as more data becomes available, I hope work like this will 
encourage people to think quantitatively about infection dynamics and how the virus and 
immune response fit together throughout infection.  
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Chapter 5 : Modelling human 
infectivity to mosquitoes 
In this chapter I aim to put the previous chapters’ work in context at the population level, by 
considering the link between virus dynamics and the infectivity of an individual to a 
mosquito. Using data from mosquito biting experiments I consider the infectivity throughout 
infection of patients infected with different serotypes for both primary and secondary cases. I 
then explore the implications for our understanding of dengue transmission and for 
interventions such as antivirals and the release of Wolbachia-infected mosquitoes. I first 
begin this chapter with a brief discussion of dengue transmission models to date and the 
treatment of infectivity heterogeneity within and between cases in these models. I then 
present the data used in this section, followed by my analysis. I conclude with a discussion of 
the relevance of these results for understanding transmission. I also consider what this could 
mean for prediction of impact of and the best use of control measures, and what data and 
work is next needed to aid our understanding. 
5.1.1. Combining within- and between- host models 
Whether it is necessary or appropriate to explicitly include within host dynamics in a between 
host transmission model depends on the questions considered and the amount of information 
available. In the context of evolutionary modelling, work by Mideo and others presents a 
general framework for when it is necessary to include within host dynamics (Mideo et al., 
2008a). Later work considers the interaction between population level and within host 
dynamics and what this means for immune escape (Pepin et al., 2010, Volkov et al., 2010). 
Both levels of dynamics have been combined for measles (Heffernan and Keeling, 2008). 
There has also been consideration of the interaction between the initial virus dose and 
immunity (Steinmeyer et al., 2010, Volkov et al., 2010). 
Here we focus on the impact of specific interventions and the relevance of within host 
dynamics in considering these. A limiting factor in how much complexity should be 
implemented in models is the amount of data available for model calibration. This varies 
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between diseases; for a directly transmitted pathogen such as influenza, within- host 
modelling has typically considered viral dynamics in the nasal passage (Baccam et al., 2006), 
a plausible proxy for infectivity. However, there is the additional factor that the level of 
transmission may be linked to symptoms such as sneezing. With dengue, an indirectly 
transmitted pathogen, the relevant proxy for infectivity is viral titre in peripheral blood, as 
this is what is ingested by a mosquito in a blood meal.  
A few examples exist in the literature (for foot and mouth disease and influenza specifically) 
of models which consider virus dynamics throughout infection and what this means for 
transmission without incorporating a within-host model explicitly (Ferguson et al., 2006, 
Charleston et al., 2011). The closer attention paid by these analyses to the timing and level of 
infectivity (in particular in relation to symptoms) has refined our understanding of the likely 
effectiveness of different control measures. 
The area of research most developed with respect to biting data or feeding assays is malaria. 
Though of course malaria has a more complex biology within the human and mosquito, and 
malaria is a much longer living infection, there are parallels which can be drawn and lessons 
which can be learnt. 
Correlations between levels of relevant malaria parasite life stages in the human and 
subsequent mosquito infection is similar to the work undertaken here correlating dengue virus 
titres in the human and subsequent mosquito infection. Recent work in malaria has compared 
membrane feeding and direct feeding experiments, finding that infectivity is higher in direct 
feeding experiments, but concluding that membrane feeding is a useful tool to determine 
infectivity between individuals and the impact of interventions (Bousema et al., 2013). This is 
relevant to the work here which uses dengue membrane feeding to assess individual 
infectivity and the impact of wolbachia infected mosquitoes.  
The final parallel between malaria and dengue is the idea of the infectious reservoir 
(Drakeley et al., 2000). Though a slightly different concept for a long lived infection such as 
malaria, the assessment of the contribution of different severities of infections, with different 
levels of parasites to transmission is highly important for control.  
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5.2. Data and methods 
5.2.1. Data description 
I present below the two datasets used in this chapter. Briefly, these data are collected from 
mosquito feeding experiments using blood from humans infected with dengue. The virus titre 
of each individual is recorded; mosquitoes are then fed on blood from each individual 
through membranes (see Figure 5-1). The individuals incorporate different values of virus 
titre in humans, across different days of infection, with a resulting proportion of mosquitoes 
that become infected when feeding on each blood sample. Mosquitoes were then tested using 
PCR- with the outcome infected or not-infected. The data were collected by collaborators at 
OUCRU; I thank them for sharing the data for my work. These data will be published in the 
next few months. There is both data on wild type and Wolbachia- infected mosquitoes. 
A mosquito infection was assessed using diagnostic RT-PCR. I assume detectable virus using 
this method indicates the relevant body tissue was infected, and undetectable virus implies no 
infection. I do not make any assumptions about the infectiousness from mosquitoes to 
humans as we do not have data on this. Rather, these biting experiment data quantify how 
infective a human is to a mosquito (the susceptibility of mosquito to infection after feeding 
on a human) as a function of the virus titre in the blood. We also characterise the whole dose-
response curve, not just the virus titre threshold required to infect say 50% of mosquitoes 
(MID-50).  
 
 
251 
 
Figure 5-1: Membrane feeding. Picture © Cameron Simmons.  
5.2.2. First dataset of wild type mosquitoes 
The first dataset has data on DENV1 and DENV2 patients with wild type mosquitoes. I take 
only the values of virus titre, not the day of infection as the input. The outcomes shown in 
Figure 5-2 (DENV1) and Figure 5-3 (DENV2) are proportion of mosquitoes with infected 
abdomens at day 14 after feeding in red. There were 25 DENV1 patients with virus titres 
from around 10
4
 to 10
10
/ ml plasma and 14 DENV2 patients with virus titres from around 10
4
 
to 10
11
/ ml plasma. For each blood sample 40 engorged mosquitoes were tested for dengue 
infection. This dataset does not contain data for wMel infected mosquitoes. 
In the second dataset two groups of mosquitoes were tested: wild type (WT) and Wolbachia-
infected (with the wMel strain), both derived from mosquito populations from Tri Nguyen, 
Vietnam. wMel has been shown to be partially blocking against dengue (Hoffmann et al., 
2011, Walker et al., 2011) and I consider the impact of this on the infectivity of patients to a 
mosquito infected with wMel infected (referred to hereafter as wMel mosquitoes). The 
outcomes shown in Figure 5-2 (DENV1) and Figure 5-3 (DENV2) are proportion of 
mosquitoes with infected abdomens (or abdomen) at day 14 after feeding, shown in black for 
WT and green for wMel infected. There are two ways this proportion was ascertained. 
Firstly, 40 mosquitoes were assayed from each of the WT and wMel groups after being fed 
on 5 DENV1 and 7 DENV2 patient’s blood samples. The DENV2 cases have titres from 
around 10
7
-10
10
 (DENV1 titres below). Mosquito infection was assessed using RT-PCR. In 
addition, a second set of experiments were conducted within this dataset in which quantitative 
PCR testing for viral RNA was performed on day 14 after feeding in the abdomens and in 
saliva of mosquitoes fed on blood from DENV1 patients. This was done for 11 patient’s 
blood samples. For 9 patients, 25 mosquitoes from each of the WT and wMel groups were 
tested, for the remaining two patients, 20 of each mosquito group were tested. Overall for this 
second dataset the DENV1 cases have titres from around 10
4
 to 10
10
. I use this mosquito 
virus titre data to provide additional information on the proportion of mosquitoes infected as 
a function of viral titre, again viewing undetectable viral titre as indicating no infection. I do 
not use the mosquito virus titre levels directly but discuss how this could be used in future 
work.  
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Overall, the resulting abdomen infection data (combining both datasets) are shown in Figure 
5-2 and Figure 5-3 for DENV1 and DENV 2 respectively. Figure 5-4 shows the data on 
infection detected in saliva for DENV1 (dataset 2 alone). 
It is assumed that the dengue virus needs to be in the saliva for a mosquito to pass it on via an 
infected bite, however this is fairly difficult to measure (though experimental work is on-
going to improve this). For this reason and because there was a larger number of experiments 
for the abdomen than saliva, for DENV1 I use both the saliva (Figure 5-4) and abdomen 
measures (Figure 5-2) and only abdomen for DENV2 (Figure 5-3). The wMel DENV1 saliva 
data have two low titre outliers that have a higher infectivity for the wMel infected 
mosquitoes than for the wild type mosquitoes (see Figure 5-4). The analysis was therefore 
run with and without these outliers. 
253 
 
 
 Figure 5-2: Human virus titre vs. proportion of mosquitoes in which viral RNA was 
detected in the abdomen, for mosquitoes fed on blood from DENV1 patients.  
Results shown for wild type (red and black corresponding to datasets 1 and 2 
respectively) and wMel-infected mosquitoes (green points, dataset 2). Binomial exact 
confidence intervals shown.  
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Figure 5-3: Human virus titre vs. proportion of mosquitoes in which viral RNA was 
detected in the abdomen, for mosquitoes fed on blood from DENV2 patients.  
Results shown for wild type (red and black corresponding to datasets 1 and 2 
respectively) and wMel-infected mosquitoes (green points, dataset 2). Binomial exact 
confidence intervals shown.  
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Figure 5-4: Human virus titre vs. proportion of mosquitoes in which viral RNA was 
detected in saliva, for mosquitoes fed on blood from DENV1 patients (dataset 2).  
Results shown for wild type (red points) and wMel-infected mosquitoes (green points). 
Binomial exact confidence intervals shown.  
 
 
5.2.3. Modelling infectivity over time 
I am interested in estimating the infectivity of a dengue patient to mosquitoes during their 
infection. In order to derive such estimates, it is necessary to derive a functional relationship 
between the titre of virus in human blood and the probability that a mosquito feeding on 
blood with that titre will become infected.  
Putting to one side the uncertainty around the earliest stages of human dengue infection (to 
which I return later), the earlier chapters of this thesis give information on viral dynamics in 
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infected people. The biting experiment data described above provides information on the 
relationship between virus titres and infectivity. Combining the two allows me to estimate the 
‘instantaneous’ infectivity of a person at each point in their infection. Integrating this 
infectivity curve over the entire duration of infection gives a measure of the total infectivity 
of an individual.  
Denoting the probability of mosquito infection as a function of viral titre as p(v), I assume the 
functional form p(v) = pmax (1-exp (-v/M)), where v is the human virus titre per ml of plasma 
and pmax and M are parameters to be estimated using the data. The parameter pmax can be 
thought of as the highest possible probability, and the parameter M determines the threshold 
virus dose in the dose response curve. This function form can be derived by assuming that (1- 
pmax) mosquito bite on an infected person fail to cause mosquito infection irrespective of titre, 
and that for the other fraction pmax of feeds, each virion per ml of infected blood poses a 
hazard 1/M of infection to the mosquito. 
A binomial log-likelihood was used to fit this model to the counts of tested and infected 
mosquitoes fed on each patient’s blood, given by y log (p(v)) + (n - y) log (1 – p(v)), where n 
is the number of mosquitoes tested, y the number infected and p(v) predicted proportion 
infected from the model. This log likelihood was then summed across all virus titres.  
In order to represent the uncertainty in these estimates I sample from the joint posterior 
distributions of the parameters. I fit the model separately to each serotype and for wild type 
and wMel mosquitoes.  
To represent between patient variation in viral dynamics, I use the work presented in Chapter 
3. I mainly use the parameters of the model with α, η and IP fitted as patient specific (groups 
fit separately), but in order to consider the uncertainty in early infection I also consider the 
model with just α and IP fitted as patient specific. Sampling from the joint posterior 
distributions of the parameters from the model fits to the patient data presented in Chapter 3, 
I simulate viral dynamics over time, generating synthetic patient datasets. This is done 
separately for primary and secondary infections and DENV1 and DENV2 infections.  
For each simulated patient viral titre profile, I then apply the infectivity model (again 
sampling from the posterior of that model) to estimate infectivity to mosquitoes over time, 
and total infectivity. To get average measures of infectivity for the different groups by 
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serotypes and by primary or secondary disease, for each individual at each time point I take 
the median of these samples of infectivity. Next, for each group at each time point I take the 
median of the median infectivity profiles of all patients (overall median), which is simply a 
way of combining the information from each individual into a summary measure. Other 
summary measures could be considered, but are not in the work presented here. These are the 
infectivity profiles presented for each group.  
The basic reproduction number, R0 (the number of infected patients resulting from 1 infected 
patients in a totally susceptible population) is often used as a summary measure of infectivity. 
Here, we are not talking about a totally susceptible population, as much of the population will 
have some prior immunity (and we are including the infectivity of the secondary cases), so R 
the effective reproduction number is more appropriate. I will not be looking at complete 
onward transmission from human to mosquito to human, but at the portion of this R 
expression that takes into account the infectivity of a person to a mosquito throughout 
infection. Often this takes the form of transmission probability x length of infectiousness. In 
this chapter I will be considering how this transmission probability changes throughout 
infection, so will use the area under the curve (AUC) of the infectivity profile, as the total 
infectivity of an individual over their infection. I will compare results here to the previous 
assumptions about infectivity used in dengue models. I will also use this measure to look at 
heterogeneity in infectivity between patients and groups, and how interventions could impact 
transmission. I present AUC for the “average profiles” per group determined as described 
above (overall median), but also the distributions of AUCs across individuals in each group 
(individual medians, inter quartile range (IQR), min. and max.).  
In order to begin to consider the contribution of inapparent or asymptomatic human 
infections to transmission, I searched the literature for information on the proportions of 
dengue cases that are thought to be asymptomatic or subclinical (the definition of 
asymptomatic varies). In general those defined as asymptomatic patients are cases that will 
not appear at a healthcare facility as dengue and therefore not included in case counts. I also 
used information on virus titres from blood donors found to be infected with dengue to begin 
to understand asymptomatic infectivity.  
To evaluate the potential impact of antivirals on infectivity, I took the virus curves generated 
by the model presented in Chapter 3 (for each individual with median parameters) with 
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antiviral included, and then map these to infectivity using the same relationship as for the 
non-antiviral virus curves. To evaluate the possible impact of wMel infected mosquitoes on 
dengue transmission, I use the original simulated virus dynamics curves and then map these 
to infectivity using the relationship between virus titre and probability of infection derived for 
wMel infected mosquitoes.  
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5.3. Results 
5.3.1. Infectivity model fits 
Figure 5-5 and Figure 5-6 show the fit of the infectivity model to the biting experiment 
infected abdomen data (model estimates shown as 600 samples from the posterior 
distributions) for DENV1 and DENV2 respectively. Median parameter estimates for these 
models with 95% credible intervals are given in Table 5-1. Figure 5-7 shows fit to the saliva 
data for DENV1 (showing the fit including the outliers or not (see Data and methods)). 
Median and 95% credible intervals are again given in Table 5-2. Estimates from the saliva 
data are considerably more uncertain than those from the abdominal data.  
The wMel virus titres to infectivity probability relationships are markedly different for 
DENV1 and DENV2. For DENV1, wMel alters the level at which the infectivity begins to 
rise (compared to the wild type) and for DENV2 wMel alters the final level of infectivity 
reached (compared to wild type). I will consider this further in later sections.  
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Figure 5-5: Model fit for infectivity (probability of an infected abdomen) as a function 
of virus titre for DENV1.   
Lines show model output, points show the data. Wild type mosquito data and fits shown 
in green, wMel in data red and black, model fit purple. 
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Figure 5-6: Model fit for infectivity (probability of an infected abdomen) as a function 
of virus titre for DENV2.  
Lines show model output, points show data. Wild type mosquito data shown in red/ 
black and model fit in grey, wMel in green and model fit in blue. 
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Figure 5-7: Model fit infectivity (probability of infected saliva) as a function of virus 
titre for DENV1.  
Wild type mosquito data shown as black points, model fit as brown lines, model output 
and black points data. wMel infected mosquito data shown as green (non-outlier) and 
purple (outlier) points, model fit as lime green (fit to all data) and forest green (fit to 
data excluding two outliers) lines.  
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Dataset Tissue Mosquito Serotype pmax M 
1+2 Abdomen WT 2 0.97 
0.96, 0.98 
10
7.46
 
(10
7.40
, 10
7.53
) 
1+2 Abdomen wMel 2 0.44 
(0.39, 0.51) 
10
7.23
 
(10
7.03
, 10
7.42
) 
1+2 Abdomen WT 1 0.97 
(0.96, 0.98) 
10
6.77 
(10
6.61
, 10
6.93
)
 
1+2 Abdomen wMel 1 0.92 
(0.90, 0.94) 
10
8.07 
(10
7.96
, 10
8.21
) 
2 Saliva WT 1 0.79 
(0.74, 0.84) 
10
7.25
 
(10
5.70
 , 10
7.82
) 
2 (excl outliers) Saliva wMel 1 0.40 
(0.34, 0.47) 
10
8.31
 
(10
8.17
 , 10
8.66
) 
2 (with outliers) Saliva wMel 1 0.35 
(0.30, 0.47) 
10
3.68
 
(10
2.70
,10
4.07
) 
 
Table 5-1: Median parameter estimates and 95% credible intervals of the infectivity 
model fitted to mosquito biting experiment data.  
The model output and data is shown in Figure 5-5 (DENV1 WT and wMel abdomen), 
Figure 5-6 (DENV2 WT and wMel abdomen), and Figure 5-7 (DENV1 WT and wMel 
saliva).  
 
 
5.3.2. Infectivity over time 
For this section I will consider the infectivity of patients and patient groups (serotypes and 
primary/secondary infection) to a wild type mosquito throughout infection. I will use 
simulation patient viral dynamics from the models presented in Chapter 3, and the 
relationship between virus titre and probability of infection estimates in the previous section 
(see Figure 5-5, Figure 5-6 and Figure 5-7).  
To begin I present results considering infectivity heterogeneity. In Figure 5-8 and Figure 5-9, 
I plot the infectivity (as measured by mosquito infected saliva and bodies respectively) over 
time for representative DENV1 patients (the same set of patients used in Chapter 3) from the 
first virus titre dataset, derived using simulated viral titre curves from the model with α, η and 
IP fitted as patient specific model. Corresponding results for DENV2 (abdomen infectivity) 
are shown in Figure 5-10. We see great variation between patients in infectivity over time and 
total infectivity. For example, with the data and model fit here, DENV2 patient 1 and DENV1 
patient 11 are predicted to have barely been infective, compared with high infectivity in other 
patients. The distribution of the total infectivity (area under infectivity curves) across all 
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patients (not just the selected ones plotted in the previous figures) for DENV1 and DENV2 is 
characterised in Table 5-2 (individual median AUCs). 
I also combine these patients’ infectivity profiles to get a median infectivity over time for 
each patient group (overall median). Median infectivity profiles for the different groups of the 
first virus titre dataset are shown in Figure 5-11 and Figure 5-12 (solid lines).  
These curves and the summary infectivity measures given in Table 5-2 allow us to consider 
the differences in infectivity profiles between primary and secondary DENV1 infections. 
Focusing on the median virus titre profiles estimated using the α, η, IP patient specific model 
for DENV1 in Figure 5-11 (solid lines) we note high infectivity continuing for longer in 
primary than secondary DENV1 cases.. This is reflected in the total infectivity measures (see 
Table 5-2), where for DENV1 we see a slightly greater infectivity for primary DF (4.78) than 
for secondary DF and DHF (4.11, 4.09 respectively). 
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Figure 5-8: Predicted infectivity over time for DENV1 for selected patients (saliva 
infection).  
Plots show days since infection against probability of mosquito saliva infection, if bitten 
by mosquito on that day. Model with α, η and IP patient specific model fitted to first 
virus titre dataset of Chapter 3 to generate simulated viral titre profiles and the 
infectivity model shown in Figure 5-7 (parameters in Table 5-1) used to map to 
infectivity. Selected patients chosen as used in Chapter 3. First Row: Primary DF, 
Second Row: Secondary DF, Third Row: Secondary DHF.  
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Figure 5-9: As Figure 5-8, but for infection measured in abdomen (infectivity model as 
shown in Figure 5-5).   
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Figure 5-10: As Figure 5-9 but for DENV2 (infectivity model as shown in Figure 5-6). 
First Row: Secondary DF, Second Row: Secondary DHF.  
 
Group AUC 
(individual median, IQR, 
min and max) 
overall median 
Primary DF 
DENV1 
4.60 
3.89, 4.87 
1.79, 6.86 
4.78 
Secondary 
DF DENV1 
3.36 
1.81, 4.60 
0.000160, 6.07 
4.11 
Secondary 
DHF 
DENV1 
3.82 
2.76, 4.52 
0.00587, 5.56 
4.09 
Secondary 
DF DENV2 
0.170 
0.0152, 1.52 
0.000118, 4.14 
0.111 
Secondary 
DHF 
DENV2 
2.33 
1.14, 3.16 
0.00124, 3.98 
1.73 
 
Table 5-2: Total infectivity (AUC) for wild type mosquitoes (infectivity model fitted to 
abdomen data) for the first virus titre dataset of Chapter 3.  
Distributions for each individual (median, inter quartile range, min and max) and 
medians across patients for the α, η, IP patient specific model.   
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Figure 5-11: Median infectivity over time since infection for DENV1 (wild type 
abdomen infection).  
Plot shows days since infection against probability of mosquito abdomen infection, if 
bitten by mosquito on that day α, η, IP or α, IP patient specific model used to get virus 
output first dataset (from Chapter 3) and the relationship to map these virus titres to 
infectivity shown in Figure 5-5. Red: primary DF median infectivity. Green: secondary 
DF median infectivity, Blue: secondary DHF median infectivity. Dashed Line α, IP 
patient specific model used for virus output, full line α, η, IP patient specific model used 
for virus output. AUCs for α, η, IP patient specific model shown in Table 5-2 and for α, 
IP patient specific model shown in Table 5-3. 
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Figure 5-12: Median infectivity over time since infection for DENV2 (wild type 
abdomen infection).  
Plot shows days since infection against probability of mosquito abdomen infection, if 
bitten by mosquito on that day α, η, IP or α, IP patient specific model used to get virus 
output first dataset (from Chapter 3) and the relationship to map these virus titres to 
infectivity shown in Figure 5-6. Green: secondary DF median infectivity, Blue: 
secondary DHF median infectivity. Dashed Line α, IP patient specific model used for 
virus output, full line α, η, IP patient specific model used for virus output. AUCs for α, 
η, IP patient specific model shown in Table 5-2 and for α, IP patient specific model 
shown in Table 5-3. 
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Next, it is of interest to see if the differences in virus specific parameters noted between 
serotypes in previous chapters result in differences in predicted infectivity. The fundamental 
question is whether the differences in virus titre-infectivity relationships between serotypes 
found earlier in this chapter will add to or reverse the differences in virus dynamics found in 
Chapter 3.  
Here I consider this question for the first patient dataset considered in Chapter 3 and will 
return to serotype differences with the second dataset later in the current chapter. In Figure 
5-5 and Figure 5-6 we see that best fit relationship between virus titre and probability of 
infecting a mosquito look qualitatively similar for DENV1 and DENV2 in wild-type 
mosquitoes, with the main difference being a slightly higher infectious dose for DENV2 
compared with DENV1 (parameter M in Table 5-1). However, in the individual patient 
infectivity profiles (Figure 5-9 and Figure 5-10) there is greater variability seen in the 
selected DENV2 patients than in the DENV1 patients, and this is reflected in Figure 5-11 and 
Figure 5-12 (which are medians across all not just selected patients) where DENV2 patient 
population appears to be much less infective than the DENV1 population. When comparing 
the total infectivity of DENV1 vs. DENV2 secondary infections, DENV1 is estimated to be at 
least twice as infective as DENV2 (Table 5-2). We see a great difference in DENV2 
secondary DF and DHF infectivity, but I think we cannot be sure this is not currently down to 
the small sample size.  
However, the extent of these estimated differences are perhaps misleading. In order to assess 
the overall infectivity of an individual, the early unobserved period of infection must be taken 
into account. In Chapter 3 I tested models varying which parameters were fitted as patient 
specific, as group specific or assumed constant across all patients. In some models which 
fitted fewer patient specific parameters (particularly the model which fitted only α and, IP as 
patient specific) using fewer parameters overall allowed viral peaks to be better imputed for 
those patients in which a resolved peak in viral titres was not observed. By re-simulating viral 
titre profiles from the model which fitted only α and, IP as patient specific, we see 
differences in imputation of the unobserved portion of the viral load curves have a great 
impact on the predicted infectivity of the individuals (Figure 5-8 vs. Figure 5-13). With the 
less heavily parameterised model (Figure 5-13), there is less heterogeneity, though still some 
in the timing of infectivity, and all patients are predicted to have a period of near maximal 
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infectivity. With this model, DENV1 patient 11 is now predicted to have a similar infectivity 
profile to the other patients, in contrast to the estimates from the previous model (Figure 5-8).  
For DENV1 mosquito abdomen infection, the median infectivity for each patient group is 
shown for both virus dynamics models in Figure 5-11 (α, η, IP patient specific model full 
line, α, IP patient specific model dashed line). For secondary DHF the simpler model shifts 
the infectivity curve to the left, with the secondary DHF becoming infectivity earlier than the 
primary DF, but being infective for a similar length of time. The primary and secondary DF 
median infectivity profiles look fairly similar for both models (with similar total infectivity), 
with primary DF infections being maximally infective for longer than secondary infections 
under both models.  
The change in virus dynamics model makes a much larger difference to estimates of 
infectivity for secondary DENV2 cases, however, with the total estimated infectivity for 
secondary DF increasing from 0.111 in the earlier model (Table 5-2) to 2.75 for the less 
parameterised model (Table 5-3), and from 2.23 to 2.83 for secondary DHF. Median 
infectivity over time for both models for DENV2 is shown in Table 5-2 (α, η, IP patient 
specific model as solid line, α, IP patient specific model as dashed line). However, DENV2 is 
still predicted to be less infective than DENV1. 
In the remaining sections I use the more complex α, η, IP patient specific virus dynamics 
model, as this was the better fit to the virus titre data, but the sensitivity to imputation of 
unobserved viral dynamics in early infection should be borne in mind.  
Group AUC 
(individual median, IQR, min and max) 
overall median 
Primary DF DENV1 4.46 
4.37, 4.89 
4.35, 6.16 
4.62 
Secondary DF DENV1 4.23 
4.18, 4.56 
4.14 5.86 
4.22 
Secondary DHF DENV1 4.04 
4.00, 4.44 
3.97, 5.24 
4.19 
Secondary DF DENV2 2.73 
2.65 ,2.85 
2.54, 3.30 
2.75 
Secondary DHF DENV2 2.89 2.83 
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2.75, 2.99 
2.52, 3.32 
 
Table 5-3: As Table 5-2 but using simulated viral titre profiles from the model which 
fitted α and IP as patient specific parameters. 
 
 
Figure 5-13: As Figure 5-8 but using simulated viral titre profiles from the model which 
fitted α and IP as patient specific parameters. 
 
As a validation exercise, I now consider infectivity using the model fit to the second virus 
titre dataset (data presented in Chapter 2 and model fit in Chapter 3). In this dataset there are 
both primary and secondary DENV1 and DENV2 cases. Table 5-2 shows the median 
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infectivity profiles calculated from the Chapter 3 model fits to the first dataset and Table 5-4 
shows the infectivity profiles calculated from the model fit to this validation dataset. The 
infectivity profiles for both datasets are shown in Figure 5-14 and Figure 5-15. 
  
Figure 5-14: Median infectivity over time since infection for DENV1 (wild type 
abdomen infection) for both virus titre datasets.   
Plot shows days since infection against probability of mosquito abdomen infection, if 
bitten by mosquito on that day. Model fitting α, η, IP as patient specific used to estimate 
viral titre profiles for both datasets (see Chapter 3) with these being mapped to 
infectivity using the relationship shown in Figure 5-5. For the first virus titre dataset 
(shown for comparison) Red: primary DF median infectivity. Green: secondary DF 
median infectivity, Blue: secondary DHF median infectivity (as Figure 5-11). Second 
dataset – Black: Primary median infectivity, Orange: Secondary median infectivity. 
Total infectivity measures for the second virus titre dataset is shown Table 5-2. 
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The second dataset shows similar differences between primary and secondary DENV1 
infections as were seen previously, though here the primary cases are substantially more 
infective than secondary, with the secondary cases not reaching maximal infectivity (see 
Table 5-4 and Figure 5-14). Total median infectivity for DENV1 in the second dataset is 2.91 
for primary and 1.87 for secondary infection (see Table 5-4) both values being lower than 
seen for the first dataset. It is also clear from the infectivity profiles in Figure 5-14, that the 
first dataset estimates greater infectivity than the second for DENV1 cases. There are also 
differences for DENV2 (see Figure 5-15) though some of the estimates for DENV2 seem 
unrealistically low. 
  
Figure 5-15: Median infectivity over time for DENV2 (wild type abdomen infection) for 
both virus titre datasets.   
Plot shows days since infection against probability of mosquito abdomen infection, if 
bitten by mosquito on that day. Model fitting α, η, IP as patient specific used to estimate 
viral titre profiles for both datasets (see Chapter 3) with these being mapped to 
infectivity using the relationship shown in Figure 5-6. For the first virus titre datasets 
(shown for comparison) – Green: secondary DF median infectivity, Blue: secondary 
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DHF median infectivity (as Figure 5-12). Second dataset – Black: Primary median 
infectivity, Orange: Secondary median infectivity. Total infectivity measures for the 
second virus titre dataset are shown in Table 5-4. 
 
The second dataset allows me to compare primary and secondary infections with DENV2. 
For DENV2 we see a reversal of the relationship for DENV1 with the median measures, with 
the primary cases predicted as being barely infective, but the secondary reaching fairly high 
probability of infectivity (albeit not for long) (see Table 5-4). The group sizes here are fairly 
small however, so further work is needed.  
The total infectivity of DENV1 and DENV2 secondary cases in the second dataset are fairly 
similar (1.87 for DENV1 and 2.03 for DENV2, see Table 5-4). However, in primary infection 
DENV1 is much more infective than DENV2 (total infectivity of 2.91 vs. 0.06, see Table 5-4. 
This could however be due be due to the small number (n=7) of cases of primary DENV2 in 
the dataset, which may therefore not accurately represent the full population of cases. 
 
Group AUC 
(individual median, IQR, min and 
max) 
overall median 
Primary DF 
and DHF 
DENV1 
3.09 
2.31, 3.80 
0.00159, 5.24 
2.91 
 
Secondary DF 
and DHF 
DENV1 
2.22 
0.147, 3.32 
0.000367, 4.94 
1.87 
 
Primary DF 
and DHF 
DENV2 
0.0497 
0.0375, 1.14 
0.0234, 4.74 
0.0608 
 
Secondary DF 
and DHF 
DENV2 
2.57 
0.693, 3.04 
0.000527, 4.22 
 
 
2.03 
 
Table 5-4: Total (AUC) infectivity (wild type abdomen infection) for the second virus 
titre dataset.  
For each group median, inter quartile range, min and max shown and medians across 
patients derived from virus titre profiles estimated using the model fitting α, η, IP as 
patient specific (Chapter 3) and relationship between virus titres and probability of 
infection as shown in Figure 5-5, Figure 5-6 and Figure 5-7. 
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5.3.3. Asymptomatic or inapparent infections 
There are two main questions when considering the contribution to the force of infection of 
asymptomatic or inapparent cases. Firstly, what proportion of dengue infections are 
asymptomatic, and second how infectious are those infections.  
Estimates of the proportion of infections that are asymptomatic/inapparent vary greatly 
between studies (Rothman, 2010). A summary of all papers is shown in Table 5-5, a similar 
table appears in (Rothman, 2010). There may be differences between adults and children and 
between serotypes. In addition, the definition of an inapparent case varies between studies 
(e.g. no symptoms at all, or not appearing at a healthcare facility). Truly asymptomatic cases 
of course impose no health burden directly, but may contribute to transmission.  
As we see from Table 5-5 there appears to be large variations in the estimated proportion of 
asymptomatic infections compared to clinical cases. Aside from possible differences in 
definition of an asymptomatic case, this could be a function of primary/ secondary infections, 
time between infections (due to transmission intensity), serotypes/ genotypes or serotype/ 
genotype combinations in secondary infections and age. In the studies it was possible to 
determine differential ratios for primary and secondary infections, there is a suggestion of 
more asymptomatic cases to every symptomatic one in primary infection compared to 
secondary.  
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Paper 
Country/ 
Study Type 
Definition Serotype 
Asymptomatic 
Ratio 
Endy et al. 
2002 
Thailand/ 
Cohort 
HAI x4 increase 
change without 
associated febrile 
illness: Identified DF 
and DHF cases 
Cases: 
DENV1 : 
25% 
DENV2: 
35% 
DENV3 : 
41% 
DENV4: 1% 
1998: 1.19 
1999: 1.00 
2000: 1.75 
Yoon et 
al. 2012 
Thailand/ 
Cluster 
EIA Positive 
asymptomatic: any 
symptoms 
DENV1 and 
DENV4 
Primary: 
0.2 
Sec 
0.3 
Yoon et 
al. 2012 
Thailand/ 
Cohort 
EIA change across 
season asymptomatic: 
community 
treatment+ 
hospitalised 
DENV1 and 
DENV4 
All: 
1.8 
Burke et 
al. 1988 
Thailand/ 
Cohort 
No symptoms or 
absent less than 1day 
school (with HAI x4 
increase change): 
Absent more than 1 
day school with or 
without DHF 
DENV1 and 
DENV2 and 
* 
Primary:  
10.11 
Sec: 
5.25 
Guzman 
et al. 2000 
Cuba/ 
Population 
Wide 
Prevalence of DENV2 
antibodies in <15 year 
olds: Cases of DF and 
DHF 
DENV2 and 
previous 
possible 
infection 
DENV1 
Primary: 30.00 
Sec: 
** 
Porter et 
al. 2005 
Indonesia/ 
Cluster 
HAI x4 increase 
change without 
associated febrile 
illness: time off work 
All 4 (most 
cases 
DENV2) 
3.11 
Yew  et 
al. 2009 
Singapore/ 
Population 
Wide 
Serology: Hospital 
Cases 
unknown 23.00 
Reyes et 
al. 2010 
Nicaragua/ 
Cluster 
Cases around cluster 
identified by IgM 
compared to those 
identified by  RT-PCR 
(not a real ratio) 
 
DENV2 
Primary: 2 
asymptomatic 
only 
Sec: 3 
asymptomatic, 
4 UFI***, 3 
DF 
Mammen 
et al. 2008 
Thailand/ 
Cluster 
by ELISA no of cases 
inapparent: non-
hospitalised dengue: 
hospitalised dengue 
unknown 
Primary:  
5:1:0 
Sec: 
7:11:1 
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* Current serotypes unknown but in the pre-illness sera 4/7 DHF cases had neutralising antibodies to only 
DENV1, compared to 4/48 of asymptomatic cases. 
** “virtually all secondary DEN-2 infections in adults resulted in clinical disease” (Guzman et al., 2000) 
*** UFI: Undifferentiated Febrile Illness 
Sec: Secondary 
Table 5-5: Ratio of asymptomatic to symptomatic cases shown as calculated from each 
of the studies listed.  
(Burke et al., 1988, Guzman et al., 2000, Endy et al., 2002, Porter et al., 2005, Mammen 
et al., 2008, Yew et al., 2009, Reyes et al., 2010, Yoon et al., 2012). Definition of 
asymptomatic case given and serotypes in study given if known. 
5.3.3.1. Virus titres in asymptomatic patients  
In this section I would like to consider the infectivity of an asymptomatic individual. 
Currently the prospect of dengue being transmitted in blood donations, and whether blood 
donations in endemic countries should be screened for dengue virus is under review. Though 
obviously collected for a different reason, from my point of view, these studies may give 
some measure of viraemia in asymptomatic patients. There is the possibility that these 
patients are not asymptomatic but incubating patients, and although patients are meant to 
report becoming ill after giving blood, we cannot be certain this would happen. A good 
overview of this area is given in a paper by Teo et al. (Teo et al., 2009). 
There are two surveys from blood donations during two dengue outbreaks in Puerto Rico 
2005and 2007 respectively (Mohammed et al., 2008, Stramer et al., 2012). In both outbreaks, 
samples were tested using transcriptase mediated amplification (TMA) (as used to test blood 
for other infections), virus culture and RT-PCR for virus detection and for IgM. In 2005, 
overall, 0.07% (12 of 16521) donations tested positive by TMA, and 4 by RT-PCR. In 2007, 
0.19% (29 of 15350) donations tested positive by TMA and 12 by RT-PCR. The virus titres 
for these individuals are given in Table 5-6. 
In a similar study in Honduras and Brazil (Linnen et al., 2008), the dengue viraemia rates in 
asymptomatic patients were 0.3% in Honduras and 0.04% in Brazil. Among those repeat 
positive using TMA the viral loads in Honduras (copies per mL) are given in Table 5-7. The 
limit of detection here appears to be very low (but is not explicitly stated in the paper). Cases 
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were classified as either primary or secondary by using IgG positivity as an indicator of a 
secondary infection.  
With this information and the relationships derived in the previous sections, it is possible to 
say something for the DENV1 and DENV2 cases about each individual and how infectious 
they would have been if bitten by a wild –type Tri Nguyen mosquito. The extrapolated 
infectivity values for the respective patients are shown in the sixth column of Table 5-6 and 
Table 5-7.  
I found two reported instances of dengue virus transferred by blood donations. An individual 
who developed fever 3 days after transfusion, with the donor being asymptomatic at the time 
but developing DF 1 day after donation (Chuang et al., 2008). Another case was in 
Singapore, where the donor developed acute febrile illness the day after donating. The two 
blood recipients had DF with some evidence of capillary leakage and the platelet recipient 
had asymptomatic seroconversion (Tambyah et al., 2008). The viral loads in these cases are 
not known. There is also evidence of a recipient dying of DHF after a blood donation in 
Puerto Rico (Stramer et al., 2012). 
Though of course this is not a complete picture of asymptomatic infections, but is currently 
the only data available on asymptomatic virus titres. Though the majority of people’s titres 
mean they would be minimally infective, there are some people with high titres, leading to 
high probability of infecting a mosquito if bitten at this point.  
Serotype Virus 
Titre/ml 
plasma 
Primary/ 
Secondary 
Year Predicted prob. 
of virus in 
abdomen of 
mosquito 
DENV2 1.12x10
9
 Unknown 2007 0.97 
DENV2 5.08x10
8
 Unknown 2007 0.97 
DENV2 1.35x10
8
 Unknown 2007 0.96 
DENV3 7.25x10
7
 Unknown 2007 ? 
DENV3 1.37x10
7
 Unknown 2007 ? 
DENV3 1.18x10
7
 Unknown 2007 ? 
DENV3 7.67x10
6
 Unknown 2007 ? 
DENV1 4.49x10
6
 Unknown 2007 0.51 
DENV2 2.82x10
6
 Unknown 2007 0.089 
DENV3 6.39x10
5
 Unknown 2007 ? 
DENV3 3.5x10
5
 Unknown 2007 ? 
DENV3 1x10
5
 Unknown (x16) 2007 ? 
unknown <10
3
 Unknown 2007 ? 
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DENV2 7.14x10
3
 P 2005 2.38 x10
-4
 
DENV3 8.12x10
7
 S 2005 ? 
DENV2 7.74x10
5
 S 2005 0.026 
DENV2 <2.0x10
3
 P 2005 6.68 x10
-5
 
unknown <10
3
 6 secondary 1 
primary 
2005 ? 
Table 5-6: Virus titres from blood transfusions in Puerto Rico (Mohammed et al., 2008, 
Stramer et al., 2012).  
Virus titres listed with their serotype, and whether classified as primary or secondary 
shown (Mohammed et al., 2008, Stramer et al., 2012). Columns 1 -4 are from the 
published data, column 5 was estimated using the relationships derived in this thesis 
(relationships shown in Figure 5-5 and Figure 5-6).  
 
Country Serotype Virus Titre 
copies /ml 
plasma 
Primary/ 
Secondary 
Predicted 
prob. of virus 
in abdomen of 
mosquito 
Honduras DENV4 4.4x10
2
 P ? 
Honduras DENV4 3.9x10
3
 S ? 
Honduras DENV4 4.2x10
4
 S ? 
Honduras DENV1 4.7x10
2
 P 7.69x10
-5
 
Honduras DENV4 78 S ? 
Honduras DENV1 2.3x10
2
 P 3.77 x10
-5
 
Honduras DENV1 7.4x10
3
 S 1.21x10
-3
 
Honduras DENV2 3 P 1.00x10
-7
 
Honduras Not-detected Not-detected S ? 
Brazil DENV1 12 P 4.81x10
-5
 
Brazil DENV3 294 P ? 
Brazil Not-detected Not-detected S ? 
Table 5-7: Virus titres from blood transfusions in Honduras and Brazil (Linnen et al., 
2008).  
Virus titres shown with their serotype, and whether classified as primary or secondary. 
Columns 1 -4 are from the published data, column 5 was estimated using relationships 
derived in this thesis (shown in Figure 5-5 and Figure 5-6). Secondary classified as IgG 
positive at time of sample. 
5.3.4. Impact of Wolbachia infection (wMel strain) on 
mosquito susceptibility 
Here, I assess how wMel infection of mosquitoes affects their susceptibility to infection. I 
estimate how wMel will alter the median infectivity profiles of each serotype and for primary 
secondary and the different disease severities, compared with wild-type mosquitoes. The total 
infectivity values for both datasets are shown in Table 5-8 and Table 5-9, and median 
infectivity profiles (with wild type for comparison) for both datasets are shown in Figure 5-16 
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and Figure 5-17. I concentrate on the infected abdomen outcome because of the ability to 
compare between serotypes and because of the issues with outliers for wMel saliva outcome.  
Group AUC 
(individual median, IQR, 
min and max) 
overall median 
 
Primary DF DENV1 2.56 
1.96, 2.82 
0.183, 4.54 
2.52 
 
Secondary DF DENV1 1.72 
0.22, 2.85 
7.82e-06, 4.37 
1.20 
 
Secondary DHF DENV1 2.22 
0.654, 2.90 
0.000278, 3.82 
2.25 
Secondary DF DENV2 0.131 
0.011 0.883 
9.11e-05, 2.02 
0.0876 
Secondary DHF DENV2 1.21 
0.658 1.56 
0.000972, 1.94 
0.944 
Table 5-8: Total infectivity to wMel mosquitoes (abdomen infection) for first virus titres 
dataset of Chapter 3.  
For each groups median, inter quartile range, min and max, and medians across 
patients for the model with α, η, IP  patient specific (see Chapter 3), with infectivity over 
time for selected patients shown in Figure 5-8, Figure 5-9 and Figure 5-10 and 
relationship between virus titres and probability of infection as shown in Figure 5-5, 
Figure 5-6 and Figure 5-7.   
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Group AUC 
(individual median, IQR, min and 
max) 
overall median 
 
Primary DF and 
DHF DENV1 
1.46 
0.467, 2.00 
6.30 x10
-5
, 2.70 
0.872 
 
Secondary DF 
and DHF 
DENV1 
0.0853 
0.0112, 0.610 
1.24x10
-5
, 3.25 
0.0787 
Primary DF and 
DHF DENV2 
0.00960 
0.00629, 0.277 
0.00419, 1.74 
0.0135 
 
Secondary DF 
and DHF 
DENV2 
0.887 
0.141, 1.09 
8.26x10
-5
, 1.62 
0.518 
Table 5-9: Total infectivity to wMel mosquitoes (abdomen infection) for second virus 
titres dataset of Chapter 3.  
For each groups median, inter quartile range, min and max, and medians across 
patients for the model with α, η, IP patient specific (see Chapter 3), with infectivity over 
time for selected patients shown in Figure 5-8, Figure 5-9 and Figure 5-10 and 
relationship between virus titres and probability of infection as shown in Figure 5-5, 
Figure 5-6 and Figure 5-7.   
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Figure 5-16: Median infectivity over time since infection for DENV1 wMel abdomen 
infection with wild type for comparison.   
Plot shows days since infection against probability of mosquito abdomen infection, if 
bitten by wMel mosquito on that day. The model with α, η, IP fitted as patient specific is 
used to derive virus profiles for both virus titre datasets (see Chapter 3) and the 
relationship to map these virus titres to infectivity is shown in Figure 5-5. Full lines 
show infectivity to wild type mosquitoes and dotted lines show corresponding infectivity 
to wMel mosquitoes. First virus titre dataset – Red: primary DF median infectivity. 
Green: secondary DF median infectivity, Blue: secondary DHF median infectivity. 
Second virus tire dataset – Black: primary median infectivity. Orange: secondary 
median infectivity.  
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Figure 5-17: As Figure 5-16, but for DENV2. 
 
Using the median total infectivity measures (see Table 5-8) we see wMel mosquitoes have 
reduced susceptibility to all serotypes for both primary and secondary infection (see also 
Figure 5-16 and Figure 5-17). For DENV1, the first dataset shows a halving of infectivity for 
primary DF (4.78 to 2.52) and secondary DHF, (4.09 to 2.25) but there is an even greater 
reduction for secondary DF from (4.11 to 1.20). There is a slight reduction for DENV2 
secondary DF (0.111 to 0.0876) - though this measure is already low and at the lower titres 
for DENV2 there is little difference in the predicted infectivity between wild type and wMel 
(see Figure 5-3). There is a greater reduction for DENV2 secondary DHF (1.73 to 0.944). It is 
also important to note the heterogeneity in these reductions, with the minimum infectivity for 
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DENV1 primary DF changing from 1.79 with wild type mosquitoes to 0.183 for wMel 
infected mosquitoes. 
The timing of the infectivity profile is also important: with DENV1 the wMel infectivity 
profile shows an individual becoming highly infective later in infection compared with wild 
type, with a shorter duration of high infectivity overall. 
For DENV1, it is also of interest to note that although we do not see any great difference in 
the model parameters governing the immune responses between the secondary DF and DHF 
or in the infectivity profiles for wild type mosquitoes, we do see a difference when these 
slightly different virus profiles are translated to a median wMel infectivity, with secondary 
DF less infective than secondary DHF (see Figure 5-16 and Table 5-8).  
We can also see evidence of differences in the between the two serotypes (Figure 5-16). The 
peak of DENV2 wMel infectivity is much lower than for DENV1. The later start (and overall 
shortening) of infectivity with wMel compared to wild type as seen for DENV1 is not seen 
for DENV2.  
5.3.5. Impact of antivirals on transmission 
The work in Chapter 3 that considered the impact of antivirals on virus dynamics is extended 
here to consider the impact of these antivirals on infectivity. I take the virus dynamics 
profiles from the model with median parameters with the antiviral that blocks all virus 
production (see Chapter 3) and use the human virus titre- infectivity profiles from the current 
chapter to estimate infectivity over time in the presence of antiviral treatment. I do this for 
individual patients, and present the median, IQR, min. and max. AUC with and without the 
antiviral. I consider antiviral in this way because of the complexities of estimating incubation 
periods and the impact this has on timing of antiviral administration. 
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Group AUC without 
antiviral 
AUC with antiviral 
Primary DF 4.57 
3.87, 4.83 
1.86, 6.89 
3.02 
2.34, 3.43 
 0.77, 3.82 
Secondary DF 3.39 
1.84, 4.57  
0.0004, 6.14 
2.26 
1.52, 2.82 
0.0003, 4.02 
Secondary DHF 3.81 
2.71, 4.52 
 0.013, 5.6 
2.68 
1.93, 3.16 
0.009, 4.01 
Table 5-10: Impact of antiviral blocking virus production on DENV1 infectivity (using 
the AUC). 
Table 5-10 presents the median AUCs for the three patient groups from the first virus dataset 
with and without an antiviral. Of course the antiviral only has an impact after administration, 
so on the latter stage of infection. What occurs in early infection will impact how much of 
transmission is truncated due to an antiviral. With the assumptions here of the α, η, IP as 
patient specific parameters model, in primary and secondary overall AUC is reduced to 
around 2/3 of the original estimate without the antiviral. This reduction is fairly consistent 
across groups, despite the varying estimates of infectivity.  
5.4. Discussion 
In this chapter I have begun to consider consequences for transmission of the within-host 
dengue virus infection dynamics modelled in the previous chapters.  
Using data from biting experiments on human subjects’ blood, virus data from throughout 
infection and a within host model of virus dynamics, I have considered the infectivity over 
time of an individual with dengue infection. I have also considered the contribution of 
asymptomatic or inapparent infections to transmission, by collating data from the literature to 
understand the proportion of asymptomatic cases to clinical cases. Using data from dengue 
virus titres in blood donations I then made an attempt at understanding the infectivity of 
asymptomatic cases. I considered how all these results can inform dengue transmission 
models. I also considered what this work can tell us about the use of control measures and 
their impact on dengue transmission.  
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5.4.1. Dengue infectivity 
My analysis found great heterogeneity in infectivity between patients, reflecting 
heterogeneity in the virus titres over time (as observed in Chapter 3). This is illustrated by 
AUC measurements in infectivity which vary from 1.79 to 6.86 for primary DF DENV1 (a 
roughly 2.5/3 fold variation in this and therefore in each individual’s R0. This variation is 
more marked for secondary DF DENV1, though this is probably also partly due to the large 
amounts of missing data.  
This infectivity heterogeneity, combined with biting rate variation, will have a critical impact 
on the predictions of a transmission model, as has been shown theoretically (Woolhouse et 
al., 1997). I return to the impact of infectivity heterogeneity when discussing control 
measures in this framework. 
Though this heterogeneity may be important, in most transmission models an average 
infectivity is used. Of the two models that used more complex infectivity assumptions Otero 
et al. (Otero et al., 2011) using data from (Nishiura and Halstead, 2007) assume a total 
infectivity (using the same scale as I do earlier in this chapter) of 3.5 with differing infectivity 
over 5 days of infection (see Error! Reference source not found.). This is comparable with 
the values estimated in this work, though we find considerable variation across patient groups 
(0.17 - 4.6). The median measures these have been calculated in two different ways (three 
including the antiviral section), with minimal differences between the methods. Comparing 
these values with other transmission models that have included mosquitoes, Bartley et al. 
(Bartley et al., 2002) assumed a transmission probability of 0.75 across 4.5 days which gives 
an total infectivity of 3.375 – not dissimilar to those estimated here.  
While the median values of total infectivity I have estimated may be comparable to those 
previously assumed in some modelling work, the difference between the two viral datasets I 
considered is marked however, with the lower peak titres in the second dataset translating 
into a much lower infectivity over time and smaller total infectivity values for DENV1 in this 
dataset compared to the first. The timing of infectivity may also be important and can be 
considered in this way. The importance of a closer consideration of infectivity throughout 
infection in different patient groups comes to the fore when considering how this infectivity 
will be modulated by control measures.  
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Regarding primary versus secondary infection infectivity differences, previous models 
considering the cycling of dengue serotype dynamics have all used a few key assumptions. 
The Vaughn et al. 2000 paper is most often cited (Vaughn et al., 2000), leading to the 
conclusion that secondary infections are more infective. However, just because severe disease 
(a small proportion of even secondary infections) is associated with higher viraemia in that 
study does not mean that most secondary cases are more infectious, and may not even mean 
that on average secondary cases are more infectious. Indeed, we found few differences in 
viral dynamics between secondary DF and DHF cases in the datasets we considered. There 
are two things to consider here: how are virus titres differ between primary and secondary 
infection, and how such differences translate to infectivity. With respect to the latter, previous 
thinking has hinged on the assumption that a higher virus peak inevitably implies higher 
infectivity. With the functional forms for the relationship between virus titre and probability 
of infecting a mosquito here (see Figure 5-2 and Figure 5-3), we can see that this is not 
necessarily the case. It is obvious that even if peak viral titre is higher, we may have already 
reached saturation (or near saturation) of mosquito infection probability, so a further 
increases in titre may not significantly increase infection probability. A higher peak will only 
matter for infectivity if the lower peak is below the point at which infectivity saturates. In the 
data here, this threshold is around 10
7
-10
8
virus copies/ml. There may however be other 
benefits of a higher virus titres for example with interrupted feeding.  
Considering virus titres, we do not see a great difference in the primary and secondary peak 
titres- but with the caveat that measurements appear typically to start later in infection in 
secondary cases (Chapter 2 and Chapter 3). On average for a DENV1 infection, I find 
primary infections slightly more infective than secondary, with differences noted in both 
duration and level of infectivity (observed in both virus titre datasets considered). This is due 
to the sharper virus decrease observed in secondary infection compared with primary. For 
DENV2 with the data here, the inverse is true, with primary infections appearing barely 
infectious. There is little data here for DENV2 however, so we need to be cautious 
interpreting these results. However, it would be interesting if these differences between 
primary and secondary differences hold up, as asymmetry between serotypes has rarely been 
considered in modelling work previously. Infection history may play an important role here 
too, with the primary infecting serotype also possibly being of importance for secondary 
infection. Also, our data on viral titre misses a large portion of the infection, which includes 
the virus peak in many cases. Hence the assumptions made about early (unobserved) are 
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vitally important; when I used a less heavily parameterised viral dynamics model our 
conclusions about the infectiousness of primary and secondary infection changes. 
Assumptions about the infectivity of primary versus secondary infection used in transmission 
models are therefore an area that I believe deserves much greater attention. The central 
argument that secondary cases are more infectious overall has, in the work presented here, 
been shown to be far from obvious, with differences in the temporal profile of viraemia and 
infectivity perhaps being more relevant. However, the work here only considers clinical 
cases; another area in which primary and secondary infections may differ is in the proportion 
of cases that are symptomatic. 
The contribution of asymptomatic or subclinical cases to the transmission reservoir is a much 
debated issue for dengue and has important consequences for transmission dynamics and the 
impact of interventions. If Halstead’s logic (Halstead, 2008) was to be followed (see Section 
Error! Reference source not found.) we might expect the contribution of asymptomatic 
patients to transmission to be less than that of symptomatic cases (though they might be more 
prevalent). 
In order to begin to assess the infectivity of asymptomatic infections, I took reported 
measures of virus titres from asymptomatic cases (detected from blood donations) and 
translated these into a probability of infecting a mosquito if bitten, using the relationships 
derived in this thesis. Though these estimates are approximate, I think it is important to start 
to think quantitatively about the infectivity of these patients. I find that though the majority 
would have very low probability of infecting a mosquito (~ 10
-5
) some might have a much 
higher probability (~0.97). Since we have no information on the point during in infection at 
which these blood samples were taken, these values do not allow us to estimate average total 
infectivity, but the higher values observed make it difficult to rule out 
asymptomatic/inapparent infections from contributing significantly to transmission.   
I also collated information on the proportion of infections that are asymptomatic or 
inapparent, building on earlier work (Rothman, 2010). The resulting estimates can be used in 
transmission models, as has been done to some extent by Sriprom et al. and Wikramaratna et 
al. (Sriprom et al., 2007, Wikramaratna et al., 2010). The collated data shows substantial 
variation in the proportion of inapparent infections between study sites and designs, and by 
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serotype and immune history – though it is important to note that different studies use very 
different definitions of ‘inapparent’ or ‘asymptomatic’. Indeed, more recent studies of 
asymptomatic transmission have considered not entirely asymptomatic cases but ones that are 
merely mildly symptomatic. Such cases may be a particularly important group for 
transmission and a greater understanding of their viral dynamics and therefore infectivity 
would be of use. This is because mildly symptomatic (as well as asymptomatic) patients 
could be continuing life as usual and therefore continuing to be exposed to mosquitoes.  
Linking primary vs. secondary differences and the asymptomatic cases, is the question of 
whether a primary case is more likely to be asymptomatic than a secondary infection. Our 
datasets do not allow us to address this question, as they only include clinical dengue cases. 
From Table 5-5, one study estimates the ratio of asymptomatic to symptomatic infections to 
be twice as large in primary than secondary cases ((Burke et al., 1988)). This may also fit in 
with another common assumption in transmission modelling papers that susceptibility to 
infection is greater in someone who has already experienced an infection (though it is not 
clear if this is susceptibility to infection or disease).  
Another difference that is rarely highlighted in transmission models is the difference between 
serotypes. Observed differences may be heavily influenced by the immune history of 
individuals. In Vietnam, where we all four serotypes circulate (albeit with one typically 
dominating at a time) the immunity history distribution of a population will be highly 
complex. In general, there are three points in the transmission cycle that could lead to 
differential infectivity: 1) the relationship between virus titre and infectivity to a mosquito; 2) 
the virus titres in an individual and 3) the infection in the mosquito and subsequent infection 
of a human. I did not consider the third here, but began to focus on the first two. In the work 
in this thesis I explore differences between the serotypes in virus titres in an individual during 
infection (Chapter 3), and in the relationship between virus titres and mosquito infection 
(work in this chapter. Results in this chapter show that together these may translate into 
important differences in infectivity. For example, considering total infectivity, for some 
patient groups DENV1 is estimated to be twice as infective as DENV2 (see Table 5-2), which 
could have important implications for transmission and for model predictions.  
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5.4.2. Predictions of interventions 
All the areas highlighted above: heterogeneity, primary/ secondary differences, serotypes 
differences, asymptomatic infections, and the uncertainty in all these things (especially in the 
early infection period) become even more important when considering the impact of an 
intervention.  
5.4.2.1. Wolbachia (wMel strain) 
I considered the impact of Wolbachia infection of mosquitoes (wMel strain) without 
considering a full transmission model, though work is on-going to include these results in a 
transmission model. I also did not consider the invasion dynamics of Wolbachia in the vector 
population (which has been considered in other models, e.g. (Barton and Turelli, 2011)), nor 
any life-shortening impact of Wolbachia (also considered in other models, e.g. (Schraiber et 
al., 2012)). Both these will of course also be important in determining the success of 
Wolbachia in controlling transmission of dengue, but here I solely consider the impact of 
wMel infection on the susceptibility of mosquitoes to dengue infection, as represented by a 
reduction in human infectiousness.  
Overall, my analysis indicates that patients bitten by wMel infected mosquitoes will have 
around half the infectivity of an individual bitten by a wild-type mosquito (considered using 
the AUC see Table 5-2). There are however differences predicted across groups and 
serotypes. There are also differences between patients in the extent to which wMel has an 
impact, since at low virus titres the impact may perhaps be less (though the data are limited to 
estimate impacts in this regime). The two serotypes also highlight the two different ways that 
wMel could change the relationship between virus titre and probability of mosquito infection 
(see Figure 5-4 and Figure 5-5). Firstly, wMel might change the peak of infectivity reached, 
and secondly, it might change the threshold viral titre above which infectivity saturates. In the 
results presented in this chapter, for DENV2 the peak infectivity is altered by wMel infection, 
but the threshold titre does not appear to alter (see Figure 5-3). When translated into 
infectivity during infection this means that the peak of infectivity alters, but the length of 
infectivity does not (see Figure 5-16). For DENV1, by contrast, the peak of infectivity does 
not alter, but threshold titre does (see Figure 5-2). This translates to the duration but not the 
magnitude of peak infectivity altering (Figure 5-16). These results imply a later onset of 
infectivity for DENV1 (but not DENV2) with wMel infected mosquitoes, which could be of 
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benefit for control, as transmission prior to symptoms or healthcare seeking behaviour will be 
reduced. This might be of particular use if antiviral treatment were available which could be 
administered on arrival to hospital and could reduce infectivity further.  
If the differences between serotypes suggested by my analysis prove real (bearing in mind the 
very limited data available currently), then the serotypes circulating at the time introduction 
of Wolbachia- infected mosquitoes may be important to the impact seen, so monitoring of 
circulating virus serotypes is likely to be essential.  
There are of course other ways that Wolbachia could impact infectivity. These include 
altering the EIP within the mosquito or by altering the infectivity of an infected mosquito to 
humans. These are not considered in this thesis and their impact on transmission may not be 
straightforward.  
The benefit of Wolbachia as an intervention is that it affects all human infections, not just 
clinical cases. This is in contrast with interventions targeted at symptomatic dengue cases, 
e.g. antivirals, where an individual’s infectivity will only be affected by an antiviral if they 
are treated with it.  
5.4.2.2. Antivirals and vaccines  
With the viral dynamics model with α, η, IP as patient specific parameters, I predict a 
reduction in the infectivity of a patient with a DENV1 primary and secondary infection if 
they are treated immediately on arrival to hospital (with infectivity predicted to be around 2/3 
of that without the antiviral). Of course an antiviral can only have an impact on the 
infectiousness of an individual once it has been administered, so will only impact the latter 
stages of infection, so this proportion change will be altered if more transmission is occurring 
in the early stages than currently predicted by the model. The predicted heterogeneity 
between individuals in the impact of an antiviral on virus dynamics is also reflected in 
estimates of the impact on infectivity, much of which arises from the predicted variability in 
the timing of treatment onset.   
An important factor in determining how easy a particular pathogen is to control is the timing 
of the onset of infectivity relative to symptoms (Fraser et al., 2004), since treatment at a 
healthcare facility typically only follows symptoms becoming apparent. My analysis predicts 
that most dengue cases are already near maximally infective on arrival to hospital and 
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typically have been for some time. Of course, if effective antiviral treatment were readily 
available, this might lead to changes in patient behaviour and earlier seeking of healthcare, 
perhaps leading to a larger impact of antivirals on treatment than estimated here. Prophylactic 
treatment (e.g. within households) might also be a possibility which could mean infections 
caught earlier and therefore reduce a greater proportion of infectivity. Antivirals may also 
have a role in protecting against infection, though we cannot know if this would be the case 
without testing antivirals on subsequently infected individuals.   
Finally, the interventions considered above may be combined with vaccination in the future. 
Along with the usual questions concerning efficient vaccine rollout, dengue has its own 
particular issues when considering possible vaccines. For prediction of vaccination impact, 
understanding serotype interactions and cross-immunity will be important, as will be the 
extent to which a potentially partially effective vaccine reduces infectivity as well as disease.   
For understanding the impact of a vaccine, we must know how it modifies susceptibility and 
infection dynamics within an individual and the consequent impacts on transmission at a 
population level. For dengue this is particularly challenging due to the spatiotemporal 
variation in serotype and genotype dynamics and resulting heterogeneity in infection/immune 
history in the human population. The recent vaccine phase IIb Sanofi vaccine trial results 
(Sabchareon et al., 2012) highlight these challenges of interpretation. The results suggest 
differences in impact between serotypes, with a post-hoc analysis showing no efficacy 
against DENV2 and a wide range of vaccine efficacy against other serotypes. Predicting the 
population impact of a vaccine with such a complex profile will require trial results to be 
translated into an understanding of vaccine impact on viral dynamics and therefore 
infectivity.  
5.4.3. Limitations 
The main limitation of this work is that the biting experiments were conducted using 
membrane feeding assays. Firstly membrane feeding as opposed to feeding directly on 
humans may alter the relationship between virus titres and infectivity as localised reactions to 
the mosquito feed in humans cannot be taken into account. Further work is ongoing to 
understand the differences between the membrane feeding and direct human feeding. 
Secondly the work is undertaken in lab conditions and the mosquitoes are left to feed until 
engorged. This means interrupted feeding or multiple feeding from different hosts is not 
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taken into account. Future work would be possible in restricting feeding time or using 
membrane feeding, allowing mosquitoes to have multiple feeds of different virus titre blood. 
This issue of feeding time may impact the finding of a plateau of infectivity, it may be that if 
smaller feeds were taken, within the almost full infectivity that we observe across multiple 
virus titres here, the higher titre blood would be more infectious than the lower. 
 
In this work I am assessing the relationship between viral titre and infectivity to a mosquito, 
given that a mosquito feeds. There is also much work to be done on understanding any 
relationship between time during infection and the probability of a mosquito feeding. This 
could be altered in two ways. It could be that symptoms such as fever alter the attractiveness 
of humans to mosquitoes (and this may be changing along with viral titre). Symptoms may 
also influence behaviour, which could influence the possibility of coming into contact with a 
mosquito. This could work in two ways: the more ill an individual is, the more stationary they 
are (maybe at home in bed) so the greater possibility of a mosquito bite, or the milder the 
symptoms the more likely they are out and about in the day being exposed to mosquitoes.  
It was of interest to note whether we observed differences between the infectivity in 
hospitalised and community based cases. The difference in the total infectivity measure seen 
between the two virus titre datasets (see Table 5-2 and Table 5-4) is particularly noticeable, 
though for DENV1, the two datasets show the same difference between primary and 
secondary infections. In the within-host fitting work, I noted differences in estimates of the 
parameter  (the parameter governing the immune response proliferation) between the virus 
titre datasets, so it could be this driving the differences in infectivity estimated. The 
difference could also be due to infrequent measures in the second dataset with measurements 
only taken every day, possibly resulting in missing some viral peaks. The difference between 
datasets highlights the need for further work with additional datasets, from multiple settings 
in order to fully understand virus dynamics in different treatment settings and therefore 
infectivity. 
As highlighted in previous sections, understanding the early stage of infection is very 
important. There is some worry in the use of the model in considering the early phase of the 
virus dynamics, due to the limited data available for model validation in this period. The 
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early dynamics are particularly important for really understanding differences between 
primary and secondary infection dynamics and thus the impact of control measures as 
discussed above. The results in this thesis show that depending on model assumptions, 
estimates of total infectivity can vary greatly, particularly for DENV2 secondary infections 
which show a much higher infectivity for the less parameterised model which fits only α, IP 
as patient specific (see Table 5-2 and Table 5-3). There are also important changes in the 
estimated timing of infectivity (e.g. Figure 5-11 and Figure 5-12) depending on the viral 
dynamics model used. What other factors might be modulating infectivity is also important in 
the early stage where we cannot be sure that the same virus tire will lead to the same 
probability of infection as the data shows in later infection. Early infection could differ for a 
few reasons: a change in the “infectious” proportion of virions over time or differences in 
other immunological or clinical measures that may affect the probability of mosquito biting 
or infection. 
We have been unable to consider infectivity in DENV3 and DENV4 here due to the absence 
of data, but there is also a need for more data on DENV2. Overall, more biting experiment 
data would be valuable, since when estimating the functional form for the relationship 
between virus titre and infectivity, some results are heavily influenced by a single data point. 
The influence of two outliers is noted in Figure 5-7 for the wMel saliva data. On-going work 
is collecting more data to reduce this uncertainty. 
There are two main areas of this work where complexity has been missed. In the human there 
will almost certainly be other variables that impact infectivity, such as antibody levels. Work 
including these in a full model of the relationship between biological parameters in the 
human and ultimate human infectivity is ongoing by others. In the mosquito, I have only 
considered the probability of an infection, not the details of any subsequent infection such as 
the extrinsic incubation period or the onward infectivity of each mosquito. The infectivity of 
infected mosquitoes to humans is the missing link here in completing the transmission cycle. 
There is very little known about this issue, meaning any transmission model currently has to 
make some large assumptions.  
5.4.4. Future work 
The work in this and earlier chapters suggests a number of exciting future directions for 
research.  
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First, the biting experiment data reported above was from a single strain of Aedes aegypti 
(taken from Try Nguyen, Vietnam). Addition work would be needed to test whether there is 
variation in mosquito susceptibility (and the impact of Wolbachia) between different Aedes 
aegypti populations.   
More work is needed to characterise how mosquito pathogenesis (e.g. extrinsic incubation 
period) depends on the viral titre of the infecting blood meal and how such dependencies vary 
between serotypes and between wild-type and Wolbachia-infected mosquitoes. Firstly, 
quantifying viral density in the mosquito at multiple time points post infection and from 
multiple tissues will be of use. Virus titres in the mosquito were available in the current 
dataset, but I did not make use of these data here. A more complex probabilistic model could 
be derived for the dependence of mosquito viral titre as a function of human blood virus 
titres, and could be used to begin to evaluate the impact of Wolbachia on viral replication in 
the mosquito. More speculative models for Wolbachia infected mosquitoes could test 
different ways Wolbachia could slow or modify viral dynamics in the mosquito, either by 
increasing the immune response or blocking the virus production directly through 
competition (Bian et al., 2010)), and how this might vary in different body tissues (e.g. 
abdomen, head, saliva).  
With also more complex statistical models, the over dispersion in the data should be taken 
into account, possibly with the use of a beta- binomial likelihood. Further work with the 
augmented datasets will certainly use this method.  
Throughout this thesis an important theme has been the need to understand the early infection 
period and asymptomatic cases. The data I used in earlier chapters to estimate the human 
incubation period comes from historical human challenge studies with dengue virus. With the 
prospect of development of vaccines and antivirals, challenge studies are once again being 
discussed for dengue (Gunther et al., 2011). Whilst the ethical considerations of such studies 
need to be debated, they would be invaluable for improving understanding of early infection 
and how it is modified by prior immunity (see Chapter 3). Some experimental infection 
studies with vaccine derived strains experimental infections have occurred (Gunther et al., 
2011, but by injecting virus rather than through mosquito challenge (so the amount of virus 
can be controlled), and it is unclear how easily results from such artificial studies would 
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translate to natural infection. Such studies considering both immunological processes during 
infection, and infectivity, would contribute greatly to the understanding of dengue infection.  
Uncertainty around early infection dynamics and asymptomatic/inapparent infections can 
also be derived from case cluster studies either in households or workplaces as in (Beckett et 
al., 2005, Reyes et al., 2010, Yoon et al., 2012). Frequent sampling over time from those 
around infected cases may allow the pre-symptomatic dynamics of infection to be 
systematically characterised. Such studies would also provide more information of the timing 
(i.e. serial interval distribution) of infections in households and schools or workplaces. In a 
paper on a cluster study in Jakarta, the authors say virus will be quantified from those around 
index patients (Beckett et al., 2005). However, results have not yet been published and the 
data is not yet available. Follow-up after a viraemic blood donation may also be possible and 
would aid our understanding of asymptomatic virus titres over time.  
In this thesis I have only considered immune dynamics during acute infection. An interesting 
extension of this work would be to consider immune dynamics after infection (e.g. waning of 
immunity and immune boosting) and the relationship with subsequent infections. This will be 
relevant to understanding the impact of a vaccine. This could help understand the immune 
landscape that seems to be so important for dengue virus transmission dynamics (Recker et 
al., 2009, Lourenco and Recker, 2010, OhAinle et al., 2011).  
Though I use the output from the within-host model in the work in this chapter I have not 
explicitly integrated the within host model into a transmission model, though this would be 
relatively straightforward to do, particular in an agent-based model. 
Since I used datasets exclusively from the Vietnam setting (and conclusions can really only 
be drawn strongly for one serotype (DENV1)), further studies of virus dynamics over as 
much of the infection as possible, in different settings and for different serotypes are needed 
to validate and strengthen the conclusions reached above.  
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5.4.5. Conclusions 
This thesis has aimed to look at dengue on multiple levels- from the cellular, to the 
individual, and up to the transmission between individuals l. In combining modelling and 
data at different scales, we can learn much about the whole system and the dependencies 
between scales. For example, thinking at a cellular level about infection processes and the 
differences between primary and secondary cases and serotypes informs what we know about 
transmission. I estimate certain groups or serotypes could contribute more to infection than 
others. In the work here, primary DENV1 cases are estimated to contribute most to 
transmission. There are issues however with the early infection missing titres and how this 
impacts these results. 
Modelling the secondary processes in more depth allowed us to think about how the early 
possibly detrimental immune responses and the clearance of infection fit together. At this 
level, fitting more simple models to data, I found parameter differences between primary and 
secondary DENV1 infections consistent with both antigenic sin and enhancement in 
secondary infection fitted the data. Differences between serotypes were noted, but with an 
unclear picture coming out about what could be creating these differences. Individual 
heterogeneity can be estimated by allowing the model immune response parameters to vary 
between individuals. I considered various theoretical antivirals in the model, and hope that 
this provokes closer thought about how an antiviral would best work and be tested. 
In further considering the role of the immune response in controlling infection, using 
antibody and virus data from throughout infection, I developed a mechanistic model fit to 
data consistent with antibody playing a role in controlling infection. This work was also 
informative about the proliferation of antibody throughout infection. Here heterogeneity was 
recreated once again by the immune response parameters, but with an emphasis on the initial 
antibody titres and the scaling factor used (in some way a measure of the efficacy of the 
immune response measured). My work illustrates the start of how modelling, coupled with 
data, can be a powerful tool for exploring hypotheses about pathogenesis.  
Linking within-host dynamics to the between individual scale, I considered the infectivity of 
dengue cases throughout infection. The differences I found between serotypes and primary 
and secondary require further study, but the message for transmission modelling is that such 
heterogeneity cannot be ignored, and may impact predictions of a model. When thinking 
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about interventions using the simple measure of total infectivity (the area under the 
infectivity curve), I found that both Wolbachia infected mosquitoes and to a lesser extent 
antivirals may have a substantial impact on transmission. Important but uncertain factors such 
as the events in early infection, heterogeneity between individuals, timing of symptoms and 
the proportion of asymptomatic patients and their infectivity and possible differences 
between serotypes, will impact interventions in different ways, and need to be more fully 
understood before the population level impact of these interventions can be fully assessed.  
Work with wolbachia in particular highlighted the need to consider the dynamics of infection 
when considering infectivity and the impact of interventions.   
In all sections of this thesis cluster studies, human challenge studies and follow up of 
viraemic blood donators with data collected on multiple levels, would be of huge use, and the 
methods developed in this thesis could be applied readily to these, hopefully forthcoming, 
datasets. It is an interesting time for dengue research, with vaccines, antivirals and novel 
mosquito control all under serious consideration. This thesis presents a different way of 
thinking about dengue infection, considering dynamics and their mechanistic explanations. 
Combined with data on multiple levels of infection, I hope this can aid our understanding of 
dengue, and ultimately how we can best control it.  
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